


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update January 24 - January 31, 2021,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 04 2021

944 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashbord](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[German \(ICU\) bed capacity](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford Universtiy Press](#)

[Cambridge Univeristy Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[Retracted papers](#)

[AAN - Neurology resources](#)

[COVID-19 risk tools - Apps](#)

[COVID-19 resources \(Harvard\)](#)

[Web app for SARS-CoV2 mutations](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

[COVID-19 prevention network](#)

[Covid-Plex trial - \(plasma exchange & convalescent plasma trial\)](#)

**Re: Plasma exchange and convalescent plasma in COVID-19 patients with
multi-organ failure –
The COVID-19 PLEX + Convalescent Plasma trial –
Enrollment initiated**

The Covid-Plex trial is an investigator initiated, multicenter, parallel-group, open-label randomized clinical trial aiming to randomize patients with severe COVID-19 to standard care or standard care plus plasmapheresis and convalescent plasma.

If you are interested to participate Please contact Wladimir Szpirt, Nicholas Carlson Anders, or Perner Bo Feldt-Rasmussen. Depts. Of Intensive Care Therapy and Nephrology, Copenhagen University Hospital Rigshospitalet, Denmark

Covid-Plex trial

Mainstream Media

New York Times - Corona update

New Vaccine Puzzle: Who Should Get Which Shot?

In the Vaccine Scramble, Cancer Patients Are Left Behind

Russia's Vaccine Is Safe and Effective, Published Study Shows

The Virus Variant Spreading in Britain May Make Vaccines Less Effective

Had Covid? You May Need Only One Dose of Vaccine, Study Suggests

One Case, Total Lockdown: Australia's Lessons for a Pandemic World

As Virus Variants Spread, 'No One Is Safe Until Everyone Is Safe'

How the Search for Covid-19 Treatments Faltered While Vaccines Sped Ahead

Coronavirus Vaccine Tracker

Coronavirus Drug and Treatment Tracker

Washington Post - Corona update

Can OTC pain relievers reduce vaccine effectiveness?

These are the top coronavirus vaccines to watch

More experts now recommend medical masks. Good ones are hard to find.

A fast, at-home coronavirus test will be available to Americans this year

Many who have received the coronavirus vaccine wonder: What can I safely do?

New diabetes cases linked to covid-19

Are the coronavirus vaccines safe for someone with cancer, dementia, or MS?

To boost immunity, forget 'magic pills.' Focus on sleep, exercise, diet, and stress.

Three reasons a negative coronavirus test doesn't mean you're not infected

Guardian - Corona update

A quarter of people in France, Germany, and the US may refuse Covid vaccine

Coronavirus live: international travel 'biggest factor in death rate'

About 4,000 Covid variants across the world, says UK minister

Covid: Oxford trial to test the efficacy of mix of vaccines for individuals

One Pfizer/BioNTech jab gives '90% immunity' from Covid after 21 days

Key Articles

1. **A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations.** Infect Dis (Lond) 2021;1-10 Piri SM, Edalatfar M, Shool S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508989>

The risk of re-infection with SARS-CoV-2 is real, and exploring the risk and consequences of a second hit is important. This review compiled the evidence collected in 66 publications. Rates of recurrences range from 2.3% to 21.4%. On average, re-infections were reported 20 days after discharge (range: 1-98). Younger patients were at an increased risk, but most of these cases had similar or decreased disease severity; only 2.6% did worse than the first episode. Reactivation of an earlier infection, new infections, and false-negative testing were the three most likely causes. Immunized patients (IgG-IgM positive) were not exempt from reoccurrences.

2. **What can we learn from Israel's rapid roll out of COVID 19 vaccination?**

Isr J Health Policy Res 2021; 10:5 McKee M, Rajan S.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33499901>

The Israeli vaccine roll-out is heralded as one of the most successful programs. With a population of 9.3 million, 11 out of 100 Israeli's received their first shot at the end of 2020. The articles summarize the success factors and warn for specific hurdles that need to be addressed. The relatively small population size and a strong public health infrastructure contributed significantly. Well organized and centrally coordinated delivery of vaccines including prioritization of well-defined groups, and large cadre of skilled health workers were crucial as well. IT played a vital role but those not that digitally competent were reached as well; in most cases these were most likely economically and educationally disadvantaged groups. The Israeli model can be used a proof of principle for countries with similar health infrastructure and financial resources.

3. **Causes and Circumstances of Death Among Patients Hospitalized with COVID-19: A Retrospective Cohort Study.** Ann Am Thorac Soc 2020;

Ketcham SW, Bolig T, Molling DJ *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33315531>

Approximately 15-30% of the hospitalized COVID-19 patients 15-30% will die. Specific causes of death, as well as the most common organ system failures, remain unclear. This single large (± 1000 beds) US hospital performed a retrospective analysis of adult patients hospitalized for laboratory-confirmed COVID-19 patients. Compared to a historical cohort of admitted for non-COVID-related respiratory failure, The most common causes of death were pulmonary dysfunction (56.1% vs. 21.6%; $p < 0.01$) and septic shock (26.8% vs. 26.2%). Covid-19 patients were less likely to die from cardiac (7.3% vs 16.1%; $p = 0.04$) or neurologic (6.1% vs 19.5%; $p < 0.01$) causes. These observations emphasize the importance of appropriate respiratory support and early recognition and treatment of infection. COVID-19 patients are more likely to experience fatal complications as a direct consequence of their infection

compared to patients with non-COVID-related infections in whom downstream complications are a more likely cause of death.

4. **Pathophysiological Processes Underlying the High Prevalence of Deep Vein Thrombosis in Critically Ill COVID-19 Patients.** Front. Physiol. 2020; 11:608788 Voicu S, Ketfi C, Stăpanian A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33488398>
5. **Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the United Kingdom: An early data-driven analysis.** J Travel Med 2021; Zhao S, Lou J, Cao L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33506254>
6. **Multi-Organ Involvement in COVID-19: Beyond Pulmonary Manifestations.** J Clin Med 2021; 10Thakur V, Ratho RK, Kumar P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33498861>
7. **Vaccines are not yet a silver bullet: The imperative of continued communication about the importance of COVID-19 safety measures.** Brain Behav Immun Health 2021; 12:100204 Su Z, Wen J, McDonnell D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33495754>
8. **The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients.** Am. J. Otolaryngol. 2021; 42:102892 Singh CV, Jain S, Parveen S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493729>
9. **No association between use of ACE inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEDicaTion (COMET) study.** Br. J. Clin. Pharmacol. 2021; Sablerolles RSG, Hogenhuis FEF, Lafeber M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33507556>
10. **COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options.** Infect Dis Ther 2021; 1:1-21 Rebold N, Holger D, Alosaimy S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495967>
11. **Mechanisms of thrombosis and cardiovascular complications in COVID-19.** Thromb Res 2021; 200:1-8 Page EM, Arivins RAS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33493983>
12. **COVID-19 in pregnancy: a systematic review of chest CT findings and associated clinical features in 427 patients.** Clin Imaging 2021; 75:75-82 Oshay RR, Chen MYC, Fields BKK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33508754>
13. **Habitual use of vitamin D supplements and risk of coronavirus disease 2019 (COVID-19) infection: a prospective study in UK Biobank.** Am. J. Clin. Nutr. 2021; Ma H, Zhou T, Heianza Y, Qi L.

14. **A systematic review of clinical and laboratory parameters of 3,000 COVID-19 cases.** Obstet Gynecol Sci 2021; Goel H, Gupta I, Mourya M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499580>
 15. **COVID-19: Characteristics and Therapeutics.** Cells 2021; 10Chilamakuri R, Agarwal S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494237>
-

Basic Science (49 articles)

1. **A narrative review on the basic and clinical aspects of the novel SARS-CoV-2, the etiologic agent of COVID-19.** Ann Transl Med 2020; 8:1686Hokello J, Sharma AL, Shukla GC, Tyagi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490198>
2. **Mutational sensitivity of D614G in spike protein of SARS-CoV-2 in Jordan.** Biochem Biophys Rep 2021; 25:100896Al-Zyoud W, Haddad H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506114>
3. **The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients.** Biochem. Biophys. Res. Commun. 2021; 543:45-49Smits VAJ, Hernández-Carralero E, Paz-Cabrera MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515911>
4. **Precision shielding for COVID-19: metrics of assessment and feasibility of deployment.** BMJ Glob Health 2021; 6Ioannidis JPA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514595>
5. **Luteolin and abysynone II as potential inhibitors of SARS-CoV-2: an in silico molecular modeling approach in battling the COVID-19 outbreak.** Bull Natl Res Cent 2021; 45:27Shawan M, Halder SK, Hasan MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495684>
6. **COVID-19: Characteristics and Therapeutics.** Cells 2021; 10Chilamakuri R, Agarwal S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494237>
7. **Intractable COVID-19 and Prolonged SARS-CoV-2 Replication in a CAR-T-cell Therapy Recipient: A Case Study.** Clin Infect Dis 2021; Hensley MK, Bain WG, Jacobs J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507235>
8. **Absence of vaccine-enhanced disease with unexpected positive protection against SARS-CoV-2 by inactivated vaccine given within three days of virus challenge in Syrian hamster model.** Clin Infect Dis 2021; Li C, Chen YX, Liu FF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515458>
9. **RAAS blockade and COVID-19: Mechanistic Modeling of mas and AT1 Receptor Occupancy as Indicators of Pro- and Anti-Inflammatory Balance.** Clin Pharmacol Ther 2021; Hallow KM, Dave I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506503>
10. **Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.** Comput Struct Biotechnol J 2021; 19:467-476Zhu H, Du W, Song M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505639>

11. **Role of Poly(ADP-ribose) polymerase (PARP1) in viral infection and its implication in SARS-CoV-2 pathogenesis.** Curr. Drug Targets 2021; Rajawat J, Chandra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494667>
12. **Phenylbenzopyrone of flavonoids as a potential scaffold to prevent SARS-CoV-2 replication by inhibiting its MPRO main protease.** Curr. Pharm. Biotechnol. 2021; Potshangbam AM, Nongdam P, Kumar AK, Rathore RS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504301>
13. **Genomic Study of COVID-19 Corona Virus Excludes Its Origin from Recombination or Characterized Biological Sources and Suggests a Role for HERVS in Its Wide Range Symptoms.** Cytol Genet 2020; 54:588-604 El-Shehawi AM, Alotaibi SS, Elseehy MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487779>
14. **A Streamlined Whole Blood CyTOF Workflow Defines A Circulating Immune Cell Signature of COVID-19.** Cytometry A 2021; Geanon D, Lee B, Gonzalez-Kozlova E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496367>
15. **An Alternative "Trojan Horse" Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology.** Endocr. Metab. Immune Disord. Drug Targets 2021; Balzanelli MG, Distratis P, Aityan SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504318>
16. **Association of ACE inhibitors and Angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: a pathway-based analytical study.** Eur. J. Pharmacol. 2021:173899 Parit R, Jayavel S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508281>
17. **Cholesterol Metabolism Pathways- Are the Intermediates more Important than the Products?** Febs j. 2021; Wang Y, Yutuc E, Griffiths WJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506652>
18. **Nicotinic Cholinergic System and COVID-19: In Silico Identification of Interactions Between $\alpha 7$ Nicotinic Acetylcholine Receptor and the Cryptic Epitopes of SARS-Co-V and SARS-CoV-2 Spike Glycoproteins.** Food Chem. Toxicol. 2021; 149:112009 Lagoumintzis G, Chasapis CT, Alexandris N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503469>
19. **Impact of COVID-19 on Mitochondrial-Based Immunity in Aging and Age-Related Diseases.** Front. Aging Neurosci. 2020; 12:614650 Ganji R, Reddy PH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510633>
20. **Identifying Transcriptomic Signatures and Rules for SARS-CoV-2 Infection.** Front Cell Dev Biol 2020; 8:627302 Zhang YH, Li H, Zeng T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505977>
21. **Structural Insight Into the SARS-CoV-2 Nucleocapsid Protein C-Terminal Domain Reveals a Novel Recognition Mechanism for Viral Transcriptional Regulatory Sequences.** Front Chem 2020; 8:624765 Yang M, He S, Chen X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511102>
22. **SARS-CoV-2 Causes a Systemically Multiple Organs Damages and Dissemination in Hamsters.** Front. Microbiol. 2020; 11:618891 Song Z, Bao L, Yu P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510731>
23. **Mutational analysis of SARS-CoV-2 ORF8 during six months of COVID-19 pandemic.** Gene Rep 2021; 23:101024 Alkhansa A, Lakkis G, El Zein L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490718>
24. **Epigenetic Evolution of ACE2 and IL-6 Genes: Non-Canonical Interferon-Stimulated Genes Correlate to COVID-19 Susceptibility in Vertebrates.** Genes

- (Base) 2021; 12Sang ER, Tian Y, Miller LC, Sang Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33503821>
25. **Rapid spread of mutant alleles in worldwide SARS-CoV-2 strains revealed by genome-wide single nucleotide polymorphism and variation analysis.** Genome Biol. Evol. 2021; Zhu Z, Liu G, Meng K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512495>
 26. **A Missing Link: Engagements of Dendritic Cells in the Pathogenesis of SARS-CoV-2 Infections.** Int J Mol Sci 2021; 22Alamri A, Fisk D, Upreti D, Kung SKP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33498725>
 27. **Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods.** J Biomol Struct Dyn 2021:1-8Chandra A, Gurjar V, Ahmed MZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491573>
 28. **Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19.** J Biomol Struct Dyn 2021:1-18Ishola AA, Joshi T, Abdulai SI *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33491579>
 29. **Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 - a computational modeling.** J Biomol Struct Dyn 2021:1-16Noor H, Ikram A, Rathinavel T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33491580>
 30. **Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in-vitro.** J. Enzyme Inhib. Med. Chem. 2021; 36:497-503Liu H, Ye F, Sun Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491508>
 31. **Host-cell recognition through GRP78 is enhanced in the new UK variant of SARS-CoV-2, in silico.** J Infect 2021; Elfiky AA, Ibrahim IM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33493496>
 32. **Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.** J Infect Public Health 2020; 14:227-237Gurung AB, Ali MA, Lee J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33493919>
 33. **A parsimonious approach for recognizing SARS-CoV-2 and host interactions.** J Med Virol 2021; Ganguly B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506962>
 34. **Role of Toll-like receptors in the pathogenesis of COVID-19.** J Med Virol 2021; Khanmohammadi S, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506952>
 35. **Antimicrobial Activity, DFT Calculations, and Molecular Docking of Dialdehyde Cellulose/Graphene Oxide Film Against Covid-19.** J. Polym. Environ. 2021:1-13Dacroy S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488314>
 36. **Latent periodicity-2 in coronavirus SARS-CoV-2 genome: evolutionary implications.** J. Theor. Biol. 2021:110604Yin C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33508323>
 37. **Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the United Kingdom: An early data-driven analysis.** J Travel Med 2021; Zhao S, Lou J, Cao L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506254>
 38. **Antiviral activity of bioactive phytocompounds against coronavirus: An update.** J. Virol. Methods 2021:114070Bhattacharya R, Dev K, Sourirajan A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33497729>

39. **The Novel Coronavirus Enigma: Phylogeny and Analyses of Coevolving Mutations Among the SARS-CoV-2 Viruses Circulating in India.** JMIR Bioinform Biotech 2020; 1:e20735 Banerjee A, Sarkar R, Mitra S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33496683>
40. **SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis.** Life Sci 2021; 270:119124 Aghbash PS, Eslami N, Shamekh A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33508291>
41. **From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.** Molecules 2021; 26 Matsoukas J, Apostolopoulos V, Zulli A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33504092>
42. **A contemporary insight of metabolomics approach for COVID-19: Potential for novel therapeutic and diagnostic targets.** Nepal J Epidemiol 2020; 10:923-927 Asim M, Sathian B, Banerjee I, Robinson J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33495710>
43. **Identification and molecular characterization of mutations in nucleocapsid phosphoprotein of SARS-CoV-2.** PeerJ 2021; 9:e10666 Azad GK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33505806>
44. **Identification of 37 Heterogeneous Drug Candidates for Treatment of COVID-19 via a Rational Transcriptomics-Based Drug Repurposing Approach.** Pharmaceuticals (Basel) 2021; 14 Gelemanović A, Vidović T, Stepanić V, Trajković K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33504008>
45. **Molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT-IR, FT-Raman), drug likeness and molecular docking of the novel anti COVID-2 molecule (2E)-N-methyl-2-[(4-oxo-4H-chromen-3-yl)methylidene]-hydrazinecarbothioamide (Dimer) - quantum chemical approach.** Spectrochim. Acta. A Mol. Biomol. Spectrosc. 2020; 251:119388 Jenepha Mary SJ, Pradhan S, James C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503560>
46. **Edible plant-derived exosomal microRNAs: Exploiting a cross-kingdom regulatory mechanism for targeting SARS-CoV-2.** Toxicol. Appl. Pharmacol. 2021:115425 Kalarikkal SP, Sundaram GM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516820>
47. **Genotype-phenotype correlation identified a novel SARS-CoV-2 variant possibly linked to severe disease.** Transbound Emerg Dis 2021; Loney T, Khansaheb H, Ramaswamy S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506644>
48. **Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.** Viruses 2021; 13 Lockbaum GJ, Reyes AC, Lee JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503819>
49. **Biological and Clinical Consequences of Integrin Binding via a Rogue RGD Motif in the SARS CoV-2 Spike Protein.** Viruses 2021; 13 Makowski L, Olson-Sidford W, J WW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498225>

Biomarkers - Genetics (109 articles)

1. **Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19).** 3 Biotech 2021; 11:89 Bessalah S, Jebahi S, Mejri N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500874>

2. **Magnetic Bead-Based Immunoassay Allows Rapid, Inexpensive, and Quantitative Detection of Human SARS-CoV-2 Antibodies.** ACS Sens 2021; Huergo LF, Selim KA, Conzentino MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496577>
3. **CRISPR Systems for COVID-19 Diagnosis.** ACS Sens 2021; Rahimi H, Salehiabar M, Barsbay M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502175>
4. **Biomarkers of COVID-19 and technologies to combat SARS-CoV-2.** Adv Biomark Sci Technol 2020; 2:1-23Zhang L, Guo H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511330>
5. **Bone Marrow and Peripheral Blood Findings in Patients Infected by SARS-CoV-2.** Am J Clin Pathol 2021; Harris CK, Hung YP, Nielsen GP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502434>
6. **Association between laboratory parameters and CT severity in patients infected with Covid-19: A retrospective, observational study.** Am J Emerg Med 2021; 42:110-114Yilmaz A, Sabirli R, Seyit M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503532>
7. **Soluble ACE2 as a potential therapy for COVID-19.** Am. J. Physiol. Cell Physiol. 2021; Krishnamurthy S, Lockey RF, Kolliputi N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502950>
8. **The CB index predicts prognosis of critically ill COVID-19 patients.** Ann Transl Med 2020; 8:1654Cao L, Zhang S, Wang E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490166>
9. **Chinese Expert Consensus on the Nucleic Acid Detection of SARS-CoV-2.** Ann Transl Med 2020; 8:1631Liu Z, Tong Y, Wu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490143>
10. **Evaluation of the relation between cardiac biomarkers and thorax computerized tomography findings in COVID-19 patients.** Biomark. Med. 2021; Ileri C, Dogan Z, Ozben B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501850>
11. **Differential Signaling and Virus Production in Calu-3 Cells and Vero Cells upon SARS-CoV-2 Infection.** Biomol Ther (Seoul) 2021; Park BK, Kim D, Park S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504682>
12. **Optical technologies for the detection of viruses like COVID-19: Progress and prospects.** Biosens. Bioelectron. 2021; 178:113004Lukose J, Chidangil S, George SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497877>
13. **CRISPR-based detection of SARS-CoV-2: A review from sample to result.** Biosens. Bioelectron. 2021; 178:113012Nouri R, Tang Z, Dong M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497879>
14. **Development of a portable MIP-based electrochemical sensor for detection of SARS-CoV-2 antigen.** Biosens. Bioelectron. 2021; 178:113029Raziq A, Kidakova A, Boroznjak R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515985>
15. **Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.** Biosens. Bioelectron. 2021; 178:113008Yang HS, Racine-Brzostek SE, Karbaschi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515984>
16. **Precision shielding for COVID-19: metrics of assessment and feasibility of deployment.** BMJ Glob Health 2021; 6Ioannidis JPA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514595>

17. **Multi-organ proteomic landscape of COVID-19 autopsies.** Cell 2021; Nie X, Qian L, Sun R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503446>
18. **Engineered Aptamers for Enhanced COVID-19 Theranostics.** Cell. Mol. Bioeng. 2021:1-13Acquah C, Jeevanandam J, Tan KX, Danquah MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488836>
19. **Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic COVID-19 patients.** Cell Rep Med 2021:100193Goh YS, Chavatte JM, Jielling AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495757>
20. **Laboratory action plan for emerging SARS-CoV-2 variants.** Clin Chem 2021; Filkins L, SoRelle JA, Schoggins J, Park JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515256>
21. **Serum albumin concentrations are associated with disease severity and outcomes in coronavirus 19 disease (COVID-19): a systematic review and meta-analysis.** Clin. Exp. Med. 2021:1-12Paliogiannis P, Mangoni AA, Cangemi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511503>
22. **Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors.** Clin Infect Dis 2021; 72:249-253Erikstrup C, Hother CE, Pedersen OBV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501969>
23. **Intractable COVID-19 and Prolonged SARS-CoV-2 Replication in a CAR-T-cell Therapy Recipient: A Case Study.** Clin Infect Dis 2021; Hensley MK, Bain WG, Jacobs J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507235>
24. **Occurrence and Timing of Subsequent Severe Acute Respiratory Syndrome Coronavirus 2 Reverse-transcription Polymerase Chain Reaction Positivity Among Initially Negative Patients.** Clin Infect Dis 2021; 72:323-326Long DR, Gombar S, Hogan CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501950>
25. **From Easing Lockdowns to Scaling Up Community-based Coronavirus Disease 2019 Screening, Testing, and Contact Tracing in Africa-Shared Approaches, Innovations, and Challenges to Minimize Morbidity and Mortality.** Clin Infect Dis 2021; 72:327-331Nachega JB, Grimwood A, Mahomed H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501963>
26. **First Reported Nosocomial Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 in a Pediatric Dialysis Unit.** Clin Infect Dis 2021; 72:265-270Schwierzeck V, König JC, Kühn J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501962>
27. **Trends in biosensing platforms for SARS-CoV-2 detection: A critical appraisal against standard detection tools.** Curr Opin Colloid Interface Sci 2021:101418Aziz A, Asif M, Ashraf G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495685>
28. **Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia.** Cytokine 2021; 140:155438Quartuccio L, Fabris M, Sonaglia A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493861>
29. **The impact of COVID-19 infection on the cytokine profile of pregnant women: A prospective case-control study.** Cytokine 2021; 140:155431Tanacan A, Yazihan N, Erol SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503581>
30. **A Streamlined Whole Blood CyTOF Workflow Defines A Circulating Immune Cell Signature of COVID-19.** Cytometry A 2021; Geanon D, Lee B, Gonzalez-

- Kozlova E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496367>
31. **Strand-Specific Reverse Transcription PCR for Detection of Replicating SARS-CoV-2.** Emerg Infect Dis 2021; 27:632-635 Hogan CA, Huang C, Sahoo MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496233>
 32. **Prevalence of SARS-CoV-2 Antibodies in First Responders and Public Safety Personnel, New York City, New York, USA, May-July 2020.** Emerg Infect Dis 2021; 27:Sami S, Akinbami LJ, Petersen LR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493106>
 33. **Smart materials-integrated sensor technologies for COVID-19 diagnosis.** Emergent Mater 2021:1-17 Erdem ñ, Derin E, Sagdic K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495747>
 34. **Facilitators and Barriers to Nursing Implementation of Continuous Glucose Monitoring (CGM) in Critically Ill COVID-19 Patients.** Endocr. Pract. 2021; Faulds ER, Jones L, McNett M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515756>
 35. **Large-scale IgM and IgG SARS-CoV-2 serological screening among healthcare workers with a low infection prevalence based on nasopharyngeal swab tests in an Italian university hospital: perspectives for public health.** Environ. Res. 2021:110793 Vimercati L, Stefanizzi P, De Maria L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508260>
 36. **Comparison of real time and droplet digital PCR to detect and quantify SARS-CoV-2 RNA in plasma.** Eur. J. Clin. Invest. 2021:e13501 Tedim AP, Almansa R, Domínguez-Gil M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512013>
 37. **Comparison of nine different commercially available molecular assays for detection of SARS-CoV-2 RNA.** Eur J Clin Microbiol Infect Dis 2021; Eberle U, Wimmer C, Huber I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512617>
 38. **Integration of heparin-binding protein and interleukin-6 in the early prediction of respiratory failure and mortality in pneumonia by SARS-CoV-2 (COVID-19).** Eur J Clin Microbiol Infect Dis 2021; Saridaki M, Metallidis S, Grigoropoulou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515095>
 39. **Is COVID-19 lockdown associated with vitamin D deficiency?** Eur. J. Public Health 2021; Lippi G, Ferrari A, Targher G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508085>
 40. **Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients.** Exp Hematol Oncol 2021; 10:5 Bao C, Tao X, Cui W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504359>
 41. **Application of a prediction model with laboratory indexes in the risk stratification of patients with COVID-19.** Exp. Ther. Med. 2021; 21:182 Ye J, Zhang X, Zhu F, Tang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488791>
 42. **Is lymphopenia different between SARS and COVID-19 patients?** Faseb.j 2021; 35:e21245 Yan S, Wu G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495994>
 43. **Cholesterol Metabolism Pathways- Are the Intermediates more Important than the Products?** Febs.j 2021; Wang Y, Yutuc E, Griffiths WJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506652>
 44. **Identifying Transcriptomic Signatures and Rules for SARS-CoV-2 Infection.** Front Cell Dev Biol 2020; 8:627302 Zhang YH, Li H, Zeng T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505977>
 45. **SARS-CoV-2 Viral RNA Shedding for More Than 87 Days in an Individual With an Impaired CD8+ T Cell Response.** Front. Immunol. 2020; 11:618402 Turner JS, Day A, Alsoussi WB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488630>

46. **Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19.** Front Med (Lausanne) 2020; 7:613475Li XZ, Qiu Y, Jeffery L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511147>
47. **High Prevalence of Hypocalcemia in Non-severe COVID-19 Patients: A Retrospective Case-Control Study.** Front Med (Lausanne) 2020; 7:590805Pal R, Ram S, Zohmangaihi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490095>
48. **SARS-CoV-2 detection by self-testing: a method that makes surveillance programs possible and effective.** Gastroenterol. Hepatol. 2021; Iruzubieta P, Lazarus JV, Crespo J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515624>
49. **Rapid spread of mutant alleles in worldwide SARS-CoV-2 strains revealed by genome-wide single nucleotide polymorphism and variation analysis.** Genome Biol. Evol. 2021; Zhu Z, Liu G, Meng K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512495>
50. **Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study.** Gut 2021; Weber S, Hellmuth JC, Scherer C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514597>
51. **Detection of SARS-CoV-2 from patient fecal samples by whole genome sequencing.** Gut Pathog. 2021; 13:7Papoutsis A, Borody T, Dolai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516247>
52. **Temporal increase in D614G mutation of SARS-CoV-2 in the Middle East and North Africa.** Heliyon 2021; 7:e06035Sallam M, Ababneh NA, Dababseh D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495741>
53. **ACE2 mutation might explain lower COVID-19 burden in malaria endemic areas.** Hum. Cell 2021; De A, Tiwari A, Dash M, Sinha A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492586>
54. **ACE2 Nascence, trafficking, and SARS-CoV-2 pathogenesis: the saga continues.** Hum Genomics 2021; 15:8Badawi S, Ali BR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514423>
55. **A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations.** Infect Dis (Lond) 2021:1-10Piri SM, Edalatfar M, Shool S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508989>
56. **Clinical, biological and radiological features, 4-week outcomes and prognostic factors in COVID-19 elderly inpatients.** Infect Dis Now 2021; Palich R, Wakim Y, Itani O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495763>
57. **Different SARS-CoV-2 haplotypes associate with geographic origin and case fatality rates of COVID-19 patients.** Infect Genet Evol 2021:104730Goyal M, De Bruyne K, van Belkum A, West B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513449>
58. **Mannose binding lectin gene 2 (rs1800450) missense variant may contribute to development and severity of COVID-19 infection.** Infect Genet Evol 2021:104717Medetalibeyoglu A, Bahat G, Senkal N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515713>
59. **The difference between IgM and IgG antibody prevalence in different serological assays for COVID-19; lessons from the examination of healthcare workers.** Int Immunopharmacol 2020; 92:107360Kobashi Y, Shimazu Y, Nishikawa Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508702>

60. **Eosinopenia is a reliable marker of severe disease and unfavorable outcome in patients with COVID-19 pneumonia.** Int J Clin Pract 2021:e14047Cazzaniga M, Fumagalli L, D'Angelo L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497517>
61. **Blood biochemical parameters for assessment of COVID-19 in diabetic and non-diabetic subjects: a cross-sectional study.** Int. J. Environ. Health Res. 2021:1-14Malik SUF, Chowdhury PA, Hakim A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504213>
62. **Prevalence of SARS-CoV-2 IgG/IgM Antibodies among Danish and Swedish Falck Emergency and Non-Emergency Healthcare Workers.** Int J Environ Res Public Health 2021; 18Laursen J, Petersen J, Didriksen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494409>
63. **Neutrophil-to-lymphocyte ratio is independently associated with COVID-19 severity: An updated meta-analysis based on adjusted effect estimates.** Int. J. Lab. Hematol. 2021; Li Y, Hou H, Diao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506621>
64. **Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients.** Int. J. Lab. Hematol. 2021; Rodríguez Rodríguez M, Castro Quismondo N, Zafra Torres D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502080>
65. **Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?** Int J Mol Sci 2021; 22Gadanec LK, McSweeney KR, Qaradakhi T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498183>
66. **Development and validation of a laboratory risk score for the early prediction of COVID-19 severity and in-hospital mortality.** Intensive Crit Care Nurs 2021:103012Bennouar S, Bachir Cherif A, Kessira A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487518>
67. **Inflammatory biomarkers as independent prognosticators of 28-day mortality for COVID-19 patients admitted to general medicine or ICU wards: a retrospective cohort study.** Intern Emerg Med 2021:1-10Pitre T, Jones A, Su J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496923>
68. **Interleukin-6 as unfavorable prognostic factor in patients affected by Covid-19 and hip fracture.** J Biol Regul Homeost Agents 2021; 35Pantalone A, Bruni D, Pantalone P, Buda R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511825>
69. **Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity.** J. Clin. Invest. 2021; Falck-Jones S, Vangeti S, Yu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492309>
70. **Circulating Levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients.** J Endocr Soc 2021; 5:bvaa199Ochoa-Callejero L, García-Sanmartín J, Villoslada-Blanco P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506161>
71. **Role of cell adhesion molecules for disease development of patients with and without COVID-19 in the emergency department.** J Infect Dis 2021; Bauer W, Ulke J, Galtung N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502532>
72. **Evidence of SARS-CoV-2 Replication and Tropism in the Lungs, Airways and Vascular Endothelium of Patients with Fatal COVID-19: An Autopsy Case-Series.** J Infect Dis 2021; Bhatnagar J, Gary J, Reagan-Steiner S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502471>
73. **Neutrophil extracellular traps persist at high levels in the lower respiratory tract of critically ill COVID-19 patients.** J Infect Dis 2021; Ouwendijk WJD,

- Raadsen MP, van Kampen JJA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503244>
74. **Blood Group A Epitopes do not Facilitate Entry of SARS-CoV-2.** J Intern Med 2021; Schetelig J, Baldauf H, Wendler S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501658>
 75. **Vitamin D deficiency is associated with COVID-19 positivity and the severity of the disease.** J Med Virol 2021; Demir M, Demir F, Aygun H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512007>
 76. **Saliva samples for detection of SARS-CoV-2 in mildly symptomatic and asymptomatic patients.** J Med Virol 2021; Ediz Tutuncu E, Ozgur D, Karamese M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501645>
 77. **A rapid and cost-effective multiplex ARMS-PCR method for the simultaneous genotyping of the circulating SARS-CoV-2 phylogenetic clades.** J Med Virol 2021; Islam MT, Alam ARU, Sakib N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491822>
 78. **A rapid and cost-effective multiplex ARMS-PCR method for the simultaneous genotyping of the circulating SARS-CoV-2 phylogenetic clades.** J Med Virol 2021; Islam MT, Ul Alam A, Sakib N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491822>
 79. **Clinical Significance of Cellular Immunity Function and Inflammatory Factors Assays in Alveolar Lavage Fluid for Severe COVID-19 Pneumonia.** J Med Virol 2021; Liao L, Yang GH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506950>
 80. **Kidney injury molecule-1 is a potential receptor for SARS-CoV-2.** J. Mol. Cell. Biol. 2021; Yang C, Zhang Y, Zeng X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493263>
 81. **RT-PCR Combined with CT Examination in the Diagnosis and Prognosis Evaluation of COVID-19 Patients in Fangcang Hospital: A Case Series.** J Multidiscip Healthc 2021; 14:145-149 Zhang JF, Liu J, Ma HN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500623>
 82. **Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey.** J. Nutr. Health Aging 2021; 25:189-196 Karahan S, Katkat F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491033>
 83. **Variability in instructions for performance of nasopharyngeal swabs across Canada in the era of COVID-19 - what type of swab is actually being performed?** J. Otolaryngol. Head Neck Surg. 2021; 50:5 Hiebert NM, Chen BA, Sowerby LJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509292>
 84. **Significance of Hyponatremia Due to SARS-CoV-2 Associated ARDS in Critically Ill Patients.** J Transl Int Med 2020; 8:255-260 Redant S, Vanderhulst J, Maillart E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511052>
 85. **Selection, Identification, and Characterization of SARS-CoV-2 Monoclonal Antibody Resistant Mutants.** J. Virol. Methods 2021; 290:114084 Oladunni FS, Park JG, Chiem K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513380>
 86. **Isolating SARS-CoV-2 Strains From Countries in the Same Meridian: Genome Evolutionary Analysis.** JMIR Bioinform Biotech 2021; 2:e25995 Mastriani E, Rakov AV, Liu SL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497425>
 87. **Biosensors as a future diagnostic approach for COVID-19.** Life Sci 2021; 119:117 Abid SA, Suhail A, Al-Kadmy IMS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508293>

88. **Peripheral Blood Smear Findings of COVID-19 Patients Provide Information about the Severity of the Disease and the Duration of Hospital Stay.** Mediterr. J. Hematol. Infect. Dis. 2021; 13:e2021009Berber I, Cagasar O, Sarici A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489048>
89. **A Comprehensive Review of Detection Methods for SARS-CoV-2.** Microorganisms 2021; 9Eftekhari A, Alipour M, Chodari L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499379>
90. **Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals.** Microorganisms 2021; 9Younes S, Al-Jighefee H, Shurrah F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504067>
91. **How Ivlg Can Mitigate Covid-19 Disease: A Symmetrical Immune Network Model.** Monoclon Antib Immunodiagn Immunother 2021; Kohler H, Kaveri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513050>
92. **A contemporary insight of metabolomics approach for COVID-19: Potential for novel therapeutic and diagnostic targets.** Nepal J Epidemiol 2020; 10:923-927Asim M, Sathian B, Banerjee I, Robinson J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495710>
93. **A systematic review of clinical and laboratory parameters of 3,000 COVID-19 cases.** Obstet Gynecol Sci 2021; Goel H, Gupta I, Mourya M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499580>
94. **Viral Ribonucleic Acid Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic Coronavirus Disease 2019 Patients.** Open Forum Infect Dis 2021; 8:ofaa599Samaddar A, Gadepalli R, Nag VL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506066>
95. **The Utility of Rapid Nucleic Acid Amplification Testing to Triage Symptomatic Patients and to Screen Asymptomatic Preprocedure Patients for SARS-CoV-2.** Open Forum Infect Dis 2021; 8:ofaa607Tworek JA, Khan F, Sekedat MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506068>
96. **Why Temperature Screening for Coronavirus Disease 2019 With Noncontact Infrared Thermometers Does Not Work.** Open Forum Infect Dis 2021; 8:ofaa603Wright WF, Mackowiak PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506067>
97. **Identification and molecular characterization of mutations in nucleocapsid phosphoprotein of SARS-CoV-2.** PeerJ 2021; 9:e10666Azad GK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505806>
98. **Diagnosis of COVID-19 and the bariatric surgery population: a single center experience.** Surg. Endosc. 2021; Romero-Velez G, Pereira X, Skendelas JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492513>
99. **Benefits of COVID-19 viral screening of formerly incarcerated individuals during community reentry.** Ther Adv Infect Dis 2021; 8:2049936120985951Quan NG, Latif H, Krsak M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505680>
100. **Possible involvement of Syndecan-1 in the state of COVID-19 related to endothelial injury.** Thromb J 2021; 19:5Suzuki K, Okada H, Tomita H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504351>
101. **Genotype-phenotype correlation identified a novel SARS-CoV-2 variant possibly linked to severe disease.** Transbound Emerg Dis 2021; Loney T,

- Khansaheb H, Ramaswamy S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506644>
102. **Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study.** *Turk J Haematol* 2021; Anaklif $\pm$ f, Ergin $\sqrt{\text{ñzcan}}$ P, Polat $\tilde{\text{ñ}}$ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486940>
 103. **ABO Blood Types and COVID-19: Spurious, Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data.** *Viruses* 2021; 13Pendur JL, Breiman A, Rocher J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499228>
 104. **Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL(pro) Inhibitors.** *Viruses* 2021; 13Rawson JMO, Duchon A, Nikolaitchik OA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498923>
 105. **ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population.** *Vox Sang* 2021; Bloch EM, Patel EU, Marshall C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493365>
 106. **Quick Olfactory Sniffin' Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients.** *World Allergy Organ J* 2021; 14:100497Bagnasco D, Passalacqua G, Braido F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495704>
 107. **Comparative profile for COVID-19 cases from China and North America: Clinical symptoms, comorbidities and disease biomarkers.** *World J Clin Cases* 2021; 9:118-132Badawi A, Vasileva D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511177>
 108. **Lipidome is lipids regulator in gastrointestinal tract and it is a life collar in COVID-19: A review.** *World J. Gastroenterol.* 2021; 27:37-54Koriem KMM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505149>
 109. **Recommendations of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS) for the implementation of breath tests during the COVID-19 pandemic - November 2020.** *Z. Gastroenterol.* 2020; 58:1274Jansen PL.

Children (27 articles)

1. **Coronary aneurysms, myocardial dysfunction, and shock in a COVID-19 child, role of ECMO, immunomodulation, and cardiac CT.** *Cardiol. Young* 2021; 1-5Mustafa MR, Carter MJ, Wong J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504377>
2. **Takotsubo's syndrome presenting as cardiogenic shock in patients with COVID-19: A case-series and review of current literature.** *Cardiovasc. Revasc. Med.* 2021; Kong N, Singh N, Mazzone S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516638>
3. **New Parents Experienced Lower Parenting Self-Efficacy during the COVID-19 Pandemic Lockdown.** *Children (Basel)* 2021; 8Xue A, Oros V, Marca-Ghaemmaghami P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498886>
4. **Immediate impact of the COVID-19 pandemic on pediatric surgery: analysis of a tertiary healthcare facility.** *Cir. Pediatr.* 2021; 34:34-38Álvarez García N, Núñez

- García B, Pérez-Gaspar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507642>
5. **Pediatric surgical activity during the SARS-CoV-2 pandemic: experience at a tertiary hospital.** *Cir. Pediatr.* 2021; 34:28-33Bada-Bosch I, de Agustín JC, de la Torre M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507641>
 6. **Acute abdomen in COVID-19 disease: the pediatric surgeon's standpoint.** *Cir. Pediatr.* 2021; 34:3-8Rico Espiñeira C, Souto Romero H, Espinosa Góngora R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507637>
 7. **First Reported Nosocomial Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 in a Pediatric Dialysis Unit.** *Clin Infect Dis* 2021; 72:265-270Schwierzeck V, König JC, Kühn J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501962>
 8. **Managing children with brain tumors during the COVID-19 era: Don't stop the care!** *Comput Struct Biotechnol J* 2021; 19:705-709Capozza MA, Triarico S, Attinà G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505640>
 9. **Different Hair Loss Patterns in Two Pediatric Patients with COVID-19 Associated Multisystem Inflammatory Syndrome in Children (MIS-C).** *Dermatol Ther* 2021; Hayran Y, Yorulmaz A, Gür G, Aktaş A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506994>
 10. **Impact of the COVID-19 pandemic on quality of life and mental health in children and adolescents in Germany.** *Eur. Child Adolesc. Psychiatry* 2021; Ravens-Sieberer U, Kaman A, Erhart M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492480>
 11. **Viral co-infections among SARS-CoV-2-infected children and infected adult household contacts.** *Eur. J. Pediatr.* 2021:1-5Pigny F, Wagner N, Rohr M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502627>
 12. **PEDIATRIC BRONCHOSCOPY: RECENT ADVANCES AND CLINICAL CHALLENGES.** *Expert Rev. Respir. Med.* 2021; Goussard P, Pohunek P, Eber E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512252>
 13. **Return-to-School Evaluation Criteria for Children With Suspected Coronavirus Disease 2019.** *Front Public Health* 2020; 8:618642Vlacha V, Feketea GM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490028>
 14. **Epidemiological investigation of a COVID-19 family cluster outbreak transmitted by a 3-month-old infant.** *Health Inf Sci Syst* 2021; 9:6Lin GT, Zhang YH, Xiao MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489103>
 15. **Impact of the COVID-19 pandemic on the Emergency Department of a tertiary children's hospital.** *Ital. J. Pediatr.* 2021; 47:21Raucci U, Musolino AM, Di Lallo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514391>
 16. **Similarities and differences between the immunopathogenesis of COVID-19-related pediatric inflammatory multisystem syndrome and Kawasaki disease.** *J. Clin. Invest.* 2021; Esteve-Sole A, Anton J, Pino-Ramírez RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497356>
 17. **New guidelines for children returning to sports after Covid-19.** *J. Pediatr. Nurs.* 2021; McBride DL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514486>
 18. **Commentary: "How's It Going?" Training Experiences of Pediatric Postdoctoral Fellows During COVID-19.** *J. Pediatr. Psychol.* 2021; Ghosh S, David JG, Amaro CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496725>
 19. **Changes in pediatric trauma during COVID-19 stay-at-home epoch at a tertiary pediatric hospital.** *J. Pediatr. Surg.* 2021; Sanford EL, Zagory J, Blackwell JM *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516579>
20. **COVID-19 in Children with Asthma.** Lung 2021:1-6Chatziparasidis G, Kantar A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496842>
 21. **Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.** Lupus 2021:961203321989791Sukhdeo S, Negroponte E, Rajasekhar H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509065>
 22. **Effects of COVID-19 Lockdown on Otitis Media With Effusion in Children: Future Therapeutic Implications.** Otolaryngol Head Neck Surg 2021:194599820987458Aldv® M, Di Berardino F, Marchisio P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494659>
 23. **An early experience of COVID-19 disease in pediatric and young adult renal transplant recipients.** Pediatr. Transplant. 2021:e13972Solomon S, Pereira T, Samsonov D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502074>
 24. **Addressing the Consequences of the COVID-19 Lockdown for Children's Mental Health: Investing in School Mental Health Programs.** Psychiatr. Serv. 2021:appips202000597Hamoda HM, Chiumento A, Alonge O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502220>
 25. **Psychosocial and clinical effects of the COVID-19 pandemic in patients with childhood rheumatic diseases and their parents.** Rheumatol. Int. 2021:1-9Durcan G, Barut K, Haslak F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502554>
 26. **Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: A French study and literature review.** Rheumatology (Oxford) 2021; Cherqaoui B, Konv©-Paut I, Yager H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493353>
 27. **Clinical analysis and pluripotent stem cells-based model reveal possible impacts of ACE2 and lung progenitor cells on infants vulnerable to COVID-19.** Theranostics 2021; 11:2170-2181Zhang Z, Guo L, Lu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500718>

Clinical Features (26 articles)

1. **Objective evaluation and predictive value of olfactory dysfunction among patients hospitalized with COVID-19.** Auris Nasus Larynx 2021; Mangia LRL, Soares MB, de Souza TSC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509637>
2. **Atypical presentations of coronavirus disease 2019 (COVID-19) from onset to readmission.** BMC Infect. Dis. 2021; 21:127Yang Z, Chen X, Huang R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514323>
3. **Rare cutaneous manifestation of COVID-19.** BMJ Case Rep. 2021; 14Killion L, Beatty PE, Salim A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509895>
4. **Evaluation of patient characteristics, management and outcomes for COVID-19 at district hospitals in the Western Cape, South Africa: descriptive observational study.** BMJ Open 2021; 11:e047016Mash RJ, Presence-Vollenhoven M, Adeniji A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500292>
5. **Phenotypes of severe COVID-19 ARDS receiving extracorporeal membrane oxygenation.** Br J Anaesth 2020; Zhang J, Whebell SF, Sanderson B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487454>

6. **Clinical characteristics, maternal and neonatal outcomes of pregnant women with SARS-CoV-2 infection in Turkey.** Bratisl. Lek. Listy 2021; 122:152-157 Ozsurmeli M, Terzi H, Hocaoglu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502885>
7. **The Ocular Manifestations of COVID-19 Through Conjunctivitis.** Cureus 2020; 12:e12218 Ahuja AS, Farford BA, Forouhi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489624>
8. **Different Hair Loss Patterns in Two Pediatric Patients with COVID-19 Associated Multisystem Inflammatory Syndrome in Children (MIS-C).** Dermatol Ther 2021; Hayran Y, Yorulmaz A, Gür G, Aktaş A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506994>
9. **Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge.** EClinicalMedicine 2021; 31:100683 Raman B, Cassar MP, Tunnicliffe EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490928>
10. **Symptom Profiles and Progression in Hospitalized and Nonhospitalized Patients with Coronavirus Disease, Colorado, USA, 2020.** Emerg Infect Dis 2021; 27:385-395 Vahey GM, Marshall KE, McDonald E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496225>
11. **Covid-19 and acute conjunctivitis: Controversial data from a tertiary referral Italian center.** Eur. J. Ophthalmol. 2021:1120672121991049D'Amico Ricci G, Del Turco C, Belcastro E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499675>
12. **The Relationship Between Positivity for COVID-19 RT-PCR and Symptoms, Clinical Findings, and Mortality in Turkey.** Expert Rev Mol Diagn 2021; Ozcan E, Yavuzer S, Borku Uysal B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496627>
13. **Clinical Characteristics and Diagnostic Challenges of COVID-19: An Update From the Global Perspective.** Front Public Health 2020; 8:567395 Israfil SMH, Sarker MMR, Rashid PT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505949>
14. **The clinical course of smell and taste loss in COVID-19 hospitalized patients.** Hippokratia 2020; 24:66-71 Printza A, Katotomichelakis M, Metallidis S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488054>
15. **Olfactory Dysfunction in COVID-19 Patients: Findings from a Tertiary Rural Centre.** Indian J Otolaryngol Head Neck Surg 2021:1-7 Thakur K, Sagayaraj A, Prasad KC, Gupta A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489853>
16. **Clinical, biological and radiological features, 4-week outcomes and prognostic factors in COVID-19 elderly inpatients.** Infect Dis Now 2021; Palich R, Wakim Y, Itani O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495763>
17. **Clinical and diagnostic findings in COVID-19 patients: an original research from SG Moscati Hospital in Taranto Italy.** J Biol Regul Homeost Agents 2021; 35 Balzanelli M, Distratis P, Catucci O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491346>
18. **Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.** J Med Virol 2021; Nasreddine R, Florence E, Moutschen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506953>
19. **Clinical Features of Asymptomatic SARS-CoV-2 Infection in Hemodialysis Patients.** Kidney Blood Press. Res. 2021:1-9 Pizarro-Sánchez MS, Avello A, Mas-

- Fontao S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503627>
20. **Unforeseen risks in elbow bump - Be careful with the new corona greetings!** MMW-Fortschritte der Medizin 2020; 162:39Hess L.
 21. **A systematic review of clinical and laboratory parameters of 3,000 COVID-19 cases.** Obstet Gynecol Sci 2021; Goel H, Gupta I, Mourya M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499580>
 22. **Retinal Vessel Diameter Changes in COVID-19 Infected Patients.** Ocul Immunol Inflamm 2021;1-7A≈üf±kgarip N, Temel E, Hf±zmal± L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497297>
 23. **[The odor stick identification test for Japanese (OSIT-J) in a case of coronavirus disease 2019 (COVID-19) without pneumonia].** Rinsho Shinkeigaku. 2021; Asahara Y, Mukai T, Suda M, Suzuki M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504752>
 24. **COVID-19 related muscle denervation atrophy.** Skeletal Radiol. 2021; Bahouth S, Chuang K, Olson L, Rosenthal D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517510>
 25. **Comparative profile for COVID-19 cases from China and North America: Clinical symptoms, comorbidities and disease biomarkers.** World J Clin Cases 2021; 9:118-132Badawi A, Vasileva D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511177>
 26. **COVID-19: An overview and a clinical update.** World J Clin Cases 2021; 9:8-23Krishnan A, Hamilton JP, Alqahtani SA, Woreta TA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511168>

CNS (21 articles)

1. **Frontotemporal dementia and COVID-19: Hypothesis generation and roadmap for future research.** Alzheimers Dement (N Y) 2020; 6:e12085Ng KP, Chiew HJ, Hameed S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490361>
2. **COVID 19 with neurological symptoms, rhabdomyolysis and brain death: a case report.** Am J Clin Exp Immunol 2020; 9:114-117Aria A, Forouharnejad K, Mortazavi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489479>
3. **Cochlear implant failure following COVID 19: Report of two cases.** Am. J. Otolaryngol. 2021; 42:102910Saki N, Karimi M, Bayat A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513478>
4. **Resuscitation during the COVID-19 pandemic - Guidelines of the European Resuscitation Council.** Anesthesiologie Intensivmedizin Notfallmedizin Schmerztherapie 2021; 56:5.
5. **[Clinical and anatomical features of SARS-COV-2 with acute hemorrhagic necrotizing encephalopathy].** Arkh. Patol. 2021; 83:35-43Ermilov VV, Barkanov VB, Barkanova ON *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512126>
6. **Objective evaluation and predictive value of olfactory dysfunction among patients hospitalized with COVID-19.** Auris Nasus Larynx 2021; Mangia LRL, Soares MB, de Souza TSC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509637>
7. **Critically ill neurologic patients during the COVID-19 pandemic: A short communication.** Brain Behav Immun Health 2021; 12:100207Shah VA, Nalleballe K, Onteddu SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506229>

8. **Inflammatory leptomeningeal cytokines mediate COVID-19 neurologic symptoms in cancer patients.** *Cancer Cell* 2021; Remsik J, Wilcox JA, Babady NE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508216>
9. **COVID-19 symptoms and SARS-CoV-2 antibody positivity in a large survey of first responders and healthcare personnel, May-July 2020.** *Clin Infect Dis* 2021; Akinbami LJ, Petersen LR, Sami S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515250>
10. **Late-onset rapidly progressive MRI- negative-myelitis after COVID-19 illness.** *Clin. Neurol. Neurosurg.* 2021; 202:106513 Memon AB, Al-Hader R, Patel S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517162>
11. **Neurocognitive deficits in severe COVID-19 infection: Case series and proposed model.** *Clin. Neuropsychol.* 2021:1-20 Whiteside DM, Oleynick V, Holker E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487098>
12. **Persistent Cortical Blindness Following Posterior Reversible Encephalopathy Syndrome (PRES) as a Complication of COVID-19 Pneumonia.** *Cureus* 2021; 13:e12794 Elhassan M, Saidahmed O, Adebayo A, Archibald N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500867>
13. **Epidemiology and Clinical Course of First Wave Coronavirus Disease Cases, Faroe Islands.** *Emerg Infect Dis* 2021; 27: Kristiansen MF, Heimustovu BH, Borg S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513332>
14. **Posterior reversible encephalopathy syndrome and COVID-19: A series of 6 cases from Lombardy, Italy.** *eNeurologicalSci* 2021; 22:100306 Colombo A, Martinelli Boneschi F, Beretta S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490654>
15. **Prevalence and Risk Factors of Anxiety, Depression, and Sleep Problems Among Caregivers of People Living With Neurocognitive Disorders During the COVID-19 Pandemic.** *Front Psychiatry* 2020; 11:590343 Li Q, Zhang H, Zhang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488423>
16. **[The first Hungarian patient with Guillain-Barre syndrome after COVID-19].** *Ideggyogy Sz* 2021; 74:64-66 Al-Muhanna N, Bócsor-Molnár AK, Jarecsny T, Folyovich A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497053>
17. **Olfactory Dysfunction in COVID-19 Patients: Findings from a Tertiary Rural Centre.** *Indian J Otolaryngol Head Neck Surg* 2021:1-7 Thakur K, Sagayaraj A, Prasad KC, Gupta A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489853>
18. **A Missing Link: Engagements of Dendritic Cells in the Pathogenesis of SARS-CoV-2 Infections.** *Int J Mol Sci* 2021; 22: Alamri A, Fisk D, Upreti D, Kung SKP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498725>
19. **The neurological manifestations of COVID-19 - A case series.** *J Clin Transl Res* 2020; 6:187-189 Karambelkar PV, Rojulpote CS, Saeed F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501389>
20. **Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature.** *J. Neurovirol.* 2021; Emamikhah M, Babadi M, Mehrabani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492608>
21. **Parkinson's Disease and the COVID-19 Pandemic.** *J. Parkinsons Dis.* 2021; Fearon C, Fasano A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492244>

Coagulation (24 articles)

1. **Hypercoagulation and myocardial injury as risk factors for mortality in patients with COVID-19 pneumonia.** Am J Emerg Med 2021; Kounis NG, Koniari I, Gogos C, Assimakopoulos SF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494959>
2. **Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study.** Ann Intensive Care 2021; 11:14 Helms J, Severac F, Merdji H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492445>
3. **Our early experience with mesenteric ischemia in COVID-19 positive patients.** Ann. Vasc. Surg. 2021; Mahruqi GA, Stephen E, Abdelhedy I, Al Wahaibi K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508450>
4. **[Clinical and anatomical features of SARS-COV-2 with acute hemorrhagic necrotizing encephalopathy].** Arkh. Patol. 2021; 83:35-43 Ermilov VV, Barkanov VB, Barkanova ON *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512126>
5. **Complex and prolonged hypercoagulability in coronavirus disease 2019 intensive care unit patients: A thromboelastographic study.** Aust. Crit. Care 2020; Cordier PY, Pierrou C, Noel A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509706>
6. **Post COVID-19 sequelae: venous thromboembolism complicated by lower GI bleed.** BMJ Case Rep. 2021; 14 Kumar MA, Krishnaswamy M, Arul JN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504542>
7. **Axillary artery thrombosis resulting in upper limb amputation as a COVID-19 sequela.** BMJ Case Rep. 2021; 14 Ramachandran R, Vasudevan Pillai A, Raja S, Sailesh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500313>
8. **COVID-19 infection produces subarachnoid hemorrhage; acting now to understand its cause: A short communication.** Clin. Neurol. Neurosurg. 2021; 202:106495 Batcik OE, Kanat A, Cankay TU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493886>
9. **Incidence of hemorrhagic cerebrovascular disease due to vascular malformations during the COVID-19 national quarantine in Italy.** Clin. Neurol. Neurosurg. 2021; 202:106503 De Bonis P, Cavallo MA, Sturiale CL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493878>
10. **Pathophysiological Processes Underlying the High Prevalence of Deep Vein Thrombosis in Critically Ill COVID-19 Patients.** Front. Physiol. 2020; 11:608788 Voicu S, Ketfi C, Stăncăpanian A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488398>
11. **Observational study of thrombosis and bleeding in COVID-19 VV ECMO patients.** Int. J. Artif. Organs 2021; 39:1398821989065 Ripoll B, Rubino A, Besser M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506708>
12. **Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients.** Int. J. Lab. Hematol. 2021; Rodríguez Rodríguez M, Castro Quismondo N, Zafra Torres D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502080>
13. **Clinical Experience, Pathophysiology, and Considerations in the Prophylaxis and Treatment of Hypercoagulopathy of COVID-19: A Review Study.** Iran J Med Sci 2021; 46:1-14 Pourafkari L, Mirza-Aghzadeh-Attari M, Zarrintan A, Mousavi-Aghdas SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487787>
14. **Predicting thromboembolic complications in COVID-19 ICU patients using machine learning.** J Clin Transl Res 2020; 6:179-186 van de Sande D, van

- Genderen ME, Rosman B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501388>
15. **Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?** J Microbiol Immunol Infect 2021; Devaux CA, Camoin-Jau L, Mege JL, Raoult D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500211>
 16. **Pulmonary venous thrombosis in a patient with COVID-19 infection.** J. Thromb. Thrombolysis 2021; Pasha AK, Rabinstein A, McBane RD, 2nd. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515360>
 17. **Nonadministration of pharmacologic venous thromboembolism prophylaxis is less common in hospitalized patients with COVID-19.** J. Thromb. Thrombolysis 2021:1-5Varasteh Kia M, Lau BD, Owodunni OP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507453>
 18. **Resolution of Disseminated Intravascular Coagulation in a Patient with COVID-19 and Associated Sepsis-Induced Neutropenia.** Medicina (Kaunas) 2021; 57Di Micco P, Imperato M, Lubrano G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498929>
 19. **Laparoscopic gynecological surgery in COVID 19 pandemic.** Obstet Gynecol Sci 2021; Roy KK, Rai R, Zangmo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499581>
 20. **Subacute Mesenteric Venous Thrombosis secondary to COVID-19: A late thrombotic complication in a non-severe patient.** Radiol Case Rep 2021; Alemv^on W, Cevallos LC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495703>
 21. **[Pulmonary embolism during SARS-CoV-2 pandemic: clinical and radiological features].** Rev Clin Esp 2021; Garcv/a-Lledv/≥ A, Del Palacio-Salgado M, v/Álvarez-Sanz C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495655>
 22. **[COVID-19: Coagulopathy and thrombosis].** Rev. Med. Interne 2021; Tazi Mezalek Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509669>
 23. **Management and Prevention of Cerebrovascular Accidents in SARS-CoV-2-Positive Patients Recovering from COVID-19: a Case Report and Review of Literature.** SN Compr Clin Med 2021:1-12Yeganegi M, Fattahi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490876>
 24. **Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study.** Turk J Haematol 2021; Anaklf± f, Ergin v/ñzcan P, Polat ñ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486940>

Complications (67 articles)

1. **Review of Anesthesia Versus Intensive Care Unit Ventilators and Ventilatory Strategies: COVID-19 Patient Management Implications.** AANA J. 2021; 89:62-69Jackson K, Wands B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501910>
2. **Characteristics, management and survival of ICU patients with coronavirus disease-19 in Norway, March - June 2020. A prospective observational study.** Acta Anaesthesiol. Scand. 2021; Laake JH, Buanes EA, Småstuen MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501998>
3. **An unorthodox pathophysiology of severe cases of COVID-19 the weak heme hypothesis.** Am. J. Blood Res. 2020; 10:305-310Zamd M, Mtioui N, Maoujoud O, Ramdani B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489438>

4. **COVID 19 with neurological symptoms, rhabdomyolysis and brain death: a case report.** Am J Clin Exp Immunol 2020; 9:114-117Aria A, Forouharnejad K, Mortazavi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489479>
5. **Resuscitation during the COVID-19 pandemic - Guidelines of the European Resuscitation Council.** Anesthesiologie Intensivmedizin Notfallmedizin Schmerztherapie 2021; 56:5.
6. **Increased susceptibility to intensive care unit-acquired pneumonia in severe COVID-19 patients: a multicentre retrospective cohort study.** Ann Intensive Care 2021; 11:20Litjens JF, Bredin S, Lascarrou JB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512602>
7. **Spontaneous ilio-psoas haematomas (IPHs): a warning for COVID-19 inpatients.** Ann. Med. 2021; 53:295-301Vergori A, Pianura E, Lorenzini P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491498>
8. **COVID-19 and active primary tuberculosis in a low-resource setting: A case report.** Ann Med Surg (Lond) 2021; 62:80-83Baskara MA, Makrufardi F, Dinisari A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505676>
9. **Response to: 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis' by Lee.** Ann. Rheum. Dis. 2021; Akiyama S, Hamdeh S, Micic D, Sakuraba A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504478>
10. **The CB index predicts prognosis of critically ill COVID-19 patients.** Ann Transl Med 2020; 8:1654Cao L, Zhang S, Wang E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490166>
11. **Our early experience with mesenteric ischemia in COVID-19 positive patients.** Ann. Vasc. Surg. 2021; Mahruqi GA, Stephen E, Abdelhedy I, Al Wahaibi K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508450>
12. **Antimicrobial multidrug resistance in the era of COVID-19: a forgotten plight?** Antimicrob Resist Infect Control 2021; 10:21Pelfrene E, Botgros R, Cavaleri M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514424>
13. **Complex and prolonged hypercoagulability in coronavirus disease 2019 intensive care unit patients: A thromboelastographic study.** Aust. Crit. Care 2020; Cordier PY, Pierrou C, Noel A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509706>
14. **The evaluation of maximum condyle-tragus distance can predict difficult airway management without exposing upper respiratory tract; a prospective observational study.** BMC Anesthesiol. 2021; 21:28Wu H, Hu D, Chen X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494705>
15. **Severe COVID-19 with acute respiratory distress syndrome (ARDS) in a sickle cell disease adult patient: case report.** BMC Pulm. Med. 2021; 21:46Teulier M, Elabbadi A, Gerotziakas G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514354>
16. **Post COVID-19 sequelae: venous thromboembolism complicated by lower GI bleed.** BMJ Case Rep. 2021; 14Kumar MA, Krishnaswamy M, Arul JN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504542>
17. **Axillary artery thrombosis resulting in upper limb amputation as a COVID-19 sequela.** BMJ Case Rep. 2021; 14Ramachandran R, Vasudevan Pillai A, Raja S, Sailesh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500313>
18. **Phenotypes of severe COVID-19 ARDS receiving extracorporeal membrane oxygenation.** Br J Anaesth 2020; Zhang J, Whebell SF, Sanderson B *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487454>
19. **Coronary aneurysms, myocardial dysfunction, and shock in a COVID-19 child, role of ECMO, immunomodulation, and cardiac CT.** Cardiol. Young 2021;1-5 Mustafa MR, Carter MJ, Wong J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504377>
 20. **[Triage recommendations of the specialist societies : Background, summary and comments].** Chirurg 2021;1-5 Dutzmann J, Michalsen A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511439>
 21. **Management of life-threatening acute respiratory syndrome and severe pneumonia secondary to COVID-19 in pregnancy: A case report and literature review.** Clin Case Rep 2021; 9:137-143 Yaqoub S, Ahmad S, Mansouri Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489149>
 22. **Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity.** Clin Infect Dis 2021; 72:301-308 Lynch KL, Whitman JD, Lacanienta NP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501951>
 23. **Diabetic Ketoacidosis on Hospitalization with COVID-19 in a Previously Nondiabetic Patient: A Review of Pathophysiology.** Clin Med Insights Endocrinol Diabetes 2020; 13:1179551420984125 Eskandarani RM, Sawan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488135>
 24. **Incidence of hemorrhagic cerebrovascular disease due to vascular malformations during the COVID-19 national quarantine in Italy.** Clin. Neurol. Neurosurg 2021; 202:106503 De Bonis P, Cavallo MA, Sturiale CL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493878>
 25. **A Case of Post-COVID-19 Subacute Thyroiditis.** Cureus 2020; 12:e12301 Mehmood MA, Bapna M, Arshad M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510992>
 26. **Esophageal Rupture Associated With COVID-19: A Novel Case Report.** Cureus 2020; 12:e12256 Meloy P, Bhambri A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510977>
 27. **Anti-Glomerular Basement Membrane Disease as a Potential Complication of COVID-19: A Case Report and Review of Literature.** Cureus 2020; 12:e12089 Nahhal S, Halawi A, Basma H, Sr. *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489507>
 28. **SARS-CoV-2 Associated With Pneumothorax: A Case Report and Literature Review.** Cureus 2020; 12:e12191 Younes I, Mohammadian M, Elkattawy S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489601>
 29. **SARS-CoV-2 and Systemic Lupus Erythematosus.** Curr. Rheumatol. Rep. 2021; 23:8 Thanou A, Sawalha AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511495>
 30. **Viral co-infections among SARS-CoV-2-infected children and infected adult household contacts.** Eur. J. Pediatr. 2021;1-5 Pigny F, Wagner N, Rohr M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502627>
 31. **Bronchiolitis in COVID-19 times: a nearly absent disease?** Eur. J. Pediatr. 2021; Van Brusselen D, De Troeyer K, Ter Haar E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517482>
 32. **Room to Breathe: The Impact of Oxygen Rationing on Health Outcomes in SARS-CoV2.** Front Med (Lausanne) 2020; 7:573037 Goyal DK, Mansab F, Bhatti S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490094>

33. **Extracorporeal Membrane Oxygenation for SARS-CoV-2 Acute Respiratory Distress Syndrome: A Retrospective Study From Hubei, China.** *Front Med (Lausanne)* 2020; 7:611460 Yang X, Hu M, Yu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511146>
34. **Pathophysiological Processes Underlying the High Prevalence of Deep Vein Thrombosis in Critically Ill COVID-19 Patients.** *Front. Physiol.* 2020; 11:608788 Voicu S, Ketfi C, Stăncăpanian A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488398>
35. **Invasive Aspergillosis Associated with severe COVID-19: A Word of Caution.** *Infect Dis Now* 2021; Gouzien L, Cocherie T, Eloy O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490993>
36. **Machine learning predictive model for severe COVID-19.** *Infect Genet Evol* 2021:104737 Kang J, Chen T, Luo H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515712>
37. **Observational study of thrombosis and bleeding in COVID-19 VV ECMO patients.** *Int. J. Artif. Organs* 2021:391398821989065 Ripoll B, Rubino A, Besser M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506708>
38. **COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network.** *Intensive Care Med* 2021:1-8 Buetti N, Ruckly S, de Montmollin E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506379>
39. **A new approach to airway assessment-"Line of Sight" and more. Recommendations of the Task Force of Airway Management Foundation (AMF).** *J. Anaesthesiol. Clin. Pharmacol.* 2020; 36:303-315 Kumar R, Kumar S, Misra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487896>
40. **Multi-Organ Involvement in COVID-19: Beyond Pulmonary Manifestations.** *J Clin Med* 2021; 10Thakur V, Ratho RK, Kumar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498861>
41. **Predicting thromboembolic complications in COVID-19 ICU patients using machine learning.** *J Clin Transl Res* 2020; 6:179-186 van de Sande D, van Genderen ME, Rosman B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501388>
42. **A Rare Case of SARS-CoV-2 Infection Associated With Pituitary Apoplexy Without Comorbidities.** *J Endocr Soc* 2021; 5:bvaa203 Ghosh R, Roy D, Roy D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501401>
43. **Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy.** *J Fungi (Basel)* 2021; 7Zurl C, Hoenigl M, Schulz E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513875>
44. **SARS-CoV-2 infection in patients with autoimmune hepatitis.** *J Hepatol* 2021; Marjot T, Buescher G, Sebode M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508378>
45. **Prediction of patients requiring intensive care for COVID-19: development and validation of an integer-based score using data from Centers for Disease Control and Prevention of South Korea.** *J Intensive Care* 2021; 9:16 Heo J, Han D, Kim HJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514443>
46. **COVID-19 myopericarditis with cardiac tamponade in the absence of respiratory symptoms: a case report.** *J Med Case Rep* 2021; 15:31 Cairns L,

- Abed El Khaleq Y, Storrar W, Scheuermann-Freestone M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33494822>
47. **Systemic lupus erythematosus manifestation following COVID-19: a case report.** *J Med Case Rep* 2021; 15:29Zamani B, Moeini Taba SM, Shayestehpour M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33494816>
 48. **Susceptibility-weighted imaging reveals cerebral microvascular injury in severe COVID-19.** *J Neurol Sci* 2021; 421:117308Conklin J, Frosch MP, Mukerji SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497950>
 49. **Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature.** *J. Neurovirol.* 2021; Emamikhah M, Babadi M, Mehrabani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492608>
 50. **Pulmonary venous thrombosis in a patient with COVID-19 infection.** *J. Thromb. Thrombolysis* 2021; Pasha AK, Rabinstein A, McBane RD, 2nd.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33515360>
 51. **Nonadministration of pharmacologic venous thromboembolism prophylaxis is less common in hospitalized patients with COVID-19.** *J. Thromb. Thrombolysis* 2021:1-5Varasteh Kia M, Lau BD, Owodunni OP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33507453>
 52. **A case of urgent colonoscopic hemostasis of a cecal hemorrhagic ulceration in a patient receiving heparin for COVID-19 coagulopathy.** *JGH Open* 2021; 5:160-162Yoshida N, Hirose R, Watanabe M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33490630>
 53. **Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.** *Lupus* 2021:961203321989791Sukhdeo S, NegroponTE E, Rajasekhar H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509065>
 54. **Resolution of Disseminated Intravascular Coagulation in a Patient with COVID-19 and Associated Sepsis-Induced Neutropenia.** *Medicina (Kaunas)* 2021; 57Di Micco P, Imperato M, Lubrano G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498929>
 55. **Case Report: Massive Spontaneous Pneumothorax-A Rare Form of Presentation for Severe COVID-19 Pneumonia.** *Medicina (Kaunas)* 2021; 57Marza AM, Petrica A, Buleu FN, Mederle OA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33498180>
 56. **Coronavirus Disease 2019 (COVID-19) Severity in Patients with Thalassemias: A Nationwide Iranian Experience.** *Mediterr. J. Hematol. Infect. Dis.* 2021; 13:e2021008Karimi M, Haghpahan S, Azarkeivan A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33489047>
 57. **The incidence of arm, forearm, and hip osteoporotic fractures during early stage of COVID-19 pandemic.** *Osteoporos. Int.* 2021; Pluskiewicz W, Wilk R, Adamczyk P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515269>
 58. **Predictors of intubation in COVID-19 patients treated with out-of-ICU continuous positive airway pressure.** *Pulmonology* 2021; De Vita N, Scotti L, Cammarota G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500220>
 59. **Non-invasive respiratory support paths in hospitalized patients with COVID-19: proposal of an algorithm.** *Pulmonology* 2021; Winck JC, Scala R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33516668>
 60. **Subacute Mesenteric Venous Thrombosis secondary to COVID-19: A late thrombotic complication in a non-severe patient.** *Radiol Case Rep* 2021;

- Alemv^on W, Cevallos LC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495703>
61. **Immunosuppression in kidney transplant recipients with COVID-19 infection - where do we stand and where are we heading?** *Ren. Fail.* 2021; 43:273-280 Daoud A, Alqassieh A, Alkhader D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491531>
 62. **Development of acute kidney injury with massive granular casts and microscopic hematuria in patients with COVID-19: two case presentations with literature review.** *Ren Replace Ther* 2020; 6:59 Fujimaru T, Shimada K, Hamada T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510902>
 63. **COVID-19 promoting the development of active tuberculosis in a patient with latent tuberculosis infection: A case report.** *Respir Med Case Rep* 2021; 32:101344 Khayat M, Fan H, Vali Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495728>
 64. **[Pulmonary embolism during SARS-CoV-2 pandemic: clinical and radiological features].** *Rev Clin Esp* 2021; Garcv[√]a-Lledv[√]z A, Del Palacio-Salgado M, v[√]lvarez-Sanz C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495655>
 65. **[COVID-19: Coagulopathy and thrombosis].** *Rev. Med. Interne* 2021; Tazi Mezalek Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509669>
 66. **Syndemics & syndemogenesis in COVID-19 and rheumatic and musculoskeletal diseases: old challenges, new era.** *Rheumatology (Oxford)* 2021; Nikiphorou E, Alpizar-Rodriguez D, Gastelum-Strozzi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496334>
 67. **Utilization of extracorporeal membrane oxygenation during the COVID-19 pandemic.** *World J Crit Care Med* 2021; 10:1-11 Kichloo A, Kumar A, Amir R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505868>

Cured – Recovered (11 articles)

1. **Post-COVID-19 Syndrome (PC19S): Chronic Reactive Endotheliitis and Disseminated Vascular Disease.** *Acta Med Port* 2020; 33:859Lv[√]pez Castro J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496258>
2. **Enhanced recovery: joining the dots.** *Br J Anaesth* 2021; Fawcett WJ, Mythen MG, Scott MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516456>
3. **Nutritional status assessment in patients with Covid-19 after discharge from the intensive care unit.** *Clin Nutr ESPEN* 2021; 41:423-428 Haraj NE, El Aziz S, Chadli A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487301>
4. **A Case of Post-COVID-19 Subacute Thyroiditis.** *Cureus* 2020; 12:e12301 Mehmood MA, Bapna M, Arshad M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510992>
5. **(18)F-FDG brain PET hypometabolism in patients with long COVID.** *Eur J Nucl Med Mol Imaging* 2021:1-11 Guedj E, Campion JY, Dudouet P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501506>
6. **Prevalence of psychiatric morbidity following discharge after COVID-19 hospitalization.** *Gen. Hosp. Psychiatry* 2020; Wang PR, Oyem PC, Viguera AC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494979>
7. **A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations.** *Infect Dis (Lond)* 2021:1-10 Piri SM, Edalatfar M, Shool S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508989>

8. **Management and Prevention of Cerebrovascular Accidents in SARS-CoV-2-Positive Patients Recovering from COVID-19: a Case Report and Review of Literature.** *SN Compr Clin Med* 2021;1-12 Yeganegi M, Fattahi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490876>

Cardiovascular disease (51 articles)

1. **The Impact of COVID-19 on Elective Cardiovascular Procedures in Taiwan - A Single-Center Experience.** *Acta Cardiol Sin* 2021; 37:97-99 Liao CT, Chen ZC, Chang WT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488032>
2. **Cardiovascular Complications of COVID-19 and Associated Concerns: A Review.** *Acta Cardiol Sin* 2021; 37:9-17 Yu WL, Toh HS, Liao CT, Chang WT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488023>
3. **Widespread myocardial dysfunction in COVID-19 patients detected by myocardial strain imaging using 2-D speckle-tracking echocardiography.** *Acta Pharmacol. Sin.* 2021;1-8 Li R, Wang H, Ma F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510459>
4. **Thrombocytopoiesis and myocardial injury as risk factors for mortality in patients with COVID-19 pneumonia.** *Am J Emerg Med* 2021; Kounis NG, Koniari I, Gogos C, Assimakopoulos SF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494959>
5. **The value of ECG changes in risk stratification of COVID-19 patients.** *Ann. Noninvasive Electrocardiol.* 2021:e12815 Bergamaschi L, D'Angelo EC, Paolisso P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512742>
6. **Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey.** *Ann. Rheum. Dis.* 2021; Campochiaro C, Trignani G, Tomelleri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509795>
7. **Our early experience with mesenteric ischemia in COVID-19 positive patients.** *Ann. Vasc. Surg.* 2021; Mahruqi GA, Stephen E, Abdelhedy I, Al Wahaibi K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508450>
8. **OUTCOMES AFTER VASCULAR SURGERY PROCEDURES IN PATIENTS WITH COVID-19 INFECTION: A NATIONAL MULTICENTRE COHORT STUDY (COVID-VAS).** *Ann. Vasc. Surg.* 2021; San Norberto EM, De Haro J, Peña R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493590>
9. **Electrocardiography in Early Diagnosis of Cardiovascular Complications of COVID-19; a Systematic Literature Review.** *Arch Acad Emerg Med* 2021; 9:e10 Nemat R, Ganjoo M, Jadidi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490967>
10. **[Clinical and anatomical features of SARS-COV-2 with acute hemorrhagic necrotizing encephalopathy].** *Arkh. Patol.* 2021; 83:35-43 Ermilov VV, Barkanov VB, Barkanova ON *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512126>
11. **Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.** *BMC Infect. Dis.* 2021; 21:114 Wang W, Zhao X, Wei W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494713>
12. **Stroke etiologies in patients with COVID-19: the SVIN COVID-19 multinational registry.** *BMC Neurol.* 2021; 21:43 Ramos-Araque ME, Siegler JE, Ribo M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514335>

13. **No association between use of ACE inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEDicaTion (COMET) study.** Br. J. Clin. Pharmacol. 2021; Sablerolles RSG, Hogenhuis FEF, Lafeber M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507556>
14. **Coronary aneurysms, myocardial dysfunction, and shock in a COVID-19 child, role of ECMO, immunomodulation, and cardiac CT.** Cardiol. Young 2021;1-5 Mustafa MR, Carter MJ, Wong J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504377>
15. **Cardiac manifestation of corona virus disease 2019: a preliminary report.** Cardiovasc. J. Afr. 2021; 32:1-4 Lasisi GT, Duro-Emanuel AO, Akintomide TE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506856>
16. **Takotsubo's syndrome presenting as cardiogenic shock in patients with COVID-19: A case-series and review of current literature.** Cardiovasc. Revasc. Med. 2021; Kong N, Singh N, Mazzone S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516638>
17. **Pediatric surgical activity during the SARS-CoV-2 pandemic: experience at a tertiary hospital.** Cir. Pediatr. 2021; 34:28-33 Bada-Bosch I, de Agustín JC, de la Torre M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507641>
18. **Clinical significance of coronavirus disease 2019 in hospitalized patients with myocardial injury.** Clin. Cardiol. 2021; Briscoe M, Sykes R, Krystofiak T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501708>
19. **Hospitalization deficit of in- and outpatient cases with cardiovascular diseases and utilization of cardiological interventions during the COVID-19 pandemic: Insights from the German-wide helios hospital network.** Clin. Cardiol. 2021; K $\ddot{u}$ hnig S, Ueberham L, Pellissier V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497509>
20. **COVID-19 infection produces subarachnoid hemorrhage; acting now to understand its cause: A short communication.** Clin. Neurol. Neurosurg. 2021; 202:106495 Batick OE, Kanat A, Cankay TU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493886>
21. **Incidence of hemorrhagic cerebrovascular disease due to vascular malformations during the COVID-19 national quarantine in Italy.** Clin. Neurol. Neurosurg. 2021; 202:106503 De Bonis P, Cavallo MA, Sturiale CL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493878>
22. **RAAS blockade and COVID-19: Mechanistic Modeling of mas and AT1 Receptor Occupancy as Indicators of Pro- and Anti-Inflammatory Balance.** Clin Pharmacol Ther 2021; Hallow KM, Dave I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506503>
23. **ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease.** Clin Sci (Lond) 2021; 135:387-407 Kuriakose J, Montezano AC, Touyz RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511992>
24. **Worsening of heart failure by coronavirus disease 2019 is associated with high mortality.** ESC Heart Fail 2021; Bocchi EA, Lima I, Biselli B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498096>
25. **Association of ACE inhibitors and Angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: a pathway-based analytical study.** Eur. J. Pharmacol. 2021:173899 Parit R, Jayavel S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508281>

26. **Case Report: Emergency CABG Following Failure of PTCA in a COVID-19 Patient.** Front Cardiovasc Med 2020; 7:620610Romiti S, Totaro M, Laderchi A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33505996>
27. **Pre-existing Health Conditions and Epicardial Adipose Tissue Volume: Potential Risk Factors for Myocardial Injury in COVID-19 Patients.** Front Cardiovasc Med 2020; 7:585220Wei ZY, Qiao R, Chen J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33505992>
28. **Pathophysiological Processes Underlying the High Prevalence of Deep Vein Thrombosis in Critically Ill COVID-19 Patients.** Front. Physiol. 2020; 11:608788Voicu S, Ketfi C, Stv©panian A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33488398>
29. **Atrial Fibrillation is an Independent Predictor for In-hospital Mortality in Patients Admitted with SARS-CoV-2 Infection.** Heart Rhythm 2021; Mountantonakis SE, Saleh M, Fishbein J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33493650>
30. **Impact of the COVID-19 pandemic on phase 2 cardiac rehabilitation patients in Japan.** Heart Vessels 2021;1-6Ogura A, Izawa KP, Tawa H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33512598>
31. **Left and right ventricular dysfunction in patients with COVID-19-associated myocardial injury.** Infection 2021; Bieber S, Kraechan A, Hellmuth JC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33515390>
32. **COVID-19 and STEMI: The role of telecardiology in the management of STEMI diagnosis during COVID 19 pandemic.** Int J Cardiol Heart Vasc 2021; 32:100720De Bonis S, Salerno N, Bisignani A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33501370>
33. **Rapid Learning of Focused Cardiac Ultrasound for Early Identification of COVID-19 Complications: A Collaborative Effort.** J. Am. Soc. Echocardiogr. 2021; Sertich AP, 3rd, Singh K, Alzubaidy D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33493552>
34. **Patch Monitors for Arrhythmia Monitoring in Patients for Suspected Inherited Arrhythmia Syndrome.** J Cardiovasc Electrophysiol 2021; Cheung CC, Davies B, Gibbs K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512057>
35. **Things You Should Know in the Performing Echocardiographic Examination in Patients with COVID-19.** J Cardiovasc Imaging 2021; 29:20-30Choi JH, Park JH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33511797>
36. **Increased post myocardial infarction complications in COVID-19 outbreak: Is it dilemma?** J Cardiovasc Thorac Res 2020; 12:345-346Alizadehasl A, Mohebbi B, Habibi Khorasani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510887>
37. **Interactions between hypertension and inflammatory tone and the effect on blood pressure and outcomes in patients with COVID-19.** J. Clin. Hypertens. (Greenwich) 2021; Amar J, Touront N, Ciron AM, Pendaries C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33491247>
38. **Similarities and differences between the immunopathogenesis of COVID-19-related pediatric inflammatory multisystem syndrome and Kawasaki disease.** J. Clin. Invest. 2021; Esteve-Sole A, Anton J, Pino-Ram√rez RM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33497356>
39. **Predicting thromboembolic complications in COVID-19 ICU patients using machine learning.** J Clin Transl Res 2020; 6:179-186van de Sande D, van

- Genderen ME, Rosman B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501388>
40. **COVID-19 myopericarditis with cardiac tamponade in the absence of respiratory symptoms: a case report.** *J Med Case Rep* 2021; 15:31 Cairns L, Abed El Khaleq Y, Storrar W, Scheuermann-Freestone M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494822>
 41. **A parsimonious approach for recognizing SARS-CoV-2 and host interactions.** *J Med Virol* 2021; Ganguly B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506962>
 42. **Susceptibility-weighted imaging reveals cerebral microvascular injury in severe COVID-19.** *J Neurol Sci* 2021; 421:117308 Conklin J, Frosch MP, Mukerji SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497950>
 43. **Comprehensive Echocardiographic Findings in Critically Ill COVID-19 Patients With or Without Prior Cardiac Disease.** *J Patient Cent Res Rev* 2021; 8:68-76 Jain R, Salinas PD, Kroboth S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511256>
 44. **Pulmonary venous thrombosis in a patient with COVID-19 infection.** *J. Thromb. Thrombolysis* 2021; Pasha AK, Rabinstein A, McBane RD, 2nd. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515360>
 45. **From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.** *Molecules* 2021; 26 Matsoukas J, Apostolopoulos V, Zulli A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504092>
 46. **Anxiety levels in patients admitted to the emergency department with myocardial infarction or COVID-19 pneumonia.** *Psychol Health Med* 2021; 1-9 Vafar A, Kaviraj *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486994>
 47. **In-Hospital Cardiac Arrest in Patients with Coronavirus 2019.** *Resuscitation* 2021; Mitchell OJL, Yuriditsky E, Johnson NJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515638>
 48. **Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: A French study and literature review.** *Rheumatology (Oxford)* 2021; Cherqaoui B, Konstantinides P, Yager H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493353>
 49. **Management and Prevention of Cerebrovascular Accidents in SARS-CoV-2-Positive Patients Recovering from COVID-19: a Case Report and Review of Literature.** *SN Compr Clin Med* 2021; 1-12 Yeganegi M, Fattahi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490876>
 50. **Mechanisms of thrombosis and cardiovascular complications in COVID-19.** *Thromb Res* 2021; 200:1-8 Page EM, Arivazhagan RAS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493983>
 51. **Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension.** *World J Clin Cases* 2021; 9:47-60 Tian C, Li N, Bai Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511171>

Diagnosis (8 articles)

1. **COVID-19 Diagnosis via DenseNet and Optimization of Transfer Learning Setting.** *Cognit. Comput.* 2021; 1-17 Zhang YD, Satapathy SC, Zhang X, Wang SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488837>

2. **An Incidental Diagnosis of SARS-CoV-2 Pneumonia With Magnetic Resonance Imaging.** Cureus 2020; 12:e12115 Di Girolamo M, Muscogiuri E, Zucchelli A, Laghi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489530>
3. **COVID-19 Impact on Diagnostic Innovations: Emerging Trends and Implications.** Diagnostics (Basel) 2021; 11 Oyewole AO, Barrass L, Robertson EG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513988>
4. **Clinical Characteristics and Diagnostic Challenges of COVID-19: An Update From the Global Perspective.** Front Public Health 2020; 8:567395 Israfil SMH, Sarker MMR, Rashid PT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505949>
5. **Machine and Deep Learning towards COVID-19 Diagnosis and Treatment: Survey, Challenges, and Future Directions.** Int J Environ Res Public Health 2021; 18 Alafif T, Tehame AM, Bajaba S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513984>
6. **Clinical and diagnostic findings in COVID-19 patients: an original research from SG Moscati Hospital in Taranto Italy.** J Biol Regul Homeost Agents 2021; 35 Balzanelli M, Distratis P, Catucci O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491346>
7. **A Novel Block Imaging Technique Using Nine Artificial Intelligence Models for COVID-19 Disease Classification, Characterization and Severity Measurement in Lung Computed Tomography Scans on an Italian Cohort.** J Med Syst 2021; 45:28 Agarwal M, Saba L, Gupta SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496876>
8. **COVID-19 or non-COVID viral pneumonia: How to differentiate based on the radiologic findings?** World J Radiol 2020; 12:289-301 Eslambolchi A, Maliglig A, Gupta A, Gholamrezanezhad A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510853>

DM-MS-Obesity (12 articles)

1. **Diabetic Ketoacidosis on Hospitalization with COVID-19 in a Previously Nondiabetic Patient: A Review of Pathophysiology.** Clin Med Insights Endocrinol Diabetes 2020; 13:1179551420984125 Eskandarani RM, Sawan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488135>
2. **Facilitators and Barriers to Nursing Implementation of Continuous Glucose Monitoring (CGM) in Critically Ill COVID-19 Patients.** Endocr. Pract. 2021; Faulds ER, Jones L, McNett M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515756>
3. **Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity.** Endocrine 2021; De Groot CJ, Poitou Bernert C, Coupaye M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512658>
4. **Blood biochemical parameters for assessment of COVID-19 in diabetic and non-diabetic subjects: a cross-sectional study.** Int. J. Environ. Health Res. 2021:1-14 Malik SUF, Chowdhury PA, Hakim A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504213>
5. **The Obesity Paradox Predicts the Second Wave of COVID-19 to Be Severe in Western Countries.** Int J Environ Res Public Health 2021; 18 Krams IA, Jöers P, Luoto S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503828>

6. **Obesity considerations during the COVID-19 outbreak.** Int. J. Vitam. Nutr. Res. 2021;1:1-13Dohet F, Loap S, Menzel A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499680>
7. **Robust neutralizing antibodies to SARS-CoV-2 develop and persist in subjects with diabetes and COVID-19 pneumonia.** J. Clin. Endocrinol. Metab. 2021; Dispinseri S, Lampasona V, Secchi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513242>
8. **Limiting the Use of Oral Glucose Tolerance Tests to Screen for Hyperglycemia in Pregnancy during Pandemics.** J Clin Med 2021; 10Nachtergaele C, Vicaut E, Tatulashvili S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494289>
9. **Diabetic Foot Disease during the COVID-19 Pandemic.** Medicina (Kaunas) 2021; 57Boulton AJM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499251>
10. **COVID-19 severity in obese patients: Potential mechanisms and molecular targets for clinical intervention.** Obes. Res. Clin. Pract. 2021; Sharma JR, Yadav UCS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509701>
11. **COVID-19 Vaccination and Obesity: Optimism and Challenges.** Obesity (Silver Spring) 2021; Townsend MJ, Kyle TK, Stanford FC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506642>
12. **[The odor stick identification test for Japanese (OSIT-J) in a case of coronavirus disease 2019 (COVID-19) without pneumonia].** Rinsho Shinkeigaku. 2021; Asahara Y, Mukai T, Suda M, Suzuki M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504752>

Education and training and science (43 articles)

1. **Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium.** Asia Pac. J. Clin. Oncol. 2021; Shimizu T, Kim DW, Loong HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502085>
2. **HIV prevention research and COVID-19: putting ethics guidance to the test.** BMC Med. Ethics 2021; 22:6Rennie S, Chege W, Schrupf LA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494754>
3. **Combating the COVID-19 infodemic: a three-level approach for low and middle-income countries.** BMJ Glob Health 2021; 6Dash S, Parray AA, De Freitas L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514596>
4. **Strengthening regulatory systems for medicines in a changed world: where do we go from here?** BMJ Glob Health 2021; 6O'Brien J, Lumsden R, Macdonald J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495287>
5. **A new option for education in surgical procedures and related clinical anatomy in a virtual reality workspace.** Clin Anat 2021; Iwanaga J, Kamura Y, Nishimura Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502787>
6. **Medical student education in the time of COVID-19: A virtual solution to the introductory radiology elective.** Clin Imaging 2021; 75:67-74Belfi LM, Dean KE, Bartolotta RJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497880>
7. **Collaborative platform trials to fight COVID-19: methodological and regulatory considerations for a better societal outcome.** Clin Pharmacol Ther 2021; Collignon O, Burman CF, Posch M, Schiel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506495>

8. **Faculty Respond to COVID-19: Reflections-on-Action in Field Education.** Clin. Soc. Work J. 2021;1-11 Dempsey A, Lanzieri N, Luce V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33500593>
9. **COVID-19 Diagnosis via DenseNet and Optimization of Transfer Learning Setting.** Cognit. Comput. 2021;1-17 Zhang YD, Satapathy SC, Zhang X, Wang SH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33488837>
10. **Novel Modifications for a Virtual Interview Visit to Simulate the Traditional, Live, Site Visit for GI Fellowship Applicants for an Academic GI Fellowship Program Due to the COVID-19 Pandemic.** Dig. Dis. Sci. 2021;1-2 Cappell MS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33496874>
11. **COULD THE COVID-19 PANDEMIC BE AN OPPORTUNITY FOR IMPROVEMENT OF OUR CARE, TRAINING AND RESEARCH ACTIVITIES?** Endocrinol Diabetes Nutr 2021; 68:79-81 Escalada J, Pérez A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516387>
12. **Adaptability Promotes Student Engagement Under COVID-19: The Multiple Mediating Effects of Academic Emotion.** Front. Psychol. 2020; 11:633265 Zhang K, Wu S, Xu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488491>
13. **Return-to-School Evaluation Criteria for Children With Suspected Coronavirus Disease 2019.** Front Public Health 2020; 8:618642 Vlacha V, Feketea GM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33490028>
14. **Assessment of Awareness and Knowledge on Novel Coronavirus (COVID-19) Pandemic among Seafarers.** Healthcare (Basel) 2021; 9 Battineni G, Sagaro GG, Chintalapudi N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503921>
15. **[Effects of the SARS-CoV-2 pandemic on the otolaryngology university hospitals in the field of research, student teaching and specialist training].** HNO 2021;1-9 Stöver T, Dazert S, Plontke SK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33502578>
16. **Implementing a National Approach to Research Ethics Review during a Pandemic - the Irish Experience.** HRB Open Res 2020; 3:63 Sheehy A, Ralph James J, Horgan M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490861>
17. **Lack of viable SARS-CoV-2 among PCR-positive air samples from hospital rooms and community isolation facilities.** Infect Control Hosp Epidemiol 2021;1-17 Ong SWX, Tan YK, Coleman KK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487210>
18. **The Role of Infectious Disease trainees during the first wave of the COVID-19 pandemic: a national survey.** Infect Dis Now 2021; Bouiller K, Catho G, Marvchal ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495762>
19. **Regional COVID-19 registry in Khuzestan, Iran: A study protocol and lessons learned from a pilot implementation.** Inform Med Unlocked 2021;100520 Zarei J, Dastoorpoor M, Jamshidnezhad A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495736>
20. **Psychological Wellbeing and Academic Experience of University Students in Australia during COVID-19.** Int J Environ Res Public Health 2021; 18 Dodd RH, Dadaczynski K, Okan O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498376>
21. **A Bibliometric Network Analysis of Coronavirus during the First Eight Months of COVID-19 in 2020.** Int J Environ Res Public Health 2021; 18 Furstenu LB, Rabaioli B, Sott MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499127>
22. **COVID-19 pandemic effects on nursing education: looking through the lens of a developing country.** Int Nurs Rev 2021; Agu CF, Stewart J, McFarlane-Stewart

- N, Rae T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513283>
23. **Youth Mask-Wearing and Social-Distancing Behavior at In-Person High School Graduations During the COVID-19 Pandemic.** J. Adolesc. Health 2021; Mueller AS, Diefendorf S, Abrutyn S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500195>
 24. **The impact of COVID-19 on college students from communities of color.** J. Am. Coll. Health 2021:1-7Molock SD, Parchem B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502970>
 25. **Leveraging conversational technology to answer common COVID-19 questions.** J Am Med Inform Assoc 2021; McKillop M, South BR, Preininger A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517402>
 26. **Assessment of knowledge gaps and perceptions about COVID-19 among health care workers and general public-national cross-sectional study.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:337-344Paul G, Sharma S, Singh G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487900>
 27. **Assessment of the Awareness, Perception, Attitudes, and Preparedness of Health-care Professionals Potentially Exposed to COVID-19 in the United Arab Emirates.** J Multidiscip Healthc 2021; 14:91-102Dalky HF, Ghader N, Al Kuwari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488085>
 28. **Commentary: "How's It Going?" Training Experiences of Pediatric Postdoctoral Fellows During COVID-19.** J. Pediatr. Psychol. 2021; Ghosh S, David JG, Amaro CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496725>
 29. **Governmental actions to address COVID-19 misinformation.** J. Public Health Policy 2021:1-10Pomeranz JL, Schwid AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510401>
 30. **COVID-19 and its sequelae: a platform for optimal patient care, discovery and training.** J. Thromb. Thrombolysis 2021:1-8Becker RC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501596>
 31. **Interaction Identified as both a Challenge and a Benefit in a Rapid Switch to Online Teaching during the COVID-19 Pandemic.** J. Vet. Med. Educ. 2021:e20200063Parkes RSV, Barrs VRD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493099>
 32. **[Role of the French national registry REIN in the health monitoring of patients with end-stage chronic renal failure infected with SARS-CoV-2: Organization and initial data].** Nephrol. Ther. 2021; Lapalu S, Izaaryene G, Honoré N, Couchoud C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516618>
 33. **Waking up to the dawn of a new era: Reconceptualization of curriculum post Covid-19.** Prospects (Paris) 2021:1-13Aktan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495663>
 34. **Rethinking community participation in education post Covid-19.** Prospects (Paris) 2021:1-11Iyengar R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487758>
 35. **The educational impact of the Covid-19 rapid response on teachers, students, and families: Insights from British Columbia, Canada.** Prospects (Paris) 2021:1-15MacDonald M, Hill C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487759>
 36. **Trends in coverage of hygiene and disease prevention topics across national curriculum frameworks for primary science, physical education, and health.** Prospects (Paris) 2021:1-19Morrish D, Neesam M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495662>

37. **Enhancing rheumatology education during the COVID-19 pandemic.** Rheumatol. Int. 2021;1-6Bilal S, Shanmugam VK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33502553>
38. **Knowledge, Attitudes, Practices and Information Needs During the COVID-19 Pandemic in Indonesia.** Risk Manag. Healthc. Policy 2021; 14:163-175Sulistyawati S, Rokhmayanti R, Aji B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488129>
39. **Assessing Knowledge, Attitudes and Practices Towards COVID-19 Public Health Preventive Measures Among Patients at Mulago National Referral Hospital.** Risk Manag. Healthc. Policy 2021; 14:221-230Twinamasiko N, Olum R, Gwokyalaya AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505175>
40. **Stroke Fellow Redeployed: My Fellowship in COVID in the Epicenter of a Pandemic.** Stroke 2021;Strokeaha120030938Ibeh C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33494638>
41. **The impact of COVID-19 on surgical training: a systematic review.** Tech. Coloproctol. 2021;1-16Hope C, Reilly JJ, Griffiths G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33507436>
42. **Movement Disorders Virtual Fellowship Training in Times of Coronavirus Disease 2019: A Single-Center Experience.** Telemed J E Health 2021; Suarez-Cedeno G, Pantelyat A, Mils K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512273>
43. **Fostering global data sharing: highlighting the recommendations of the Research Data Alliance COVID-19 working group.** Wellcome Open Res 2020; 5:267Austin CC, Bernier A, Bezuidenhout L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33501381>

Elderly (12 articles)

1. **[Nursing Homes and COVID-19, An Avoidable Fatality: Results of a Multidisciplinary Approach].** Acta Med Port 2021; S^v MM, Pires AL, Cabral D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493430>
2. **Frailty is associated with in-hospital mortality in older hospitalised COVID-19 patients in the Netherlands: the COVID-OLD study.** Age Ageing 2021; Blomaard LC, van der Linden CMJ, van der Bol JM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33514998>
3. **Factors associated with survival in older patients affected by COVID-19: A retrospective cohort study.** Arch. Gerontol. Geriatr. 2021; 94:104349Saifi ES, Giorgi-Pierfranceschi M, Salvetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508512>
4. **Women and COVID-19: severity and mortality in hospitalized middle-aged and older patients.** Climacteric 2021;1-6Balcázar-Hernández L, Martínez-Murillo C, Ramos-Peñafiel C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513033>
5. **COVID-19 Australia: Epidemiology Report 33 Fortnightly reporting period ending 17 January 2021.** Commun Dis Intell (2018) 2021; 45.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33499797>
6. **The nutritional status of the elderly patient infected with COVID-19: the forgotten risk factor?** Curr. Med. Res. Opin. 2021;1Abadía Otero J, Briongos Figuero LS, Gabella Mattín M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509001>

7. **Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?** *Front. Physiol.* 2020; 11:571416Bajaj V, Gadi N, Spihlman AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510644>
8. **The Elderly and the COVID 19 Crisis: A Chronicle of Deaths Foretold, in Isolation and Total Indifference.** *Front Public Health* 2020; 8:602982Heymann D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490021>
9. **Association of clade-G SARS-CoV-2 viruses and age with increased mortality rates across 57 countries and India.** *Infect Genet Evol* 2021:104734Pandit B, Bhattacharjee S, Bhattacharjee B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508515>
10. **Nontraditional Small House Nursing Homes Have Fewer COVID-19 Cases and Deaths.** *J. Am. Med. Dir. Assoc.* 2021; Zimmerman S, Dumond-Stryker C, Tandan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516670>

Epidemiology (92 articles)

1. **Modeling and forecasting the spread of COVID-19 with stochastic and deterministic approaches: Africa and Europe.** *Adv Differ Equ* 2021; 2021:57Atangana A, $f\infty f\ddot{u}ret$ Araz S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495699>
2. **COVID-19 as an occupational disease.** *Am. J. Ind. Med.* 2021; Carlsten C, Gulati M, Hines S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491195>
3. **The socioeconomic and environmental drivers of the COVID-19 pandemic: A review.** *Ambio* 2021:1-12Wu T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507498>
4. **Evaluating the Impact of Intervention Strategies on the First Wave and Predicting the Second Wave of COVID-19 in Thailand: A Mathematical Modeling Study.** *Biology (Basel)* 2021; 10Mahikul W, Chotsiri P, Ploddi K, Pan-Ngum W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499138>
5. **Development of the reproduction number from coronavirus SARS-CoV-2 case data in Germany and implications for political measures.** *BMC Med* 2021; 19:32Khailaie S, Mitra T, Bandyopadhyay A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504336>
6. **Variation in human mobility and its impact on the risk of future COVID-19 outbreaks in Taiwan.** *BMC Public Health* 2021; 21:226Chang MC, Kahn R, Li YA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504339>
7. **Control of COVID-19 in Australia through quarantine: the role of special health accommodation (SHA) in New South Wales, Australia.** *BMC Public Health* 2021; 21:225Fotheringham P, Anderson T, Shaw M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504347>
8. **Barriers and facilitators to populational adherence to prevention and control measures of COVID-19 and other respiratory infectious diseases: a rapid qualitative evidence synthesis protocol.** *BMJ Open* 2021; 11:e045529Monteiro KS, Santino TA, Jácome AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514584>
9. **[Public trust in institutions in the first half of the Corona pandemic: findings from the COVID-19 Snapshot Monitoring (COSMO) project].** *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2021:1-9Eitze S, Felgendreff L, Korn L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512553>

10. **Comparing Dynamics and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 Transmissions Among Healthcare Workers of Adult and Pediatric Settings in Central Paris.** Clin Infect Dis 2021; 72:257-264Contejean A, Leporrier J, Canoui E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501952>
11. **Occurrence and Timing of Subsequent Severe Acute Respiratory Syndrome Coronavirus 2 Reverse-transcription Polymerase Chain Reaction Positivity Among Initially Negative Patients.** Clin Infect Dis 2021; 72:323-326Long DR, Gombar S, Hogan CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501950>
12. **From Easing Lockdowns to Scaling Up Community-based Coronavirus Disease 2019 Screening, Testing, and Contact Tracing in Africa-Shared Approaches, Innovations, and Challenges to Minimize Morbidity and Mortality.** Clin Infect Dis 2021; 72:327-331Nachega JB, Grimwood A, Mahomed H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501963>
13. **Technical supplement - COVID-19 Australia: Epidemiology reporting Last updated 19 January 2021.** Commun Dis Intell (2018) 2021; 44. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499798>
14. **So far, how effective were distancing measures during the COVID-19 pandemic?** Deutsche Medizinische Wochenschrift 2020; 145:1530-1531Klein F.
15. **Local Transmission of SARS-CoV-2 Lineage B.1.1.7, Brazil, December 2020.** Emerg Infect Dis 2021; 27Claro IM, da Silva Sales FC, Ramundo MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496249>
16. **Dynamic Public Perceptions of the Coronavirus Disease Crisis, the Netherlands, 2020.** Emerg Infect Dis 2021; 27de Vries M, Claassen L, Te Wierik MJM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493429>
17. **Early Transmission Dynamics, Spread, and Genomic Characterization of SARS-CoV-2 in Panama.** Emerg Infect Dis 2021; 27:612-615Franco D, Gonzalez C, Abrego LE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496228>
18. **Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020.** Emerg Infect Dis 2021; 27:666-669Kar SS, Sarkar S, Murali S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496645>
19. **Epidemiology and Clinical Course of First Wave Coronavirus Disease Cases, Faroe Islands.** Emerg Infect Dis 2021; 27Kristiansen MF, Heimustovu BH, Borg S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513332>
20. **Use of US Public Health Travel Restrictions during COVID-19 Outbreak on Diamond Princess Ship, Japan, February-April 2020.** Emerg Infect Dis 2021; 27Medley AM, Marston BJ, Toda M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513333>
21. **Estimating Transmission Parameters for COVID-19 Clusters by Using Symptom Onset Data, Singapore, January-April 2020.** Emerg Infect Dis 2021; 27:582-585Ng SH, Kaur P, Kremer C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496243>
22. **Prevalence of SARS-CoV-2 Antibodies in First Responders and Public Safety Personnel, New York City, New York, USA, May-July 2020.** Emerg Infect Dis 2021; 27Sami S, Akinbami LJ, Petersen LR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493106>
23. **SARS-CoV-2 Infection and Mitigation Efforts among Office Workers, Washington, DC, USA.** Emerg Infect Dis 2021; 27:669-672Sami S, Vuong N, Miller H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496649>

24. **Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India.** Emerg Infect Dis 2021; 27:586-589 Selvaraju S, Kumar MS, Thangaraj JWV *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33496222>
25. **Effects of Social Distancing Measures during the First Epidemic Wave of Severe Acute Respiratory Syndrome Infection, Greece.** Emerg Infect Dis 2021; 27:452-462 Sydsa V, Roussos S, Paraskevis D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33496221>
26. **Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020.** Emerg Infect Dis 2021; 27:628-631 Yoshiyama T, Saito Y, Masuda K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33496235>
27. **Environmental impacts of COVID-19 on Victoria, Australia, witnessed two waves of Coronavirus.** Environ. Sci. Pollut. Res. Int. 2021:1-10 Boroujeni M, Saberian M, Li J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506421>
28. **Sars-CoV-2 in Germany: association between deaths and positive rate.** Eur. J. Clin. Invest. 2021:e13500 Scherb H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497463>
29. **Population-Level Preparedness About Preventive Practices Against Coronavirus Disease 2019: A Cross-Sectional Study Among Adults in Bangladesh.** Front Public Health 2020; 8:582701 Hossain MB, Alam MZ, Islam MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505950>
30. **Serial Interval and Generation Interval for Imported and Local Infectors, Respectively, Estimated Using Reported Contact-Tracing Data of COVID-19 in China.** Front Public Health 2020; 8:577431 Li M, Liu K, Song Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33490015>
31. **Return-to-School Evaluation Criteria for Children With Suspected Coronavirus Disease 2019.** Front Public Health 2020; 8:618642 Vlacha V, Feketea GM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33490028>
32. **Exponential Damping: The Key to Successful Containment of COVID-19.** Front Public Health 2020; 8:580619 Zhang F, Zhang J, Cao M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33490016>
33. **Rapid spread of mutant alleles in worldwide SARS-CoV-2 strains revealed by genome-wide single nucleotide polymorphism and variation analysis.** Genome Biol. Evol. 2021; Zhu Z, Liu G, Meng K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512495>
34. **Epidemiological investigation of a COVID-19 family cluster outbreak transmitted by a 3-month-old infant.** Health Inf Sci Syst 2021; 9:6 Lin GT, Zhang YH, Xiao MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489103>
35. **Severe acute respiratory syndrome coronavirus 2 prevalence in 1170 asymptomatic Norwegian conscripts.** Health Sci Rep 2021; 4:e233 Borud EK, Nakstad ER, Hv•berg SE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490637>
36. **Using Community Feedback to Guide the COVID-19 Response in Sub-Saharan Africa: Red Cross and Red Crescent Approach and Lessons Learned from Ebola.** Health Secur 2021; Erlach E, Nichol B, Reader S, Baggio O.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33497272>
37. **Analysis of Policies Based on the Multi-Fuzzy Regression Discontinuity, in Terms of the Number of Deaths in the Coronavirus Epidemic.** Healthcare

- (Base) 2021; 9Wang X, Chen C, Du Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499030>
38. **Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19.** *Heliyon* 2021; 7:e05951Mustapha JO, Abdullahi IN, Ajagbe OOR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490695>
 39. **Identifying and addressing psychosocial determinants of adherence to physical distancing guidance during the COVID-19 pandemic - project protocol.** *HRB Open Res* 2020; 3:58Durand H, Bacon SL, Byrne M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490860>
 40. **The need for a disaster readiness mindset: A key lesson from COVID-19.** *Infect Control Hosp Epidemiol* 2021;1-7Su Z, McDonnell D, Ahmad J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487209>
 41. **Impact of the lockdown on the burden of COVID-19 in outpatient care in France, spring 2020.** *Infect Dis (Lond)* 2021;1-6Souty C, Guerrisi C, Masse S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512254>
 42. **Statistical data driven approach of COVID-19 in Ecuador: R0 and Rt estimation via new method.** *Infect Dis Model* 2021; 6:232-243Fernández-Naranjo RP, Váscónez-González E, Simbaña-Rivera K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506154>
 43. **Modeling the transmission of COVID-19 in the US - A case study.** *Infect Dis Model* 2021; 6:195-211Yang C, Wang J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506152>
 44. **Different SARS-CoV-2 haplotypes associate with geographic origin and case fatality rates of COVID-19 patients.** *Infect Genet Evol* 2021;104730Goyal M, De Bruyne K, van Belkum A, West B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513449>
 45. **Estimation of COVID-19 Epidemiology Curve of the United States Using Genetic Programming Algorithm.** *Int J Environ Res Public Health* 2021; 18Andelić N, Baressi Šegota S, Lorencin I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499219>
 46. **The Obesity Paradox Predicts the Second Wave of COVID-19 to Be Severe in Western Countries.** *Int J Environ Res Public Health* 2021; 18Krams IA, Jöers P, Luoto S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503828>
 47. **Susceptibility to Coronavirus (COVID-19) in Occupational Settings: The Complex Interplay between Individual and Workplace Factors.** *Int J Environ Res Public Health* 2021; 18Lesó V, Fontana L, Iavicoli I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503829>
 48. **The Impact of Policy Measures on Human Mobility, COVID-19 Cases, and Mortality in the US: A Spatiotemporal Perspective.** *Int J Environ Res Public Health* 2021; 18Li Y, Li M, Rice M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498647>
 49. **Untying the Precise Impact of COVID-19 Policy on Social Distancing Behavior.** *Int J Environ Res Public Health* 2021; 18Shahzad F, Du J, Khan I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494178>
 50. **High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacajá (Kayapó) indigenous population in the Brazilian Amazon.** *Int J Equity Health* 2021; 20:50Rodrigues EPS, Abreu IN, Lima CNC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509206>

51. **Could thermodynamics and heat and mass transfer research produce a fundamental step advance toward and significant reduction of SARS-COV-2 spread?** Int J Heat Mass Transf 2021;120983Trancossi M, Carli C, Cannistraro G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495658>
52. **A compartmental epidemic model incorporating probable cases to model COVID-19 outbreak in regions with limited testing capacity.** ISA Trans. 2021; Hasan A, Nasution Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487398>
53. **Data-driven modeling and forecasting of COVID-19 outbreak for public policy making.** ISA Trans. 2021; Hasan A, Putri ERM, Susanto H, Nuraini N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487397>
54. **Air pollution impacts from COVID-19 pandemic control strategies in Malaysia.** J Clean Prod 2021; 291:125992Othman M, Latif MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495674>
55. **The role of weather conditions in COVID-19 transmission: A study of a global panel of 1236 regions.** J Clean Prod 2021; 292:125987Zhang C, Liao H, Strobl E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495673>
56. **"Go To Travel" Campaign and Travel-Associated Coronavirus Disease 2019 Cases: A Descriptive Analysis, July-August 2020.** J Clin Med 2021; 10Anzai A, Nishiura H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494315>
57. **Indoor transmission dynamics of expired SARS-CoV-2 virus in a model African hospital ward.** J Environ Health Sci Eng 2021;1-11Adeniran JA, Mohammed IA, Muniru OI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500782>
58. **Early Acceleration of COVID-19 in Areas with Larger Nursing Homes and Certificate of Need Laws.** J Gen Intern Med 2021;1-8Kosar CM, Rahman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511570>
59. **Evaluating the Impact of New York's Executive Order on Face Mask Use on COVID-19 Cases and Mortality: a Comparative Interrupted Times Series Study.** J Gen Intern Med 2021;1-5Li L, Liu B, Liu SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501543>
60. **An extensive study on the COVID-19 pandemic, an emerging global crisis: Risks, transmission, impacts and mitigation.** J Infect Public Health 2020; 14:249-259Parthasarathy P, Vivekanandan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493922>
61. **Epidemiologic Linkage of COVID-19 Outbreaks at Two University-affiliated Hospitals in the Seoul Metropolitan Area in March 2020.** J Korean Med Sci 2021; 36:e38Park K, Lee J, Lee K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496089>
62. **Emergence of SARS-CoV-2 Variant: A Wake-Up Call for Pakistan's overburdened Healthcare System.** J Med Virol 2021; Awan UA, Khattak AA, Afzal MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506951>
63. **New guidelines for children returning to sports after Covid-19.** J. Pediatr. Nurs. 2021; McBride DL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514486>
64. **Diffusion segregation and the disproportionate incidence of COVID-19 in African American communities.** J R Soc Interface 2021; 18:20200961Bassolas A, Sousa S, Nicosia V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499765>
65. **Implementing a real-time, AI-based, people detection and social distancing measuring system for Covid-19.** J Real Time Image Process 2021;1-11Saponara S, Elhanashi A, Gagliardi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500738>

66. **Spatiotemporal characteristics of the COVID-19 resurgence in the metropolitan wholesale market of Beijing, China.** J Travel Med 2021; Wang XY, Zhang YQ, Cai LW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506242>
67. **Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the United Kingdom: An early data-driven analysis.** J Travel Med 2021; Zhao S, Lou J, Cao L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506254>
68. **Predictors of COVID-19-Confirmed Cases and Fatalities in 883 US Counties with a Population of 50,000 or More: Estimated Effect of Initial Prevention Policies.** J. Urban Health 2021; Robertson LS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492557>
69. **Isolating SARS-CoV-2 Strains From Countries in the Same Meridian: Genome Evolutionary Analysis.** JMIR Bioinform Biotech 2021; 2:e25995Mastriani E, Rakov AV, Liu SL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497425>
70. **Stay-at-Home Orders and the Common Good.** Linacre Q 2021; 88:24-31Jones-Nosacek C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487742>
71. **Estimation of Parameter of Fractional Order Covid -19 SIQR Epidemic Model.** Mater Today Proc 2021; Malik A, Kumar N, Alam K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495730>
72. **Combating an invisible enemy: the American military response to global pandemics.** Mil Med Res 2021; 8:8Dutton LK, Rhee PC, Shin AY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487173>
73. **Mathematical modeling and a month ahead forecast of the coronavirus disease 2019 (COVID-19) pandemic: an Indian scenario.** Model Earth Syst Environ 2021;1-12Ganiny S, Nisar O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490366>
74. **Assessing the impact of non-pharmaceutical interventions on the transmissibility and severity of COVID-19 during the first five months in the Western Pacific Region.** One Health 2021; 12:100213Yeoh EK, Chong KC, Chiew CJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506086>
75. **Viral Ribonucleic Acid Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic Coronavirus Disease 2019 Patients.** Open Forum Infect Dis 2021; 8:ofaa599Samaddar A, Gadepalli R, Nag VL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506066>
76. **Characterizing COVID-19 and Influenza Illnesses in the Real World via Person-Generated Health Data.** Patterns (N Y) 2021; 2:100188Shapiro A, Marinsek N, Clay I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506230>
77. **Reproducing country-wide COVID-19 dynamics can require the usage of a set of SIR systems.** PeerJ 2021; 9:e10679Postnikov EB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505808>
78. **Model for Mitigation of Workplace Transmission of COVID-19 Through Population-Based Testing and Surveillance.** Popul Health Manag 2021; Plantés PJ, Fragala MS, Clarke C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493409>
79. **Who is staying home and who is not? Demographic, socioeconomic, and geographic differences in time spent outside the home during the COVID-19 outbreak in Japan.** Prev Med Rep 2021; 21:101306Hanibuchi T, Yabe N, Nakaya T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489727>

80. **A parsimonious approach for spatial transmission and heterogeneity in the COVID-19 propagation.** *R Soc Open Sci* 2020; 7:201382Roques L, Bonnefon O, Baudrot V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489282>
81. **Catching a resurgence: Increase in SARS-CoV-2 viral RNA identified in wastewater 48 h before COVID-19 clinical tests and 96 h before hospitalizations.** *Sci Total Environ* 2021; 770:145319D'Aoust PM, Graber TE, Mercier E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508669>
82. **High prevalence of SARS-CoV-2 infection among food delivery riders. A case study from Quito, Ecuador.** *Sci Total Environ* 2021; 770:145225Ortiz-Prado E, Henriquez-Trujillo AR, Rivera-Olivero IA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513511>
83. **An Enhanced IoT Based Tracing and Tracking Model for COVID -19 Cases.** *SN Comput Sci* 2021; 2:42Rajasekar SJS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490971>
84. **A Bayesian approach to improving spatial estimates of prevalence of COVID-19 after accounting for misclassification bias in surveillance data in Philadelphia, PA.** *Spat Spatiotemporal Epidemiol* 2021; 36:100401Goldstein ND, Wheeler DC, Gustafson P, Burstyn I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509436>
85. **Forecasting COVID-19 pandemic: Unknown unknowns and predictive monitoring.** *Technol Forecast Soc Change* 2021; 166:120602Luo J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495665>
86. **Benefits of COVID-19 viral screening of formerly incarcerated individuals during community reentry.** *Ther Adv Infect Dis* 2021; 8:2049936120985951Quan NG, Latif H, Krsak M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505680>
87. **Spatiobehavioral Characteristics - Defining the Epidemiology of New Contagious Diseases at the Earliest Moment Possible.** *Trends Parasitol* 2021; Yang S, Yu C, Jia P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487571>
88. **Comparative profile for COVID-19 cases from China and North America: Clinical symptoms, comorbidities and disease biomarkers.** *World J Clin Cases* 2021; 9:118-132Badawi A, Vasileva D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511177>
89. **Necessary problems in re-emergence of COVID-19.** *World J Clin Cases* 2021; 9:1-7Chen S, Ren LZ, Ouyang HS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511167>
90. **Knowledge, attitudes, and practices related to the COVID-19 pandemic among Bangladeshi youth: a web-based cross-sectional analysis.** *Z Gesundh Wiss* 2021:1-11Banik R, Rahman M, Sikder MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489718>
91. **[Threat of a SARS-CoV-2 endemic in a large hospital specialized in rheumatic diseases-relative all clear through consistent testing].** *Z. Rheumatol.* 2021:1-3Andreica I, Guminiski B, Sokolar J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495854>
92. **[Experience and thinking on the normalization stage of prevention and control of COVID-19 in China].** *Zhonghua Yi Xue Za Zhi* 2021; 101:E001Liang WN, Yao JH, Wu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498104>

Gastro-enterology (16 articles)

1. **EVERY BREATH YOU TAKE: IMPACTS OF ENVIRONMENTAL DUST EXPOSURE ON INTESTINAL BARRIER FUNCTION - FROM THE GUT-LUNG AXIS TO COVID-19.** Am. J. Physiol. Gastrointest. Liver Physiol. 2021; Crawford MS, Nordgren TM, McCole DF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501887>
2. **Post COVID-19 sequelae: venous thromboembolism complicated by lower GI bleed.** BMJ Case Rep. 2021; 14Kumar MA, Krishnaswamy M, Arul JN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504542>
3. **Hepatic vasculopathy and regenerative responses of the liver in fatal cases of COVID-19.** Clin Gastroenterol Hepatol 2021; Kaltschmidt B, Fitzek ADE, Schaedler J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516952>
4. **Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19.** Front Med (Lausanne) 2020; 7:613475Li XZ, Qiu Y, Jeffery L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511147>
5. **Impact of the COVID-19 pandemic on the activity of advanced-practice nurses on a reference unit for inflammatory bowel disease.** Gastroenterol. Hepatol. 2021; Navarro-Correal E, Borruel N, Robles V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515625>
6. **Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study.** Gut 2021; Weber S, Hellmuth JC, Scherer C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514597>
7. **Chronic liver disease independently associated with COVID-19 severity: evidence based on adjusted effect estimates.** Hepatol Int 2021:1-6Yang H, Xu J, Liang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507484>
8. **Coronavirus Disease (COVID-19) and Peritoneal Malignancies.** Indian J Surg Oncol 2021:1-3Solanki SL, Jhingan MA, Saklani AP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488021>
9. **Commenting on the Letter (Completing the Picture in Egypt: Response to "Inflammatory Bowel Diseases in Egypt During the COVID-19 Pandemic").** Inflamm. Bowel Dis. 2021; Eltabbakh M, Alaty WA, Sakr MA, Sherief AF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512507>
10. **Completing the Picture in Egypt: Response to "Inflammatory Bowel Diseases in Egypt During the COVID-19 Pandemic".** Inflamm. Bowel Dis. 2021; Khorshid M, AbdAllah M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512472>
11. **Measuring the impact of delayed access to elective cholecystectomy through patient's cost-utility: An observational cohort study.** Int. J. Qual. Health Care 2021; Karimuddin A, Melina Albanese C, Crump T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493262>
12. **A case of urgent colonoscopic hemostasis of a cecal hemorrhagic ulceration in a patient receiving heparin for COVID-19 coagulopathy.** JGH Open 2021; 5:160-162Yoshida N, Hirose R, Watanabe M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490630>
13. **National survey regarding the timing of endoscopic procedures during the COVID-19 pandemic.** Surg. Endosc. 2021; Marroqu√n-Reyes JD, Zepeda-G√mez S, Tepox-Padr√n A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492499>
14. **High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data.** World J. Gastroenterol.

- 2020; 26:7693-7706Díaz LA, Idalsoaga F, Cannistra M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33505145>
15. **Lipidome is lipids regulator in gastrointestinal tract and it is a life collar in COVID-19: A review.** World J. Gastroenterol. 2021; 27:37-54Koriem KMM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33505149>
 16. **Recommendations of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS) for the implementation of breath tests during the COVID-19 pandemic - November 2020.** Z. Gastroenterol. 2020; 58:1274Jansen PL.

Guidelines (10 articles)

1. **Chinese Expert Consensus on the Nucleic Acid Detection of SARS-CoV-2.** Ann Transl Med 2020; 8:1631Liu Z, Tong Y, Wu J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33490143>
2. **Joint position statement on management of patient with osteoporosis during COVID-19 contingency from the AMMOM, CONAMEGER, FELAEN, FEMECOG, FEMECOT, and ICAAFYD.** Arch Osteoporos 2021; 16:18Torres-Naranjo F, De la Peñuela-Rodríguez P, López-Cervantes RE *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33495916>
3. **A new approach to airway assessment-"Line of Sight" and more. Recommendations of the Task Force of Airway Management Foundation (AMF).** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:303-315Kumar R, Kumar S, Misra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487896>
4. **New guidelines for children returning to sports after Covid-19.** J. Pediatr. Nurs. 2021; McBride DL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514486>
5. **Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines.** Nefrologia 2021; Sánchez-Álvarez E, Quiroga B, de Sequera P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33500159>
6. **Synergistic learning of lung lobe segmentation and hierarchical multi-instance classification for automated severity assessment of COVID-19 in CT images.** Pattern Recognit 2021; 113:107828He K, Zhao W, Xie X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33495661>
7. **S2k Guideline - Recommendations for Inpatient Therapy of Patients with COVID-19.** Pneumologie 2021; Kluge S, Janssens U, Welte T *et al.*
8. **Non-invasive respiratory support paths in hospitalized patients with COVID-19: proposal of an algorithm.** Pulmonology 2021; Winck JC, Scala R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33516668>
9. **Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2 - methodology, key messages and justifying information.** Rheumatology (Oxford) 2021; Schulze-Koops H, Krüger K, Hoyer BF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33502500>
10. **Recommendations of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS) for the implementation of breath tests during the COVID-19 pandemic - November 2020.** Z. Gastroenterol. 2020; 58:1274Jansen PL.

Imaging (36 articles)

1. **Sources of Revenue Loss and Recovery in Radiology Practices During the Coronavirus Disease 2019 (COVID-19) Pandemic.** Acad Radiol 2021; Carlon T, Finkelstein M, Maron SZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495075>
2. **Widespread myocardial dysfunction in COVID-19 patients detected by myocardial strain imaging using 2-D speckle-tracking echocardiography.** Acta Pharmacol. Sin. 2021;1-8Li R, Wang H, Ma F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510459>
3. **Association between laboratory parameters and CT severity in patients infected with Covid-19: A retrospective, observational study.** Am J Emerg Med 2021; 42:110-114Yilmaz A, Sabirli R, Seyit M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503532>
4. **Coronavirus Disease 2019 (COVID-19) in Italy: Double Reading of Chest CT Examination.** Biology (Basel) 2021; 10Reginelli A, Grassi R, Feragalli B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504028>
5. **Evaluation of the relation between cardiac biomarkers and thorax computerized tomography findings in COVID-19 patients.** Biomark. Med. 2021; Ileri C, Dogan Z, Ozben B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501850>
6. **Combining 3D rendering model and pixelated quantitative CT for rapid assessment of lung affected with COVID-19 and need for oxygenation.** BMJ Case Rep. 2021; 14Masoomi MA, Al-Kandari L, Al-Shammeri I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514617>
7. **Coronary aneurysms, myocardial dysfunction, and shock in a COVID-19 child, role of ECMO, immunomodulation, and cardiac CT.** Cardiol. Young 2021;1-5Mustafa MR, Carter MJ, Wong J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504377>
8. **Portable Chest Radiography as an Exclusionary Test for Adverse Clinical Outcomes During the COVID-19 Pandemic.** Chest 2021; Pagano A, Finkelstein M, Overbey J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516703>
9. **COVID-19 in pregnancy: a systematic review of chest CT findings and associated clinical features in 427 patients.** Clin Imaging 2021; 75:75-82Oshay RR, Chen MYC, Fields BKK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508754>
10. **An Incidental Diagnosis of SARS-CoV-2 Pneumonia With Magnetic Resonance Imaging.** Cureus 2020; 12:e12115Di Girolamo M, Muscogiuri E, Zucchelli A, Laghi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489530>
11. **COVID-19 pneumonia: The fight must go on.** Diagn Interv Imaging 2021; 102:61-62Revel MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494861>
12. **LungINFseg: Segmenting COVID-19 Infected Regions in Lung CT Images Based on a Receptive-Field-Aware Deep Learning Framework.** Diagnostics (Basel) 2021; 11Kumar Singh V, Abdel-Nasser M, Pandey N, Puig D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498999>
13. **COVID-19 pneumonia-ultrasound, radiographic, and computed tomography findings: a comprehensive pictorial essay.** Emerg Radiol 2021; Cellina M, Martinenghi C, Marino P, Oliva G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517546>
14. **Effect of the COVID-19 pandemic on CT scans ordered from the emergency department for abdominal complaints.** Emerg Radiol 2021; Griffith AM, Ockerse

- P, Shaaban A, Kelly C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517547>
15. **(18)F-FDG brain PET hypometabolism in patients with long COVID.** *Eur J Nucl Med Mol Imaging* 2021;1-11 Guedj E, Campion JY, Dudouet P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501506>
 16. **Clinical, biological and radiological features, 4-week outcomes and prognostic factors in COVID-19 elderly inpatients.** *Infect Dis Now* 2021; Palich R, Wakim Y, Itani O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495763>
 17. **The role of CT imaging for management of COVID-19 in epidemic area: early experience from a University Hospital.** *Insights Imaging* 2021; 12:10 Bollineni VR, Nieboer KH, Döring S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512601>
 18. **Lung ultrasound and computed tomography to monitor COVID-19 pneumonia in critically ill patients: a two-center prospective cohort study.** *Intensive Care Med Exp* 2021; 9:1 Heldeweg MLA, Lopez Matta JE, Haaksma ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491147>
 19. **Rapid Learning of Focused Cardiac Ultrasound for Early Identification of COVID-19 Complications: A Collaborative Effort.** *J. Am. Soc. Echocardiogr.* 2021; Sertich AP, 3rd, Singh K, Alzubaidy D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493552>
 20. **Lung Ultrasound in the COVID-19 Pandemic.** *J Cardiovasc Echogr* 2020; 30:S6-s10 Cianci V, Zanatta M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489730>
 21. **Echocardiography and Multimodality Cardiac Imaging in COVID-19 Patients.** *J Cardiovasc Echogr* 2020; 30:S18-s24 Cresti A, Barchitta A, Barbieri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489732>
 22. **The Role of Imaging in COVID-19 Pneumonia Diagnosis and Management: Main Positions of the Experts, Key Imaging Features and Open Answers.** *J Cardiovasc Echogr* 2020; 30:S25-s30 Landini N, Orlandi M, Fusaro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489733>
 23. **Lung Ultrasound in COVID-19 Critically Ill Patients with Acute Respiratory Distress Syndrome.** *J Cardiovasc Echogr* 2020; 30:S11-s17 Storti E, Nailescu A, Villani PG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489731>
 24. **Things You Should Know in the Performing Echocardiographic Examination in Patients with COVID-19.** *J Cardiovasc Imaging* 2021; 29:20-30 Choi JH, Park JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511797>
 25. **Radiological perspective of COVID-19 pneumonia: The early features and progressive behaviour on high-resolution CT.** *J. Med. Imaging Radiat. Oncol.* 2021; Tsujikawa T, Umeda Y, Itoh H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491340>
 26. **RT-PCR Combined with CT Examination in the Diagnosis and Prognosis Evaluation of COVID-19 Patients in Fangcang Hospital: A Case Series.** *J Multidiscip Healthc* 2021; 14:145-149 Zhang JF, Liu J, Ma HN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500623>
 27. **Susceptibility-weighted imaging reveals cerebral microvascular injury in severe COVID-19.** *J Neurol Sci* 2021; 421:117308 Conklin J, Frosch MP, Mukerji SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497950>
 28. **LETTER TO THE EDITOR: ON POTENTIAL USE OF RADIOLABELED ANTIBODIES FOR IMAGING AND TREATMENT OF COVID-19.** *J Nucl Med* 2021; Dadachova E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509969>
 29. **Lung Ultrasound for Identification of Patients Requiring Invasive Mechanical Ventilation in COVID-19.** *J Ultrasound Med* 2021; Seiler C, Klingberg C, Hv•rdstedt

- M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496362>
30. **Pulmonary vascular enlargement and lesion extent on computed tomography are correlated with COVID-19 disease severity.** Jpn J Radiol 2021;1-8Aoki R, Iwasawa T, Hagiwara E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502657>
 31. **A practical approach to imaging characteristics and standardized reporting of COVID-19: a radiologic review.** Mil Med Res 2021; 8:7Sanli DET, Yildirim D, Sanli AN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487174>
 32. **Efficient deep learning approach for augmented detection of Coronavirus disease.** Neural Comput Appl 2021:1-18Sedik A, Hammad M, Abd El-Samie FE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487885>
 33. **The spider web sign in Covid-19 pneumonia: An interesting case studied to resolution with computed tomography.** Radiol Case Rep 2021; 16:673-677Messina F, Tebala C, Turano L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488897>
 34. **RöKO DIGITAL featured by RKR-RadiologieKongress Ruhr - The successful digital special edition.** RoFo Fortschritte auf dem Gebiet der Röntgenstrahlen und der Bildgebenden Verfahren 2021; 193:96.
 35. **Molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT-IR, FT-Raman), drug likeness and molecular docking of the novel anti COVID-2 molecule (2E)-N-methyl-2-[(4-oxo-4H-chromen-3-yl)methylidene]-hydrazinecarbothioamide (Dimer) - quantum chemical approach.** Spectrochim. Acta. A Mol. Biomol. Spectrosc. 2020; 251:119388Jenepha Mary SJ, Pradhan S, James C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503560>
 36. **Lung Assessment with Point-of-Care Ultrasound in Respiratory Coronavirus Disease (COVID-19): A Prospective Cohort Study.** Ultrasound Med. Biol. 2020; Speidel V, Conen A, Gisler V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487473>
 37. **COVID-19 or non-COVID viral pneumonia: How to differentiate based on the radiologic findings?** World J Radiol 2020; 12:289-301Eslambolchi A, Maliglig A, Gupta A, Gholamrezanezhad A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510853>
 38. **Current status quo on COVID-19 including chest imaging.** World J Radiol 2020; 12:272-288Mathew RP, Jose M, Jayaram V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510852>

Immune response (24 articles)

1. **The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients.** Biochem. Biophys. Res. Commun. 2021; 543:45-49Smits VAJ, Hernández-Carralero E, Paz-Cabrera MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515911>
2. **The immunodominant and neutralization linear epitopes for SARS-CoV-2.** Cell Rep. 2021; 34:108666Lu S, Xie XX, Zhao L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503420>
3. **CERI, CEFX, and CPI: Largely Improved Positive Controls for Testing Antigen-Specific T Cell Function in PBMC Compared to CEF.** Cells 2021; 10Lehmann AA, Reche PA, Zhang T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514016>

4. **COVID-19 symptoms and SARS-CoV-2 antibody positivity in a large survey of first responders and healthcare personnel, May-July 2020.** Clin Infect Dis 2021; Akinbami LJ, Petersen LR, Sami S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515250>
5. **Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity.** Clin Infect Dis 2021; 72:301-308 Lynch KL, Whitman JD, Lacanienta NP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501951>
6. **Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam.** Emerg Infect Dis 2021; 27:663-666 Mai HK, Trieu NB, Long TH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496647>
7. **Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020.** Emerg Infect Dis 2021; 27:628-631 Yoshiyama T, Saito Y, Masuda K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496235>
8. **Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain.** Eur J Clin Microbiol Infect Dis 2021;1-7 Fuentes A, Serrano-Conde E, Roldán C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512616>
9. **Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19.** Front. Immunol. 2020; 11:598402 Cooper RS, Fraser AR, Smith L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488592>
10. **COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.** Front. Oncol. 2020; 10:599502 Botta C, Indrieri A, Garofalo E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489899>
11. **Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?** Front. Physiol. 2020; 11:571416 Bajaj V, Gadi N, Spihlman AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510644>
12. **The Strategy of Boosting the Immune System Under the COVID-19 Pandemic.** Front Vet Sci 2020; 7:570748 Alagawany M, Attia YA, Farag MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490124>
13. **The difference between IgM and IgG antibody prevalence in different serological assays for COVID-19; lessons from the examination of healthcare workers.** Int Immunopharmacol 2020; 92:107360 Kobashi Y, Shimazu Y, Nishikawa Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508702>
14. **Prevalence of SARS-CoV-2 IgG/IgM Antibodies among Danish and Swedish Falck Emergency and Non-Emergency Healthcare Workers.** Int J Environ Res Public Health 2021; 18 Laursen J, Petersen J, Didriksen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494409>
15. **Robust neutralizing antibodies to SARS-CoV-2 develop and persist in subjects with diabetes and COVID-19 pneumonia.** J. Clin. Endocrinol. Metab. 2021; Dispinseri S, Lampasona V, Secchi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513242>
16. **Interactions between hypertension and inflammatory tone and the effect on blood pressure and outcomes in patients with COVID-19.** J. Clin. Hypertens. (Greenwich) 2021; Amar J, Touront N, Ciron AM, Pendaries C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491247>
17. **Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis.** J Infect Dis 2021; Boumaza A, Gay L, Mezouar S *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33493287>

18. **Multiplexed analysis of circulating IgA antibodies for SARS-CoV-2 and Common Respiratory Pathogens in COVID-19 Patients.** J Med Virol 2021; Fang ZF, Sun BQ, Zhu AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506974>
19. **Clinical Significance of Cellular Immunity Function and Inflammatory Factors Assays in Alveolar Lavage Fluid for Severe COVID-19 Pneumonia.** J Med Virol 2021; Liao L, Yang GH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506950>
20. **How Ivlg Can Mitigate Covid-19 Disease: A Symmetrical Immune Network Model.** Monoclon Antib Immunodiagn Immunother 2021; Kohler H, Kaveri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513050>
21. **Immunological alternation in COVID-19 patients with cancer and its implications on mortality.** Oncoimmunology 2021; 10:1854424Cai G, Gao Y, Zeng S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489469>
22. **Effects of COVID-19 Lockdown on Otitis Media With Effusion in Children: Future Therapeutic Implications.** Otolaryngol Head Neck Surg 2021:194599820987458Aldv® M, Di Berardino F, Marchisio P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494659>
23. **Rare SARS-CoV-2 antibody development in cancer patients.** Semin. Oncol. 2021; Hempel L, Molnar J, Robert S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500147>
24. **ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population.** Vox Sang 2021; Bloch EM, Patel EU, Marshall C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493365>

Management miscellaneous diseases (84 articles)

1. **Emergency abdominal surgeries remain unchanged in the COVID-19 affected environment: A single-center experience at a community hospital in Japan.** Acute Med Surg 2021; 8:e623Nishida Y, Otagiri N, Tauchi K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510897>
2. **Impact of COVID-19 pandemic on visits of an urban emergency department.** Am J Emerg Med 2021; 42:78-82√âf±krf±k√βf± l≈üf±k G, √âevik Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493832>
3. **PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic.** Ann. Rheum. Dis. 2021; Spierings J, Ong V, Denton CP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514506>
4. **Lessons learned from the impact of the COVID-19 pandemic in a Vascular Surgery department and preparation for future outbreaks.** Ann. Vasc. Surg. 2021; Duarte A, Gouveia EMR, Lopes A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493593>
5. **OUTCOMES AFTER VASCULAR SURGERY PROCEDURES IN PATIENTS WITH COVID-19 INFECTION: A NATIONAL MULTICENTRE COHORT STUDY (COVID-VAS).** Ann. Vasc. Surg. 2021; San Norberto EM, De Haro J, Pe√±a R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493590>
6. **Assessing the Impact of COVID-19 on Antimicrobial Stewardship Activities/Programs in the United Kingdom.** Antibiotics (Basel) 2021; 10Ashiru-Oredope D, Kerr F, Hughes S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498716>

7. **Remote Prescription During Pandemic: Challenges and Solutions.** Arch Med Res 2021; Lim EC, Chen CY, Tan EK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500154>
8. **Joint position statement on management of patient with osteoporosis during COVID-19 contingency from the AMMOM, CONAMEGER, FELAEN, FEMECOG, FEMECOT, and ICAAFYD.** Arch Osteoporos 2021; 16:18Torres-Naranjo F, De la Pe√±a-Rodr√±guez P, L√±pez-Cervantes RE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495916>
9. **Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium.** Asia Pac. J. Clin. Oncol. 2021; Shimizu T, Kim DW, Loong HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502085>
10. **Review on the Oncology Practice in the Midst of COVID-19 Crisis: The Challenges and Solutions.** Asian Pac J Cancer Prev 2021; 22:19-24Fadavi P, Houshyari M, Yousefi Kashi AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507674>
11. **IMPACT-Scot 2 report on COVID-19 in hip fracture patients.** Bone Joint J 2021:1-10Hall AJ, Clement ND, MacLulich AMJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487012>
12. **Coronavirus infection in hip fractures (CHIP) study.** Bone Joint J 2021:1-5Mahmood A, Rashid F, Limb R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507811>
13. **Environmental sustainability in anaesthesia and critical care. Response to Br J Anaesth.** Br J Anaesth 2021; Sherman JD, Sulbaek Andersen MP, Renwick J, McGain F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487453>
14. **Covid-19 related oncologist's concerns about breast cancer treatment delays and physician well-being (the CROWN study).** Breast Cancer Res. Treat. 2021; Yao KA, Attai D, Bleicher R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517522>
15. **Cups for COVID: rapid implementation of a harm reduction initiative to support populations experiencing homelessness during the COVID-19 pandemic.** Can. J. Public Health. 2021; Steer KJD, Klassen DC, O'Gorman CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492656>
16. **COVID-19 and Its Impact on Upper Gastrointestinal (GI) Cancer Management.** Cancers (Basel) 2021; 13Fernando S, Veli M, Mohammadi B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494406>
17. **Impact of the COVID-19 Pandemic on Cancer Diagnoses in General and Specialized Practices in Germany.** Cancers (Basel) 2021; 13Jacob L, Loosen SH, Kalder M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499223>
18. **Decision-making in Surgery or Active Surveillance for Low Risk Papillary Thyroid Cancer During the COVID-19 Pandemic.** Cancers (Basel) 2021; 13Sawka AM, Ghai S, Ihekire O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498497>
19. **Surgical activation protocol COVID-19 (SAP COVID).** Cir. Cir. 2021; 89:4-11Juanz-Gonz√°lez A, Barreras-Espinoza JA, Leyva-Moraga E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498060>
20. **Immediate impact of the COVID-19 pandemic on pediatric surgery: analysis of a tertiary healthcare facility.** Cir. Pediatr. 2021; 34:34-38√°lvarez Garc√±a N, N√°ñez

- García B, Pérez-Gaspar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507642>
21. **Pediatric surgical activity during the SARS-CoV-2 pandemic: experience at a tertiary hospital.** *Cir. Pediatr.* 2021; 34:28-33Bada-Bosch I, de Agustín JC, de la Torre M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507641>
 22. **Acute abdomen in COVID-19 disease: the pediatric surgeon's standpoint.** *Cir. Pediatr.* 2021; 34:3-8Rico Espiñeira C, Souto Romero H, Espinosa Góngora R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507637>
 23. **The contrasting short-term effects of COVID-19 on dental care practices in the United States.** *Clin Exp Dent Res* 2021; Diab Z, Shara N, Chou J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496042>
 24. **Coronavirus Disease 2019 Pandemic: Impact Caused by School Closure and National Lockdown on Pediatric Visits and Admissions for Viral and Nonviral Infections-a Time Series Analysis.** *Clin Infect Dis* 2021; 72:319-322Angoulvant F, Ouldali N, Yang DD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501967>
 25. **Impact of COVID-19 on rheumatology practice in the UK-a pan-regional rheumatology survey.** *Clin Rheumatol* 2021:1-6Nune A, Iyengar KP, Ahmed A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495972>
 26. **Managing children with brain tumors during the COVID-19 era: Don't stop the care!** *Comput Struct Biotechnol J* 2021; 19:705-709Capozza MA, Triarico S, Attinà G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505640>
 27. **Impact of Quarantine During COVID-19 Pandemic on the Quality of Life of Patients with Allergic Conjunctivitis.** *Cureus* 2020; 12:e12240Al-Dairi W, Al Saeed AA, Al Sowayigh OM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505811>
 28. **Urgent Arthroplasty Interventions During the COVID-19 Pandemic: Operating Risks in Low-Prevalence Areas.** *Cureus* 2020; 12:e12197Burton HL, Burden E, King A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489606>
 29. **A District General Hospital Trauma Service Response to COVID-19: Lessons Learnt.** *Cureus* 2020; 12:e12087Prokopenko M, Khatkar H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489505>
 30. **Impact of the COVID-19 Pandemic on the Practice of Hand and Upper Extremity Surgeons.** *Cureus* 2020; 12:e12072Qazi UA, Sutton J, Farner SC, Bhandari L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489490>
 31. **COVID-19 in Patients With Hematologic-Oncologic Risk Factors: Complications in Three Patients.** *Cureus* 2020; 12:e12064Tafti D, Kluckman M, Dearborn MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489484>
 32. **Public Interest in Elective Orthopedic Surgery Following Recommendations During COVID-19: A Google Trends Analysis.** *Cureus* 2020; 12:e12123Tijerina JD, Cohen SA, Parham MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489537>
 33. **What Is the Impact of Lockdowns on Dengue?** *Curr. Infect. Dis. Rep.* 2021; 23:2Brady O, Wilder-Smith A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500682>
 34. **A cross-sectional analysis of trust of information and COVID-19 preventative practices among people with disabilities.** *Disabil Health J* 2021:101062Ipsen C, Myers A, Sage R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495098>
 35. **Access Block in Australian Emergency Departments 2017-2020.** *Emerg. Med. Australas.* 2021; Richardson DB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501766>

36. **Epilepsy and COVID-19: Updated evidence and narrative review.** Epilepsy Behav. 2021; 116:107785Kuroda N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515934>
37. **Estimating the Impact of COVID-19 on Urology: Data from a Large Nationwide Cohort.** Eur Urol Open Sci 2021; Lewicki P, Basourakos SP, Awamleh B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490992>
38. **Triage of urology service to cope with COVID-19 pandemic: A single institution study.** Excli j 2021; 20:46-51Waqar M, Ong K, Moubasher A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510591>
39. **Impact of the COVID-19 pandemic on the activity of advanced-practice nurses on a reference unit for inflammatory bowel disease.** Gastroenterol. Hepatol. 2021; Navarro-Correal E, Borrueal N, Robles V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515625>
40. **Lisbon's COVID 19 response: harm reduction interventions for people who use alcohol and other drugs in emergency shelters.** Harm Reduct J 2021; 18:13Fuertes R, Belo E, Merendeiro C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494726>
41. **Emergency Management in Dental Clinic During the Coronavirus Disease 2019 (COVID-19) Epidemic in Beijing.** Int. Dent. J. 2021; Wang C, Miao L, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509611>
42. **Optimizing clinical productivity in the otolaryngology clinic during the COVID-19 pandemic.** Int Forum Allergy Rhinol 2021; Gill AS, Oakley G, Error M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502793>
43. **Reduction of Multidrug-Resistant (MDR) Bacterial Infections during the COVID-19 Pandemic: A Retrospective Study.** Int J Environ Res Public Health 2021; 18Bentivegna E, Luciani M, Arcari L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498701>
44. **Quit Experiences among Primary Care Patients Enrolled in a Smoking Cessation Pilot RCT Early in the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Joyce AA, Styklunas GM, Rigotti NA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498834>
45. **Measuring the impact of delayed access to elective cholecystectomy through patient's cost-utility: An observational cohort study.** Int. J. Qual. Health Care 2021; Karimuddin A, Melina Albanese C, Crump T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493262>
46. **Metaplastic squamous cell breast cancer: A case report and treatment strategy during covid-19 pandemic.** Int. J. Surg. Case Rep. 2021; 79:405-408Tomasichio G, Rizzi A, Stucci LS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517214>
47. **Community optometrist-led post-operative cataract care: how many patients re-present to the hospital ophthalmic department?** Ir. J. Med. Sci. 2021;1-5O'Regan A, McGlacken-Byrne A, Chetty S, Mullaney P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495971>
48. **Impact of the COVID-19 pandemic on the Emergency Department of a tertiary children's hospital.** Ital. J. Pediatr. 2021; 47:21Raucci U, Musolino AM, Di Lallo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514391>
49. **Impact of the COVID-19 pandemic on anesthesiologists in India: A cross-sectional online survey of the practices, preparedness, and mind-set.** J.

- Anaesthesiol. Clin. Pharmacol. 2020; 36:331-336Gangakhedkar GR, Solanki SL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33487899>
50. **A rational approach to manage surgical procedures in COVID Era - A perspective based on experience in a private referral hospital.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:325-330Gupta R, Mohan B, Garg K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33487898>
 51. **Preoperative assessment for scheduling surgery during the coronavirus disease pandemic.** J. Anesth. 2021:1-6Suehiro K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33502589>
 52. **Surgical Interventions in Patients Hospitalised with COVID-19. A Review of Seven Months of Experience Working in a COVID-19 Dedicated Centre.** J Clin Med 2021; 10Rymarowicz J, Pfo̧dziwiatr M, Major P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33494183>
 53. **Legal liability facing COVID-19 in dentistry: Between malpractice and preventive recommendations.** J. Forensic Leg. Med. 2021; 78:102123Elzein R, Bader B, Rammal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516144>
 54. **COVID-19 Adaptations in the Care of Patients with Opioid Use Disorder: a Survey of California Primary Care Clinics.** J Gen Intern Med 2021:1-8Caton L, Cheng H, Garneau HC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511572>
 55. **"Advocating Every Single Day" so as Not to Be Forgotten: Factors Supporting Resiliency in Adult Day Service Centers Amidst COVID-19-Related Closures.** J Gerontol Soc Work 2021:1-12Sadarangani T, Zhong J, Vora P, Missaelides L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33509061>
 56. **Tobacco control in the context of the COVID-19 pandemic in Uganda: a policy implementation review.** J Glob Health Rep 2020; 4:e2020095Kabwama SN, Nyamurungi KN, Davidson F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506110>
 57. **Projected HIV and Bacterial STI Incidence Following COVID-Related Sexual Distancing and Clinical Service Interruption.** J Infect Dis 2021; Jenness SM, Le Guillou A, Chandra C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507308>
 58. **COVID-19 and Spinal Cord Injury: Clinical Presentation, Clinical Course, and Clinical Outcomes: A Rapid Systematic Review.** J. Neurotrauma 2021; Hoogenes B, Querée M, Townson A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502924>
 59. **Managing nonmedical opioid use among patients with cancer pain during the COVID-19 Pandemic using the CHAT model and telehealth.** J Pain Symptom Manage 2021; Amaram-Davila JS, Arthur J, Reddy A, Bruera E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33515659>
 60. **Changes in pediatric trauma during COVID-19 stay-at-home epoch at a tertiary pediatric hospital.** J. Pediatr. Surg. 2021; Sanford EL, Zagory J, Blackwell JM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33516579>
 61. **Outcomes of major head and neck reconstruction during the COVID-19 pandemic: The St. Andrew's centre experience.** J. Plast. Reconstr. Aesthet. Surg. 2021; Thacoor A, Sofos SS, Miranda BH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33495141>
 62. **Challenges of non-COVID-19 patients with chronic illness during the pandemic.** J Res Pharm Pract 2020; 9:155-157Abraham DA, Vijayakumar TM, Rajanandh MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489985>

63. **Impact of the COVID-19 pandemic on oncological and functional robotic-assisted surgical procedures.** *J. Robot. Surg.* 2021;1-8Blanc T, Pinar U, Anract J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511526>
64. **Is necessity also the mother of implementation? COVID-19 and the implementation of evidence-based treatments for opioid use disorders.** *J. Subst. Abuse Treat.* 2021; 122:108210Becker SJ, Garner BR, Hartzler BJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509413>
65. **Effects of a reorganization of cirrhosis care during the lockdown for SARS-CoV-2 outbreak.** *JHEP Rep* 2021:100229Piano S, Marzioni M, Angeli P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496684>
66. **Evaluation of Knowledge, Attitude, and Practices toward the Outbreak Pandemic (COVID-19) Virus Disease among Ophthalmologists: A Cross-Sectional Study.** *Middle East Afr J Ophthalmol* 2020; 27:164-171HB AL, Alali NM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488013>
67. **Olecranon fractures in the elderly during the COVID-19 pandemic: Is non-operative treatment reasonable? Review of the current evidence.** *Musculoskelet. Surg.* 2021:1-6Abdelmalek A, Crowther M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511549>
68. **Investigating the real impact of covid-19 pandemic on the daily neurosurgical practice?** *Neurochirurgie* 2021; Dannhoff G, Cebula H, Chibbaro S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493541>
69. **Extensive impact of COVID-19 pandemic on pelvic floor dysfunctions care: A nationwide interdisciplinary survey.** *Neurourol. Urodyn.* 2021; Sacco E, Gandi C, Li Marzi V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492706>
70. **Laparoscopic gynecological surgery in COVID 19 pandemic.** *Obstet Gynecol Sci* 2021; Roy KK, Rai R, Zangmo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499581>
71. **Immunological alternation in COVID-19 patients with cancer and its implications on mortality.** *Oncoimmunology* 2021; 10:1854424Cai G, Gao Y, Zeng S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489469>
72. **Manual vs Mechanical Oral Hygiene Procedures: Has the Role of the Dental Hygienist in Phase 2 Post-lockdown Really Changed?** *Oral Health Prev Dent* 2020; 18:1031-1037Polizzi E, Tetè G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499555>
73. **Impact of COVID-19 pandemic and national lockdown in an orthopaedic and traumatology department-a comparison with the homologous period of 2019.** *Porto Biomed J* 2021; 6:e109Ribau A, Vale J, Xarv^o-Leite F, Rodrigues-Pinto R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490702>
74. **Clinical management of individuals with Intellectual Disability: The outbreak of Covid-19 pandemic as experienced in a clinical and research center Research in Developmental Disabilities.** *Res. Dev. Disabil.* 2021; 110:103856Buono S, Zingale M, Citt^v† S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497856>
75. **Ultrasound-guided fascial plane blocks as unique anesthetic technique for total mastectomy in a covid-19 era: a case report.** *Rev. Esp. Anesthesiol. Reanim.* 2021; D^v≠as R, Mendes √Ç B, Lages N, Machado H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494912>
76. **Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2 - methodology, key messages and justifying information.** *Rheumatology*

- (Oxford) 2021; Schulze-Koops H, Krüger K, Hoyer BF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33502500>
77. **Diagnosis of COVID-19 and the bariatric surgery population: a single center experience.** *Surg. Endosc.* 2021; Romero-Velez G, Pereira X, Skendelas JP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33492513>
 78. **Drug consumption during prolonged lockdown due to Covid-19 as observed in French addiction center.** *Therapie* 2021; Chappuy M, Peyrat M, Lejeune O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33516544>
 79. **What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?** *Trans. R. Soc. Trop. Med. Hyg.* 2021; Hamley JID, Blok DJ, Walker M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515042>
 80. **Disruptions to schistosomiasis programmes due to COVID-19: an analysis of potential impact and mitigation strategies.** *Trans. R. Soc. Trop. Med. Hyg.* 2021; Kura K, Ayabina D, Toor J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515038>
 81. **Delays in lymphatic filariasis elimination programmes due to COVID-19, and possible mitigation strategies.** *Trans. R. Soc. Trop. Med. Hyg.* 2021; Prada JM, Stolk WA, Davis EL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515454>
 82. **Clearance of longstanding treatment-resistant warts during covid-19 in a transplant recipient.** *Transpl Infect Dis* 2021:e13572Erkayman MH, Bilen H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33507618>
 83. **The initial experience and response of vascular surgeons in Michigan during the COVID-19 pandemic.** *Vascular* 2021:1708538120986635Mouawad NJ, Lin JC, Coleman DM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504279>
 84. **COVID-19 lock-down significantly reduced number of surgical presentations in an emergency department.** *Wien. Klin. Wochenschr.* 2021:1-4Fahrner R, Bähler S, Lindner G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507348>

Management (47 articles)

1. **Review of Anesthesia Versus Intensive Care Unit Ventilators and Ventilatory Strategies: COVID-19 Patient Management Implications.** *AANA J.* 2021; 89:62-69Jackson K, Wands B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501910>
2. **Impact of COVID-19 Workflow Changes on Patient Throughput at Outpatient Imaging Centers.** *Acad Radiol* 2021; Chang G, Doshi A, Chandarana H, Recht M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33516590>
3. **TaibUVID nutritional supplements help rapid cure of COVID-19 infection and rapid reversion to negative nasopharyngeal swab PCR: for better public prophylaxis and treatment of COVID-19 pandemic.** *Am. J. Blood Res.* 2020; 10:397-406El Sayed SM, Aboonq MS, Aljehani YT *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33489449>
4. **Habitual use of vitamin D supplements and risk of coronavirus disease 2019 (COVID-19) infection: a prospective study in UK Biobank.** *Am. J. Clin. Nutr.* 2021; Ma H, Zhou T, Heianza Y, Qi L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515005>
5. **Emergency preparation and mitigation for COVID-19 response in an integrated pharmacy practice model.** *Am. J. Health Syst. Pharm.* 2021; Moye RA, Mason K, Flatt A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506860>

6. **COVID-19 Pandemic Impacts on U.S. Hospice Agencies: A National Survey of Hospice Nurses and Physicians.** Am. J. Hosp. Palliat. Care 2021;1049909121989987Baker Rogers JE, Constantine LA, Thompson JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499673>
7. **Resuscitation during the COVID-19 pandemic - Guidelines of the European Resuscitation Council.** Anesthesiologie Intensivmedizin Notfallmedizin Schmerztherapie 2021; 56:5.
8. **Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study.** Ann Intensive Care 2021; 11:14Helms J, Severac F, Merdji H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492445>
9. **[Contribution of a hospital pharmacy team to critical care of patients infected with SARS-CoV-2].** Ann. Pharm. Fr. 2021; Besson C, Chareyre S, Kirouani N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516718>
10. **The evaluation of maximum condyle-tragus distance can predict difficult airway management without exposing upper respiratory tract; a prospective observational study.** BMC Anesthesiol. 2021; 21:28Wu H, Hu D, Chen X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494705>
11. **Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.** BMC Infect. Dis. 2021; 21:114Wang W, Zhao X, Wei W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494713>
12. **Hospital bed capacity and usage across secondary healthcare providers in England during the first wave of the COVID-19 pandemic: a descriptive analysis.** BMJ Open 2021; 11:e042945Mateen BA, Wilde H, Dennis JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500288>
13. **Portable Chest Radiography as an Exclusionary Test for Adverse Clinical Outcomes During the COVID-19 Pandemic.** Chest 2021; Pagano A, Finkelstein M, Overbey J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516703>
14. **[Triage recommendations of the specialist societies : Background, summary and comments].** Chirurg 2021;1-5Dutzmann J, Michalsen A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511439>
15. **Management of life-threatening acute respiratory syndrome and severe pneumonia secondary to COVID-19 in pregnancy: A case report and literature review.** Clin Case Rep 2021; 9:137-143Yaqoub S, Ahmad S, Mansouri Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489149>
16. **Early experience with COVID-19 patients in a private tertiary hospital in the Philippines: Implications on surge capacity, healthcare systems response, and clinical care.** Clin Epidemiol Glob Health 2021; 10:100695Abad CL, Lansang MAD, Cordero CP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490719>
17. **Vitamin D requirement and COVID-19.** Deutsche Medizinische Wochenschrift 2020; 145:1526.
18. **Intensivpflege: Sorge vor dem Winter.** Deutsches Arzteblatt International 2020; 117:A2226Osterloh F.
19. **Key issues in emergency department management of COVID-19: proposals for improving care for patients in Latin America.** Emergencias 2021; 33:42-58Julián Jimenez A, Eduardo García D, González Del Castillo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496399>
20. **Room to Breathe: The Impact of Oxygen Rationing on Health Outcomes in SARS-CoV2.** Front Med (Lausanne) 2020; 7:573037Goyal DK, Mansab F, Bhatti S.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33490094>

21. **Extracorporeal Membrane Oxygenation for SARS-CoV-2 Acute Respiratory Distress Syndrome: A Retrospective Study From Hubei, China.** Front Med (Lausanne) 2020; 7:611460 Yang X, Hu M, Yu Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33511146>
22. **The experiences of healthcare workers during the COVID-19 crisis in Lagos, Nigeria: A qualitative study.** Germes 2020; 10:356-366 Okediran JO, Ilesanmi OS, Fetuga AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489951>
23. **Analysis of the Different Approaches Adopted in the Italian Regions to Care for Patients Affected by COVID-19.** Int J Environ Res Public Health 2021; 18:Pecoraro F, Luzi D, Clemente F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498155>
24. **Is there a need to widely prescribe antibiotics in patients hospitalized for COVID-19?** Int J Infect Dis 2021; Moretto F, Sixt T, Devilliers H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33508478>
25. **The coronavirus disease (COVID-19) - A supportive approach with selected micronutrients.** Int. J. Vitam. Nutr. Res. 2021:1-22 Grvðber U, Holick MF.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33487035>
26. **Nursing management at a Chinese fever clinic during the COVID-19 pandemic.** Int Nurs Rev 2021; Wang Y, Qiang WM, Wang C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33506989>
27. **Clinical Experience, Pathophysiology, and Considerations in the Prophylaxis and Treatment of Hypercoagulopathy of COVID-19: A Review Study.** Iran J Med Sci 2021; 46:1-14 Pourafkari L, Mirza-Aghzadeh-Attari M, Zarrintan A, Mousavi-Aghdas SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487787>
28. **Infection control strategy and primary care assistance in Campania region during the national lockdown due to COVID-19 outbreak: the experience of two tertiary emergency centers.** Ital. J. Pediatr. 2021; 47:19 Mauro A, Improda N, Zenzeri L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514406>
29. **Impact of a Public Policy Restricting Staff Mobility Between Nursing Homes in Ontario, Canada During the COVID-19 Pandemic.** J. Am. Med. Dir. Assoc. 2021; Jones A, Watts AG, Khan SU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516671>
30. **Nontraditional Small House Nursing Homes Have Fewer COVID-19 Cases and Deaths.** J. Am. Med. Dir. Assoc. 2021; Zimmerman S, Dumond-Stryker C, Tandan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516670>
31. **A new approach to airway assessment-"Line of Sight" and more. Recommendations of the Task Force of Airway Management Foundation (AMF).** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:303-315 Kumar R, Kumar S, Misra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487896>
32. **Inositol and vitamin D may naturally protect human reproduction and women undergoing assisted reproduction from Covid-19 risk.** J Reprod Immunol 2021; 144:103271 Bezerra Espinola MS, Bertelli M, Bizzarri M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33493945>
33. **COVID-19 and its sequelae: a platform for optimal patient care, discovery and training.** J. Thromb. Thrombolysis 2021:1-8 Becker RC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33501596>
34. **Successful implementation of modern critical care in the low-resources country Bosnia and Herzegovina : Single-center experience.** Med Klin

- Intensivmed Notfmed 2021; Kovacevic P, Meyer FJ, Gajic O.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33491107>
35. **Antibacterial drugs for community-acquired pneumonia.** Med. Lett. Drugs Ther. 2021; 63:10-14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512346>
 36. **From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.** Molecules 2021; 26Matsoukas J, Apostolopoulos V, Zulli A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33504092>
 37. **Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro.** Nutrients 2021; 13Salaris C, Scarpa M, Elli M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33498631>
 38. **Assessing the impact of non-pharmaceutical interventions on the transmissibility and severity of COVID-19 during the first five months in the Western Pacific Region.** One Health 2021; 12:100213Yeoh EK, Chong KC, Chiew CJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506086>
 39. **A combination of phototherapy modalities for extensive lip lesions in a patient with SARS-CoV-2 infection.** Photodiagnosis Photodyn. Ther. 2021:102196Ramires M, Mattia MB, Tateno RY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515763>
 40. **Early Physical Therapist Interventions for Patients With COVID-19 in the Acute Care Hospital: A Case Report Series.** Phys Ther 2021; 101Eggmann S, Kindler A, Perren A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492400>
 41. **S2k Guideline - Recommendations for Inpatient Therapy of Patients with COVID-19.** Pneumologie 2021; Kluge S, Janssens U, Welte T *et al.*
 42. **Predictors of intubation in COVID-19 patients treated with out-of-ICU continuous positive airway pressure.** Pulmonology 2021; De Vita N, Scotti L, Cammarota G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500220>
 43. **Non-invasive respiratory support paths in hospitalized patients with COVID-19: proposal of an algorithm.** Pulmonology 2021; Winck JC, Scala R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33516668>
 44. **Vitamin D and COVID-19: evidence and recommendations for supplementation.** R Soc Open Sci 2020; 7:201912Griffin G, Hewison M, Hopkin J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489300>
 45. **Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations.** Trials 2021; 22:100. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509275>
 46. **Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension.** World J Clin Cases 2021; 9:47-60Tian C, Li N, Bai Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511171>
 47. **Utilization of extracorporeal membrane oxygenation during the COVID-19 pandemic.** World J Crit Care Med 2021; 10:1-11Kichloo A, Kumar A, Amir R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33505868>

Mental – public health (105 articles)

1. **Loneliness during the COVID-19 pandemic.** Aging Ment. Health 2021:1-4Dahlberg L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491474>

2. **Frontotemporal dementia and COVID-19: Hypothesis generation and roadmap for future research.** *Alzheimers Dement (N Y)* 2020; 6:e12085Ng KP, Chiew HJ, Hameed S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490361>
3. **Perspectives: potential therapeutic approach with inhalation of ACE2-derived peptides for SARS-CoV-2 infection.** *Am J Clin Exp Immunol* 2020; 9:73-80Talotta R, Roberston ES. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489475>
4. **Mental Health Multimorbidity among Caregivers of Older Adults During the COVID-19 Epidemic.** *Am J Geriatr Psychiatry* 2021; Li Q, Zhang H, Zhang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509676>
5. **Modeling anxiety and fear of COVID-19 using machine learning in a sample of Chinese adults: associations with psychopathology, sociodemographic, and exposure variables.** *Anxiety Stress Coping* 2021:1-15Elhai JD, Yang H, McKay D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496211>
6. **Burnout among Healthcare Providers of COVID-19; a Systematic Review of Epidemiology and Recommendations.** *Arch Acad Emerg Med* 2021; 9:e7Sharifi M, Asadi-Pooya AA, Mousavi-Roknabadi RS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490964>
7. **Telephonic follow-up during COVID-19 to maintain continuity of care for persons with psychiatric disorders.** *Asian J Psychiatr* 2021; 57:102564Naik SS, Rahul P, Harihara S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516153>
8. **Factors Associated with Symptoms of Depression and Psychological Distress during the COVID-19 Pandemic.** *Behav Sci (Basel)* 2021; 11Guo Y, Sims OT, Qin W, Yang F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494234>
9. **Exploring nursing managers' perceptions of nursing workforce management during the outbreak of COVID-19: a content analysis study.** *BMC Nurs.* 2021; 20:27Poortaghi S, Shahmari M, Ghobadi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514351>
10. **Domestic violence and its relationship with quality of life in pregnant women during the outbreak of COVID-19 disease.** *BMC Pregnancy Childbirth* 2021; 21:88Naghizadeh S, Mirghafourvand M, Mohammadirad R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509103>
11. **Prevalence and its associated factors of depressive symptoms among Chinese college students during the COVID-19 pandemic.** *BMC Psychiatry* 2021; 21:66Yu M, Tian F, Cui Q, Wu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514336>
12. **Depressive, anxiety, and burnout symptoms on health care personnel at a month after COVID-19 outbreak in Indonesia.** *BMC Public Health* 2021; 21:227Sunjaya DK, Herawati DMD, Siregar AYM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509159>
13. **Behaviour adoption approaches during public health emergencies: implications for the COVID-19 pandemic and beyond.** *BMJ Glob Health* 2021; 6Jalloh MF, Nur AA, Nur SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514594>
14. **Barriers and facilitators to populational adherence to prevention and control measures of COVID-19 and other respiratory infectious diseases: a rapid qualitative evidence synthesis protocol.** *BMJ Open* 2021; 11:e045529Monteiro KS, Santino TA, Jácome AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514584>

15. **COVID-19 wellbeing study: a protocol examining perceived coercion and psychological well-being during the COVID-19 pandemic by means of an online survey, asynchronous virtual focus groups and individual interviews.** BMJ Open 2021; 11:e043418Ranieri V, Sem Stoltenberg A, Pizzo E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495259>
16. **Viewpoint | European COVID-19 exit strategy for people with severe mental disorders: too little, but not yet too late.** Brain Behav Immun 2021; De Picker LJ, Yolken R, Benedetti F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493625>
17. **Serum albumin concentrations are associated with disease severity and outcomes in coronavirus 19 disease (COVID-19): a systematic review and meta-analysis.** Clin. Exp. Med. 2021:1-12Paliogiannis P, Mangoni AA, Cangemi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511503>
18. **Neurocognitive deficits in severe COVID-19 infection: Case series and proposed model.** Clin. Neuropsychol. 2021:1-20Whiteside DM, Oleynick V, Holker E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487098>
19. **Anxiety Sensitivity Moderates the Impact of COVID-19 Perceived Stress on Anxiety and Functional Impairment.** Cognit. Ther. Res. 2021:1-8Manning K, Eades ND, Kauffman BY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500595>
20. **Patient Volume and Dispositions in a VA Psychiatric Emergency Room During COVID-19.** Community Ment. Health J. 2021; Mitchell L, Fuehrlein B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515359>
21. **Loneliness and social isolation: determinants of cardiovascular outcomes: Implications in COVID-19 era.** Curr. Cardiol. Rev. 2021; Sharma T, Padala PR, Mehta JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511946>
22. **Scanning the VIRUS: A study of dimensions of stress and coping with COVID-19.** Curr. Psychol. 2021:1-11Ahuja KK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488039>
23. **Mental health problems experienced by patients with rheumatic diseases during COVID-19 pandemic.** Curr. Rheumatol. Rev. 2021; Adnine A, Nadiri K, Soussan I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504309>
24. **Media use pattern as an indicator of mental health in the COVID-19 pandemic: Dataset from India.** Data Brief 2021; 34:106722Mukherjee M, Maity C, Chatterjee S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490336>
25. **So far, how effective were distancing measures during the COVID-19 pandemic?** Deutsche Medizinische Wochenschrift 2020; 145:1530-1531Klein F.
26. Deutsche Medizinische Wochenschrift 2020; 145:1811Middeke M.
27. **Stress, coping strategies and health-related quality of life during the corona pandemic in April 2020 in Germany.** Deutsche Medizinische Wochenschrift 2021; 146:E11-E20Peters E, Hübner J, Katalinic A.
28. **The psychological burden of the COVID-19 pandemic severity.** Econ. Hum. Biol. 2021; 41:100979Le K, Nguyen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497964>
29. **Dynamic Public Perceptions of the Coronavirus Disease Crisis, the Netherlands, 2020.** Emerg Infect Dis 2021; 27de Vries M, Claassen L, Te Wierik MJM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493429>
30. **Telephone screening of cognitive status (TICS) in severe COVID-19 patients: Utility in the era of social isolation.** eNeurologicalSci 2021:100322Soldati AB, Almeida C, Lima M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495738>

31. **Impact of the COVID-19 pandemic on quality of life and mental health in children and adolescents in Germany.** Eur. Child Adolesc. Psychiatry 2021; Ravens-Sieberer U, Kaman A, Erhart M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492480>
32. **Web searches for anxiolytic drugs during the COVID-19 outbreak in the USA.** Eur J Hosp Pharm 2021; Lippi G, Henry BM, Sanchis-Gomar F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504508>
33. **Impact of Coronavirus Disease (COVID-19) Pandemic on Psychological Well-Being of the Pakistani General Population.** Front Psychiatry 2020; 11:564364Khan AA, Lodhi FS, Rabbani U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510654>
34. **Prevalence and Risk Factors of Anxiety, Depression, and Sleep Problems Among Caregivers of People Living With Neurocognitive Disorders During the COVID-19 Pandemic.** Front Psychiatry 2020; 11:590343Li Q, Zhang H, Zhang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488423>
35. **Death Associated With Coronavirus (COVID-19) Infection in Individuals With Severe Mental Disorders in Sweden During the Early Months of the Outbreak- An Exploratory Cross-Sectional Analysis of a Population-Based Register Study.** Front Psychiatry 2020; 11:609579Maripuu M, Bendix M, Vihlund L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488430>
36. **Mental Health During COVID-19: Tam Giao and Vietnam's Response.** Front Psychiatry 2020; 11:589618Small S, Blanc J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488422>
37. **Who Is Listening? Spokesperson Effect on Communicating Social and Physical Distancing Measures During the COVID-19 Pandemic.** Front. Psychol. 2020; 11:564434Abu-Akel A, Spitz A, West R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510664>
38. **Compulsive Internet Pornography Use and Mental Health: A Cross-Sectional Study in a Sample of University Students in the United States.** Front. Psychol. 2020; 11:613244Camilleri C, Perry JT, Sammut S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510691>
39. **Together Against COVID-19 Concerns: The Role of the Dyadic Coping Process for Partners' Psychological Well-Being During the Pandemic.** Front. Psychol. 2020; 11:578395Donato S, Parise M, Pagani AF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488449>
40. **Early Life Stress Predicts Depressive Symptoms in Adolescents During the COVID-19 Pandemic: The Mediating Role of Perceived Stress.** Front. Psychol. 2020; 11:603748Gotlib IH, Borchers LR, Chahal R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510680>
41. **Assessing the Transitional Impact and Mental Health Consequences of the COVID-19 Pandemic Onset.** Front. Psychol. 2020; 11:607976Heanoy EZ, Shi L, Brown NR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488471>
42. **Time and Emotion During Lockdown and the Covid-19 Epidemic: Determinants of Our Experience of Time?** Front. Psychol. 2020; 11:616169Martinelli N, Gil S, Belletier C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488485>
43. **The Psychological State of Teachers During the COVID-19 Crisis: The Challenge of Returning to Face-to-Face Teaching.** Front. Psychol. 2020; 11:620718Ozamiz-Etxebarria N, Berasategi Santxo N, Idoiaga Mondragon N, Dosil Santamaría M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510694>

44. **Goals and Self-Efficacy Beliefs During the Initial COVID-19 Lockdown: A Mixed Methods Analysis.** *Front. Psychol.* 2020; 11:559114 Ritchie L, Cervone D, Sharpe BT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510663>
45. **Healthcare Workers Who Work With COVID-19 Patients Are More Physically Exhausted and Have More Sleep Problems.** *Front. Psychol.* 2020; 11:625626 van Roekel H, van der Fels IMJ, Bakker AB, Tummers LG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488489>
46. **Hospital Preparedness, Resilience, and Psychological Burden Among Clinical Nurses in Addressing the COVID-19 Crisis in Riyadh, Saudi Arabia.** *Front Public Health* 2020; 8:573932 Balay-Odao EM, Alquwez N, Inocian EP, Alotaibi RS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490012>
47. **A Resilient Health System in Response to Coronavirus Disease 2019: Experiences of Turkey.** *Front Public Health* 2020; 8:577021 Kesinkilivß B, Shaikh I, Tekin A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490014>
48. **Personality, Coping Strategies, and Mental Health in High-Performance Athletes During Confinement Derived From the COVID-19 Pandemic.** *Front Public Health* 2020; 8:561198 Leguizamo F, Olmedilla A, Nájuez A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490009>
49. **The Many Faces of Covid-19 at a Glance: A University Hospital Multidisciplinary Account From Milan, Italy.** *Front Public Health* 2020; 8:575029 Priori A, Baisi A, Banderali G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490013>
50. **Prevalence of psychiatric morbidity following discharge after COVID-19 hospitalization.** *Gen. Hosp. Psychiatry* 2020; Wang PR, Oyem PC, Viguera AC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494979>
51. **The experiences of healthcare workers during the COVID-19 crisis in Lagos, Nigeria: A qualitative study.** *Germes* 2020; 10:356-366 Okediran JO, Ilesanmi OS, Fetuga AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489951>
52. **Psychiatric symptoms, risk, and protective factors among university students in quarantine during the COVID-19 pandemic in China.** *Global Health* 2021; 17:15 Sun S, Goldberg SB, Lin D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494769>
53. **Access to Information and Degree of Community Awareness of Preventive Health Measures in the Face of COVID-19 in Spain.** *Healthcare (Basel)* 2021; 9 Gutierrez-Velasco L, Liébana-Presa C, Abella-Santos E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498281>
54. **Identifying and addressing psychosocial determinants of adherence to physical distancing guidance during the COVID-19 pandemic - project protocol.** *HRB Open Res* 2020; 3:58 Durand H, Bacon SL, Byrne M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490860>
55. **Inequality-Related Health and Social Factors and Their Impact on Well-Being during the COVID-19 Pandemic: Findings from a National Survey in the UK.** *Int J Environ Res Public Health* 2021; 18 Chen DT, Wang YJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498842>
56. **Psychological Wellbeing and Academic Experience of University Students in Australia during COVID-19.** *Int J Environ Res Public Health* 2021; 18 Dodd RH, Dadaczynski K, Okan O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498376>
57. **Prevalence and Factors Associated with Mental and Emotional Health Outcomes among Africans during the COVID-19 Lockdown Period-A Web-**

- based Cross-Sectional Study.** *Int J Environ Res Public Health* 2021; 18Langsi R, Osuagwu UL, Goson PC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494209>
58. **Anxiety and Panic Buying Behaviour during COVID-19 Pandemic-A Qualitative Analysis of Toilet Paper Hoarding Contents on Twitter.** *Int J Environ Res Public Health* 2021; 18Leung J, Chung JYC, Tisdale C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514049>
 59. **Burnout, Psychological Capital and Health during COVID-19 Social Isolation: A Longitudinal Analysis.** *Int J Environ Res Public Health* 2021; 18Meseguer de Pedro M, Fernández-Valera MM, García-Izquierdo M, Soler Sánchez MI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504110>
 60. **Anxiety in Frontline and Non-Frontline Healthcare Providers in Kelantan, Malaysia.** *Int J Environ Res Public Health* 2021; 18Mohd Noor N, Che Yusof R, Yacob MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498397>
 61. **Influence of the CoViD-19 Pandemic on Mental Workload and Burnout of Fashion Retailing Workers in Spain.** *Int J Environ Res Public Health* 2021; 18Rodríguez-López AM, Rubio-Valdehita S, Díaz-Ramiro EM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499416>
 62. **Experience and Health-Related Behavior in Times of the Corona Crisis in Germany: An Exploratory Psychological Survey Considering the Identification of Compliance-Enhancing Strategies.** *Int J Environ Res Public Health* 2021; 18Welter VDE, Welter NGE, Grovüschedl J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494536>
 63. **COVID-19-Related Intolerance of Uncertainty and Mental Health among Back-To-School Students in Wuhan: The Moderation Effect of Social Support.** *Int J Environ Res Public Health* 2021; 18Zhuo L, Wu Q, Le H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499409>
 64. **The vulnerabilities of the Brazilian health workforce during health emergencies: Analysing personal feelings, access to resources and work dynamics during the COVID-19 pandemic.** *Int. J. Health Plann. Manage.* 2021; Lotta G, Fernandez M, Corrêa M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502795>
 65. **Coronavirus Anxiety and Psychological Adjustment in College Students: Exploring the Role of College Belongingness and Social Media Addiction.** *Int J Ment Health Addict* 2021;1-14Arslan G, Yıldırım M, Zangeneh M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500688>
 66. **Psychometric Properties of the Norwegian Version of the Fear of COVID-19 Scale.** *Int J Ment Health Addict* 2021;1-19Iversen MM, Norekvål TM, Oterhals K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495690>
 67. **Year 2020: How Will It Impact Identities of Children and Youth over Time?** *Int J Ment Health Addict* 2021;1-3Khanlou N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495688>
 68. **Psychological Impact of COVID-19 Among People from the Banking Sector in Bangladesh: a Cross-Sectional Study.** *Int J Ment Health Addict* 2021;1-15Yasmin S, Alam MK, Ali FB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495689>
 69. **The repercussions of perceived threat from COVID-19 on the mental health of actively employed nurses.** *Int. J. Ment. Health Nurs.* 2021; Gv°zquez Linares JJ, Molero Jurado MDM, Martos Martvñez Å *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491869>

70. **Phone follow up to families of COVID-19 patients who died at the hospital: families' grief reactions and clinical psychologists' roles.** Int. J. Psychol. 2021; Menichetti Delor JP, Borghi L, Cao di San Marco E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33511652>
71. **The psychological impact of COVID-19 and restrictive measures in the world.** J. Affect. Disord. 2021; 283:36-51 Passavanti M, Argentieri A, Barbieri DM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33516085>
72. **Coping during COVID-19: examining student stress and depressive symptoms.** J. Am. Coll. Health 2021:1-4 Mushquash AR, Grassia E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33513079>
73. **Study of risk factors and psychological impact in physicians diagnosed with COVID-19: An online, postexposure, cross-sectional survey.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:345-349 Bajaj JS, Solanki SL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33487901>
74. **Scheduling elective surgeries following COVID-19: Challenges ahead.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:291-296 Neethirajan SGR, Manickam A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33487894>
75. **Understanding and managing pandemic-related panic buying.** J. Anxiety Disord. 2021; 78:102364 Taylor S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517219>
76. **Cognitive and Affective Risk Beliefs and their Association with Protective Health Behavior in Response to the Novel Health Threat of COVID-19.** J. Behav. Med. 2021; Magnan RE, Gibson LP, Bryan AD.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33517487>
77. **Anxiety and its association with perceived stress and insomnia among nurses fighting against COVID-19 in Wuhan: a cross-sectional survey.** J. Clin. Nurs. 2021; Shen Y, Zhan Y, Zheng H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497526>
78. **Understanding the Impact of the COVID-19 Pandemic on the Mental Health of Transgender and Gender Nonbinary Individuals Engaged in a Longitudinal Cohort Study.** J. Homosex. 2021:1-20 Kidd JD, Jackman KB, Barucco R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33502286>
79. **Coping strategies and mental health during COVID-19 lockdown.** J Ment Health 2021:1-8 Budimir S, Probst T, Pieh C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502917>
80. **Nursing students, mental health status during COVID-19 quarantine: evidence from three European countries.** J Ment Health 2021:1-6 Patelarou A, Mechili EA, Galanis P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504241>
81. **Keeping well in a COVID-19 crisis: a qualitative study formulating the perspectives of mental health service users and carers.** J Ment Health 2021:1-10 Simblett SK, Wilson E, Morris D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502941>
82. **Anxiety, perceived control and pandemic behaviour in Thailand during COVID-19: Results from a national survey.** J. Psychiatr. Res. 2021; 135:212-217 Goodwin R, Wiwattanapantuwong J, Tuicomepee A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33497875>
83. **Post-traumatic stress, anxiety, and depressive symptoms in caregivers of children tested for COVID-19 in the acute phase of the Italian outbreak.** J.

- Psychiatr. Res. 2021; 135:256-263 Orsini A, Corsi M, Pedrinelli V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33508545>
84. **Workplace violence and its association with quality of life among mental health professionals in China during the COVID-19 pandemic.** J. Psychiatr. Res. 2021; 135:289-293 Xie XM, Zhao YJ, An FR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33516081>
 85. **Distressing healthcare workers during the COVID-19 pandemic: the challenges of holiday season in the Philippines.** J Public Health (Oxf) 2021; Lagman JDN, Vergara RJD, Sarmiento PJD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503662>
 86. **Public health matters: why is Latin America struggling in addressing the pandemic?** J. Public Health Policy 2021:1-14 Martinez-Valle A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33510400>
 87. **Transactional Associations Between Parent and Late Adolescent Internalizing Symptoms During the COVID-19 Pandemic: The Moderating Role of Avoidant Coping.** J. Youth Adolesc. 2021:1-11 Lorenzo NE, Zeytinoglu S, Morales S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33495969>
 88. **Postpartum Depressive Symptoms during the Beginning of the COVID-19 Pandemic: An Examination of Population Birth Data from Central New Jersey.** Matern Child Health J 2021; McFarland MJ, McFarland CAS, Hill TD, D'Oria R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33492587>
 89. **The Impact of Poor Nutrient Intakes and Food Insecurity on the Psychological Distress among Community-Dwelling Middle-Aged and Older Adults during the COVID-19 Pandemic.** Nutrients 2021; 13 Malek Rivan NF, Yahya HM, Shahar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503860>
 90. **Pain during and after COVID-19 in Germany and worldwide: a narrative review of current knowledge.** Pain Rep 2021; 6:e893 Meyer-Frießem CH, Gierthmühlen J, Baron R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490851>
 91. **The impact of the COVID-19 pandemic on the quality of life and depression, anxiety, and stress levels of individuals above the age of eighteen.** Perspect. Psychiatr. Care 2021; Öztürk Çopur E, Karasu F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33512758>
 92. **Psychological and Behavioral Predictors of Vaccine Efficacy: Considerations for COVID-19.** Perspect. Psychol. Sci. 2021:1745691621989243 Madison AA, Shrout MR, Renna ME, Kiecolt-Glaser JK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501900>
 93. **Working on the Frontlines of the COVID-19 Pandemic: A Qualitative Study of Physical Therapists' Experience in Spain.** Phys Ther 2021; Palacios-Ceña D, Fernández-de-Las-Peñas C, Palacios-Ceña M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33517462>
 94. **Cognitive and psychophysiological impact of surgical mask use during university lessons.** Physiol. Behav. 2021:113342 Tornero-Aguilera JF, Clemente-Suárez VJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516744>
 95. **A portrait of the early and differential mental health impacts of the COVID-19 pandemic in Canada: Findings from the first wave of a nationally representative cross-sectional survey.** Prev. Med. 2021:106333 Jenkins EK, McAuliffe C, Hirani S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509605>
 96. **Anticipated mental health consequences of coronavirus in a nationally-representative sample: Context, coverage, and economic consequences.** Prev.

- Med. 2021:106441Piltch-Loeb R, Merdjanoff A, Meltzer G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33515588>
97. **Addressing the Consequences of the COVID-19 Lockdown for Children's Mental Health: Investing in School Mental Health Programs.** Psychiatr. Serv. 2021:appips202000597Hamoda HM, Chiumento A, Alonge O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33502220>
 98. **Anxiety levels in patients admitted to the emergency department with myocardial infarction or COVID-19 pneumonia.** Psychol Health Med 2021:1-9Váafülar A, KavBer f. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486994>
 99. **Exploring the association between coronavirus stress, meaning in life, psychological flexibility, and subjective well-being,ÄÉ.** Psychol Health Med 2021:1-12Arslan G, Allen KA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487048>
 100. **Factors associated with Brazilian physical therapists' perception of stress during the COVID-19 pandemic: a cross-sectional survey.** Psychol Health Med 2021:1-12Duarte H, Daros Vieira R, Cardozo Rocon P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33487038>
 101. **Iranian psychosocial status and its determinant factors during the prevalence of COVID-19 disease.** Psychol Health Med 2021:1-12Hossini Rafsanjanipoor SM, Zakeri MA, Dehghan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486996>
 102. **Psychological Impact of COVID-19 Cases on Medical Staff of Beijing Xiaotangshan Hospital.** Psychol. Res. Behav. Manag. 2021; 14:41-47Fu Y, Wang M, Zhao B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500670>
 103. **Gender differences in couples' division of childcare, work and mental health during COVID-19.** Rev Econ Househ 2021:1-30Zamarro G, Prados MJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33488316>
 104. **Psychosocial and clinical effects of the COVID-19 pandemic in patients with childhood rheumatic diseases and their parents.** Rheumatol. Int. 2021:1-9Durcan G, Barut K, Haslak F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502554>
 105. **Sleeping when the world locks down: Correlates of sleep health during the COVID-19 pandemic across 59 countries.** Sleep Health 2021; Yuksel D, McKee GB, Perrin PB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509687>

Meta-analyses - systematic reviews (6 articles)

1. **Response to: 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis' by Lee.** Ann. Rheum. Dis. 2021; Akiyama S, Hamdeh S, Micic D, Sakuraba A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504478>
2. **Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'.** Ann. Rheum. Dis. 2021; Lee YH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504479>
3. **Serum albumin concentrations are associated with disease severity and outcomes in coronavirus 19 disease (COVID-19): a systematic review and meta-analysis.** Clin. Exp. Med. 2021:1-12Paliogiannis P, Mangoni AA, Cangemi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511503>
4. **Neutrophil-to-lymphocyte ratio is independently associated with COVID-19 severity: An updated meta-analysis based on adjusted effect estimates.** Int. J.

Lab. Hematol. 2021; Li Y, Hou H, Diao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506621>

5. **A Comprehensive Review of Detection Methods for SARS-CoV-2.** Microorganisms 2021; 9Eftekhari A, Alipour M, Chodari L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499379>
6. **High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data.** World J. Gastroenterol. 2020; 26:7693-7706Díaz LA, Idalsoaga F, Cannistra M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505145>

Mortality (29 articles)

1. **Causes and Circumstances of Death Among Patients Hospitalized with COVID-19: A Retrospective Cohort Study.** Ann Am Thorac Soc 2020; Ketcham SW, Bolig T, Molling DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33315531>
2. **Frailty is associated with in-hospital mortality in older hospitalised COVID-19 patients in the Netherlands: the COVID-OLD study.** Age Ageing 2021; Blomaard LC, van der Linden CMJ, van der Bol JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514998>
3. **COVID 19 with neurological symptoms, rhabdomyolysis and brain death: a case report.** Am J Clin Exp Immunol 2020; 9:114-117Aria A, Forouharnejad K, Mortazavi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489479>
4. **Resuscitation during the COVID-19 pandemic - Guidelines of the European Resuscitation Council.** Anesthesiologie Intensivmedizin Notfallmedizin Schmerztherapie 2021; 56:5.
5. **Women and COVID-19: severity and mortality in hospitalized middle-aged and older patients.** Climacteric 2021:1-6Balcázar-Hernández L, Martínez-Murillo C, Ramos-Peñafiel C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513033>
6. **Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors.** Clin Infect Dis 2021; 72:249-253Erikstrup C, Hother CE, Pedersen OBV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501969>
7. **Novel Modifications for a Virtual Interview Visit to Simulate the Traditional, Live, Site Visit for GI Fellowship Applicants for an Academic GI Fellowship Program Due to the COVID-19 Pandemic.** Dig. Dis. Sci. 2021:1-2Cappell MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496874>
8. **Worsening of heart failure by coronavirus disease 2019 is associated with high mortality.** ESC Heart Fail 2021; Bocchi EA, Lima I, Biselli B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498096>
9. **Sars-CoV-2 in Germany: association between deaths and positive rate.** Eur. J. Clin. Invest. 2021:e13500Scherb H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497463>
10. **Gender specific excess mortality in Italy during the COVID-19 pandemic accounting for age.** Eur. J. Epidemiol. 2021:1-6Gianicolo EAL, Russo A, Bv^ochler B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495860>
11. **Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients.** Exp Hematol Oncol 2021; 10:5Bao C, Tao X, Cui W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504359>
12. **The Relationship Between Positivity for COVID-19 RT-PCR and Symptoms, Clinical Findings, and Mortality in Turkey.** Expert Rev Mol Diagn 2021; Ozcan E,

- Yavuzer S, Borku Uysal B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496627>
13. **Death Associated With Coronavirus (COVID-19) Infection in Individuals With Severe Mental Disorders in Sweden During the Early Months of the Outbreak- An Exploratory Cross-Sectional Analysis of a Population-Based Register Study.** *Front Psychiatry* 2020; 11:609579 Maripuu M, Bendix M, $\sqrt{\text{r}}\text{h} \text{lund L}$ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488430>
 14. **A Descriptive Study on Causes of Death in Hospitalized Patients in an Acute General Hospital of Southern Italy during the Lockdown due to Covid-19 Outbreak.** *Healthcare (Basel)* 2021; 9 Mascolo P, Feola A, Sementa C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503857>
 15. **Analysis of Policies Based on the Multi-Fuzzy Regression Discontinuity, in Terms of the Number of Deaths in the Coronavirus Epidemic.** *Healthcare (Basel)* 2021; 9 Wang X, Chen C, Du Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499030>
 16. **Different SARS-CoV-2 haplotypes associate with geographic origin and case fatality rates of COVID-19 patients.** *Infect Genet Evol* 2021:104730 Goyal M, De Bruyne K, van Belkum A, West B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513449>
 17. **Association of clade-G SARS-CoV-2 viruses and age with increased mortality rates across 57 countries and India.** *Infect Genet Evol* 2021:104734 Pandit B, Bhattacharjee S, Bhattacharjee B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508515>
 18. **Worldwide inverse correlation between Bacille Calmette-Guérin (BCG) immunization and COVID-19 mortality.** *Infection* 2021:1-11 Li WX. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495884>
 19. **The Impact of Policy Measures on Human Mobility, COVID-19 Cases, and Mortality in the US: A Spatiotemporal Perspective.** *Int J Environ Res Public Health* 2021; 18 Li Y, Li M, Rice M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498647>
 20. **Phone follow up to families of COVID-19 patients who died at the hospital: families' grief reactions and clinical psychologists' roles.** *Int. J. Psychol.* 2021; Menichetti Delor JP, Borghi L, Cao di San Marco E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511652>
 21. **Inflammatory biomarkers as independent prognosticators of 28-day mortality for COVID-19 patients admitted to general medicine or ICU wards: a retrospective cohort study.** *Intern Emerg Med* 2021:1-10 Pitre T, Jones A, Su J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496923>
 22. **Interpretation of COVID-19 case fatality risk measures in England.** *J. Epidemiol. Community Health* 2021; Harman K, Allen H, Kall M, Dabrera G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514625>
 23. **Evaluating the Impact of New York's Executive Order on Face Mask Use on COVID-19 Cases and Mortality: a Comparative Interrupted Times Series Study.** *J Gen Intern Med* 2021:1-5 Li L, Liu B, Liu SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501543>
 24. **Factors associated with COVID-19 severity and mortality among Hispanic patients living on the USA-Mexico border.** *J. Investig. Med.* 2021; Cervantes J, Sureen A, Galura G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514615>

25. **Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey.** *J. Nutr. Health Aging* 2021; 25:189-196Karahan S, Katkat F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33491033>
26. **Socioeconomic factors and the probability of death by Covid-19 in Brazil.** *J Public Health (Oxf)* 2021; De Negri F, Galiezz R, Miranda P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33501982>
27. **Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.** *Leuk. Lymphoma* 2021:1-16Bhogal T, Khan UT, Lee R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33508995>
28. **[Cause of Death: Lack of Movement].** *Pediatr. Padol.* 2021:1-6Pawlik L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33487757>
29. **Blood omega-3 fatty acids and death from COVID-19: A pilot study.** *Prostaglandins Leukot. Essent. Fatty Acids* 2021; 166:102250Asher A, Tintle NL, Myers M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516093>
30. **[Clinical characteristics and comorbidities associated with mortality in patients with COVID-19 in Coahuila (Mexico)].** *Rev Clin Esp* 2021; Salinas Aguirre JE, S^onchez Garc^oa C, Rodr^oiguez Sanchez R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33495654>

Online – IT – Apps (40 articles)

1. **Real-Time Telehealth Treatment Team Consultation for Self-Injury by Individuals with Autism Spectrum Disorder.** *Adv Neurodev Disord* 2021:1-13Singh NN, Lancioni GE, Medvedev ON *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33490369>
2. **Utilization of telemedicine in rhinologic practice during COVID-19 pandemic.** *Am. J. Otolaryngol.* 2021; 42:102929Alshareef M, Alsaleh S, Albaharna H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33508591>
3. **Patient satisfaction with telemedicine in rhinology during the COVID-19 pandemic.** *Am. J. Otolaryngol.* 2021; 42:102921Hentati F, Cabrera CI, D'Anza B, Rodriguez K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508592>
4. **Intensive care digital health response to emerging infectious disease outbreaks such as COVID-19.** *Anaesth. Intensive Care* 2021:310057x20975777Kirrane MD, Shrapnel S, Ramanan M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33504171>
5. **Integrated solutions to manage new normals in healthcare-lessons from corona virus disease 2019.** *Ann Med Surg (Lond)* 2021; 62:76-79Dawar S, Bhutani N, Sudan DPS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505675>
6. **Twitter Analytics to Inform Provisional Guidance for COVID-19 Challenges in the Meatpacking Industry.** *Ann Work Expo Health* 2021; Durand-Moreau Q, Mackenzie G, Adisesh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492381>
7. **Virtual Dr. Amy Goes to Clinic.** *Arch. Phys. Med. Rehabil.* 2021; Houtrow A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33497700>
8. **Making the case for strong health information systems during a pandemic and beyond.** *Arch Public Health* 2021; 79:13Schmidt AE, Abboud LA, Bogaert P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33514433>

9. **Telephonic follow-up during COVID-19 to maintain continuity of care for persons with psychiatric disorders.** Asian J Psychiatr 2021; 57:102564Naik SS, Rahul P, Harihara S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516153>
10. **Combating the COVID-19 infodemic: a three-level approach for low and middle-income countries.** BMJ Glob Health 2021; 6Dash S, Parray AA, De Freitas L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514596>
11. **Exploring the Efficacy of Telehealth for Family Therapy Through Systematic, Meta-analytic, and Qualitative Evidence.** Clin. Child Fam. Psychol. Rev. 2021; McLean SA, Booth AT, Schnabel A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492545>
12. **Medical student education in the time of COVID-19: A virtual solution to the introductory radiology elective.** Clin Imaging 2021; 75:67-74Belfi LM, Dean KE, Bartolotta RJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497880>
13. **Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives.** Curr. Oncol. 2021; 28:671-677Loree JM, Dau H, Rebić N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499380>
14. **Media use pattern as an indicator of mental health in the COVID-19 pandemic: Dataset from India.** Data Brief 2021; 34:106722Mukherjee M, Maity C, Chatterjee S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490336>
15. **Dark Web Marketplaces and COVID-19: before the vaccine.** EPJ Data Sci 2021; 10:6Bracci A, Nadini M, Aliapoulos M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500876>
16. **Compulsive Internet Pornography Use and Mental Health: A Cross-Sectional Study in a Sample of University Students in the United States.** Front. Psychol. 2020; 11:613244Camilleri C, Perry JT, Sammut S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510691>
17. **COVID-19 Pandemic Spurs Medical Telerobotic Systems: A Survey of Applications Requiring Physiological Organ Motion Compensation.** Front Robot AI 2020; 7:594673Cheng L, Tavakoli M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501355>
18. **Exploring the Applicability of Robot-Assisted UV Disinfection in Radiology.** Front Robot AI 2020; 7:590306McGinn C, Scott R, Donnelly N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501347>
19. **#Covid-19: An exploratory investigation of hashtag usage on Twitter.** Health Policy 2021; Petersen K, Gerken JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487479>
20. **The Impact of the COVID Crisis on the Innovative Potential of China's Internet Platforms.** Her Russ Acad Sci 2020; 90:779-788Danilin IV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495683>
21. **Machine learning predictive model for severe COVID-19.** Infect Genet Evol 2021:104737Kang J, Chen T, Luo H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515712>
22. **COVID-19 and STEMI: The role of telecardiology in the management of STEMI diagnosis during COVID 19 pandemic.** Int J Cardiol Heart Vasc 2021; 32:100720De Bonis S, Salerno N, Bisignani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501370>
23. **Machine and Deep Learning towards COVID-19 Diagnosis and Treatment: Survey, Challenges, and Future Directions.** Int J Environ Res Public Health 2021;

- 18Alafif T, Tehame AM, Bajaba S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513984>
24. **Smartphone Use during the COVID-19 Pandemic: Social Versus Physical Distancing.** Int J Environ Res Public Health 2021; 18David ME, Roberts JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503907>
 25. **Phone follow up to families of COVID-19 patients who died at the hospital: families' grief reactions and clinical psychologists' roles.** Int. J. Psychol. 2021; Menichetti Delor JP, Borghi L, Cao di San Marco E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511652>
 26. **Leveraging conversational technology to answer common COVID-19 questions.** J Am Med Inform Assoc 2021; McKillop M, South BR, Preininger A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517402>
 27. **Patch Monitors for Arrhythmia Monitoring in Patients for Suspected Inherited Arrhythmia Syndrome.** J Cardiovasc Electrophysiol 2021; Cheung CC, Davies B, Gibbs K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512057>
 28. **Technology Use to Bridge the Gap of Social Distancing during COVID-19.** J Geriatr Med Gerontol 2020; 6Padala KP, Jendro AM, Wilson KB, Padala PR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511321>
 29. **Cancer patient experience of telephone clinics implemented in light of COVID-19.** J. Oncol. Pharm. Pract. 2021:1078155221990101Dalby M, Hill A, Nabhani-Gebara S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504269>
 30. **Governmental actions to address COVID-19 misinformation.** J. Public Health Policy 2021:1-10Pomeranz JL, Schwid AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510401>
 31. **Telephone follow-up in urogynecology in the era of COVID-19 pandemic.** J Turk Ger Gynecol Assoc 2021; Frigerio M, Barba M, Manodoro S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506670>
 32. **Academic Nurse-Managed Community Clinics Transitioning to Telehealth: Case Report on the Rapid Response to COVID-19.** JMIR Nurs 2020; 3:e24521Sutter R, Cuellar AE, Harvey M, Hong YA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496682>
 33. **Putting the network to work: Learning networks in rapid response situations.** Learn Health Syst 2021; 5:e10251Vinson AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490384>
 34. **Visual SLAM for robot navigation in healthcare facility.** Pattern Recognit 2021; 113:107822Fang B, Mei G, Yuan X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495660>
 35. **Knowledge, Attitudes, Practices and Information Needs During the COVID-19 Pandemic in Indonesia.** Risk Manag. Healthc. Policy 2021; 14:163-175Sulistyawati S, Rokhmayanti R, Aji B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488129>
 36. **An Enhanced IoT Based Tracing and Tracking Model for COVID -19 Cases.** SN Comput Sci 2021; 2:42Rajasekar SJS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490971>
 37. **Patient and Physician Satisfaction with Telehealth During the COVID-19 Pandemic: Sports Medicine Perspective.** Telemed J E Health 2021; Kirby DJ, Fried JW, Buchalter DB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512302>
 38. **Physician Perspective and Key Satisfaction Indicators with Rapid Telehealth Adoption During the Coronavirus Disease 2019 Pandemic.** Telemed J E Health

- 2021; Saiyed S, Nguyen A, Singh R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513045>
39. **Expanding Access to Fetal Telecardiology During the COVID-19 Pandemic.** Telemed J E Health 2021; Schwartz BN, Klein JH, Barbosa MB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513044>
40. **Knowledge, attitudes, and practices related to the COVID-19 pandemic among Bangladeshi youth: a web-based cross-sectional analysis.** Z Gesundh Wiss 2021:1-11 Banik R, Rahman M, Sikder MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489718>

Other – Miscellaneous (67 articles)

1. **Covidophobia: From Cytokine Storm to Mass Hysteria, a New Subtype of Hypochondriasis?** Acta Med Port 2020; 33:856 Gama Marques J, Madruga Dias J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496255>
2. **[The Impact of the COVID-19 Pandemic in the Management of Occupational Injuries].** Acta Med Port 2020; 33:857 Relvas Silva M, Monteiro E, Santos Carvalho M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496256>
3. **Air quality change during the COVID-19 pandemic lockdown over the Auvergne-Rhône-Alpes region, France.** Air Qual Atmos Health 2021:1-12 Sbais SE, Mejjad N, Norelyaqine A, Bentayeb F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488840>
4. **Expressive Flamenco ©: An Emerging Expressive Arts-Based Practice.** Am J Dance Ther 2021:1-33 Sánchez García L, Pinna-Perez A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500594>
5. **Take a Moment: Reflections on a Pandemic, Suffering, and Humanity.** Am J Ophthalmol. 2021; Al-Khersan H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497674>
6. **The Experience of Teleworking with Dogs and Cats in the United States during COVID-19.** Animals (Basel) 2021; 11 Hoffman CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494484>
7. **When a pandemic and an epidemic collide: COVID-19, gut microbiota, and the double burden of malnutrition.** BMC Med 2021; 19:31 Littlejohn P, Finlay BB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504332>
8. **Social distancing during the COVID-19 pandemic: quantifying the practice in Michigan - a "hotspot state" early in the pandemic - using a volunteer-based online survey.** BMC Public Health 2021; 21:245 Cassidy-Bushrow AE, Baseer M, Kippen K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514350>
9. **Strengthening regulatory systems for medicines in a changed world: where do we go from here?** BMJ Glob Health 2021; 6 O'Brien J, Lumsden R, Macdonald J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495287>
10. **An Environmental Dilemma for China During the COVID-19 Pandemic: The Explosion of Disposable Plastic Wastes.** Bull. Environ. Contam. Toxicol. 2021; Liu J, Vethaak AD, An L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515068>
11. **Effects of the COVID-19 Pandemic on Spontaneous Reporting: Global and National Time-Series Analyses.** Clin. Ther. 2020; Hauben M, Hung E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509646>
12. **Worry about COVID-19 in relation to cognitive-affective smoking processes among daily adult combustible cigarette smokers.** Cogn. Behav. Ther. 2021:1-

- 15Shepherd JM, Fogle B, Garey L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511905>
13. **Corona: Following comprehensible logic.** Deutsches Arzteblatt International 2020; 117:A2055Wanner P.
 14. **Protective Immunity and Persistent Lung Sequelae in Domestic Cats after SARS-CoV-2 Infection.** Emerg Infect Dis 2021; 27:660-663Chiba S, Halfmann PJ, Hatta M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496650>
 15. **Maintaining efficient logistics and supply chain management operations during and after coronavirus (COVID-19) pandemic: learning from the past experiences.** Environ Dev Sustain 2021:1-22Illahi U, Mir MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488274>
 16. **The interactive effects of ambient air pollutants-meteorological factors on confirmed cases of COVID-19 in 120 Chinese cities.** Environ. Sci. Pollut. Res. Int. 2021:1-11Zhou J, Qin L, Meng X, Liu N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501581>
 17. **"The Graying Minority": Lived Experiences and Psychosocial Challenges of Older Transgender Adults During the COVID-19 Pandemic in India, A Qualitative Exploration.** Front Psychiatry 2020; 11:604472Banerjee D, Rao TSS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488427>
 18. **How Times of Crisis Serve as a Catalyst for Creative Action: An Agentic Perspective.** Front. Psychol. 2020; 11:600685Beghetto RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488463>
 19. **Uses and Perceptions of Music in Times of COVID-19: A Spanish Population Survey.** Front. Psychol. 2020; 11:606180Cabedo-Mas A, Arriaga-Sanz C, Moliner-Miravet L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510681>
 20. **The Role of Attitudes, Affect, and Income in Predicting COVID-19 Behavioral Intentions.** Front. Psychol. 2020; 11:567397Clemens KS, Matkovic J, Faasse K, Geers AL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488444>
 21. **Motivation and Commitment to Sports Practice During the Lockdown Caused by Covid-19.** Front. Psychol. 2020; 11:622595Leyton-Román M, de la Vega R, Jiménez-Castuera R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505343>
 22. **Creative Adaptability: Conceptual Framework, Measurement, and Outcomes in Times of Crisis.** Front. Psychol. 2020; 11:588172Orkibi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510671>
 23. **Knowledge, Attitudes, and Practices Toward COVID-19 Among Construction Industry Practitioners in China.** Front Public Health 2020; 8:599769Zheng L, Chen K, Ma L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490020>
 24. **Challenges, inequalities and COVID-19: Examples from indigenous Oaxaca, Mexico.** Glob Public Health 2021:1-11Cohen JH, Mata-Sánchez ND. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491559>
 25. **Primary care perspectives on pandemic politics.** Glob Public Health 2021:1-16Goodyear-Smith F, Kinder K, Eden AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491583>
 26. **Let's Not Joke about It Too Much! Exposure to COVID-19 Messaging, Attitudes and Protective Behavioral Intentions.** Healthcare (Basel) 2021; 9Curşeu PL, Coman AD, Fodor OC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504058>
 27. **Covid-19, Dow Jones and equity market movement in ASEAN-5 countries: evidence from wavelet analyses.** Heliyon 2021; 7:e05851Kamaludin K, Sundarasan S, Ibrahim I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506122>

28. **Covid-19 and the power of rules.** Hist Philos Life Sci 2021; 43:11Brady M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33502620>
29. **Novel pathogens, same old habits. A call for evidence-based research in the fight against COVID-19.** Infect Dis Now 2021; Legnani C, Legnani C, Dusi E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33495764>
30. **Will COVID-19 Lead to a Resurgence of Vaccine-Preventable Diseases?** Infect Drug Resist 2021; 14:119-124Khatiwada AP, Shrestha N, Shrestha S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33500634>
31. **Assessment of the Quality of Life during COVID-19 Pandemic: A Cross-Sectional Survey from the Kingdom of Saudi Arabia.** Int J Environ Res Public Health 2021; 18Algahtani FD, Hassan SU, Alsaif B, Zrieq R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33498152>
32. **Health Advertising during the Lockdown: A Comparative Analysis of Commercial TV in Spain.** Int J Environ Res Public Health 2021; 18Blanco-Herrero D, Gallardo-Camacho J, Arcila-Calderón C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504002>
33. **COVID-19-Related Changes in Perceived Household Food Waste in the United States: A Cross-Sectional Descriptive Study.** Int J Environ Res Public Health 2021; 18Cosgrove K, Vizcaino M, Wharton C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513709>
34. **Refugees in Canada during the First Wave of the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Edmonds J, Flahault A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33499071>
35. **The Influence of Human-Animal Interactions on Mental and Physical Health during the First COVID-19 Lockdown Phase in the U.K.: A Qualitative Exploration.** Int J Environ Res Public Health 2021; 18Shoesmith E, Shahab L, Kale D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499354>
36. **Public perspectives on firearm sales in the United States during the COVID-19 pandemic.** J Am Coll Emerg Physicians Open 2021; 2:e12293Khubchandani J, Price JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490995>
37. **Impact of Race and Socioeconomic Status on Outcomes in Patients Hospitalized with COVID-19.** J Gen Intern Med 2021;1-8Quan D, Luna Wong L, Shallal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506402>
38. **Medicare's Stewardship Role to Improve Care Delivery: Opportunities for the Biden Administration.** J. Health Polit. Policy Law 2021; Berenson R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33493320>
39. **Taking the Long View: COVID-19 Priorities for the Biden Administration.** J. Health Polit. Policy Law 2021; Galea S, Ettman CK, Maani N, Abdalla SM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33493275>
40. **The Spatial Impacts of COVID-19 Restrictions on LGBTIQ Wellbeing, Visibility, and Belonging in Tasmania, Australia.** J. Homosex. 2021;1-16Grant R, Gorman-Murray A, Briohny Walker B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492203>
41. **'Wisdom in the time of COVID-19'.** J. Investig. Med. 2021; 69:305-306Cobos E, Goldis G, McCallum R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495300>
42. **Promoting racial equity in COVID-19 resource allocation.** J. Med. Ethics 2021; Bruce L, Tallman R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514637>
43. **The benefits of peer transparency in safe workplace operation post pandemic lockdown.** J R Soc Interface 2021; 18:20200617Wey A, Champneys A, Dyson RJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501885>

44. **Emergence of Additive Manufacturing in global scale during the crisis of 2019-nCoV (novel corona virus).** Mater Today Proc 2021; Tambrallimath V, Keshavamurthy R, Badari A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495731>
45. **Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic.** Med. Decis. Making 2021;272989x21990371Yaesoubi R, Havumaki J, Chitwood MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504258>
46. **The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules.** Molecules 2021; 26Torre BG, Albericio F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504104>
47. **The brain tumor not-for-profit and charity experience of COVID-19: reacting and adjusting to an unprecedented global pandemic in the 21st century.** Neurooncol Adv 2021; 3:vdaa166Amidei C, Arzbaeher J, Maher ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501430>
48. **Virtual barriers: unpacking the sustainability implications of online food spaces and the Yellowknife Farmers Market's response to COVID-19.** Nutr. J. 2021; 20:12Radcliffe J, Skinner K, Spring A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514376>
49. **COVID-19-Related Quarantine Effect on Dietary Habits in a Northern Italian Rural Population: Data from the Brisighella Heart Study.** Nutrients 2021; 13Cicero AFG, Fogacci F, Giovannini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499027>
50. **Patterns of Change in Dietary Habits and Physical Activity during Lockdown in Spain Due to the COVID-19 Pandemic.** Nutrients 2021; 13Pv©rez-Rodrigo C, Gianzo Citores M, Hervs Bvrbara G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494314>
51. **'MI' reflections on a pandemic-governed 2020.** Oral Health Prev Dent 2020; 18:1-2Banerjee A, Sculean A, Petersen PE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499553>
52. **Physical activity and dietary behaviors: a phenomenological analysis of experiences of Ghanaians during the COVID-19 lockdown.** Pan Afr. Med. J. 2020; 37:199Ansah EW, Sarfo JO, Apaak D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505568>
53. **Unexpected sequelae of the COVID-19 pandemic: A strange case of myoclonus in the Tasmanian winter.** Perit. Dial. Int. 2021; 41:101-103Dang MH, Rodman B, Raj R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499779>
54. **Research Note: Indian poultry industry vis-à-vis coronavirus disease 2019: a situation analysis report.** Poult. Sci. 2020:100828Kolluri G, Tyagi JS, Sasidhar PVK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516485>
55. **Violation of the Global Ceasefire in Nagorno-Karabagh: A Viral Amplification of Aggression.** Prehosp. Disaster Med. 2021:1-8Chekijian S, Bazarchyan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509320>
56. **Impact of COVID-19 on Resettled Refugees.** Prim. Care. 2021; 48:57-66Brickhill-Atkinson M, Hauck FR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516424>
57. **The disparities faced by the LGBTQ+ community in times of COVID-19.** Psychiatry Res 2021; 297:113725Sachdeva I, Aithal S, Yu W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497972>

58. **Predictors of households at risk for food insecurity in the United States during the COVID-19 pandemic.** Public Health Nutr. 2021;1-19 Lauren BN, Silver ER, Faye AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500018>
59. **Determinants of household vulnerability to food insecurity during COVID-19 lockdown in a mid-term period in Iran.** Public Health Nutr. 2021;1-26 Pakravan-Charvadeh MR, Savari M, Khan HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494852>
60. **Patents related to pathogenic human coronaviruses.** Recent Pat Biotechnol 2021; Dos Santos M, Ferreira AVF, da Silva JO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504319>
61. **COVID: The alert launched to the executive by the French Scientific Council.** Revue Medicale Suisse 2020; 16:2018-2019 Nau JY.
62. **Fundamentally uncaring: The differential multi-scalar impacts of COVID-19 in the U.S.** Soc. Sci. Med. 2021; 272:113707 Lopez PJ, Neely AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517126>
63. **Double jeopardy; What happens when an epidemic is followed by an earthquake?** Spat Spatiotemporal Epidemiol 2021; 36:100402 Ćurković M, Svetina L, Košec A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509429>
64. **A path forward for qualitative research on sustainability in the COVID-19 pandemic.** Sustain Sci 2021;1-7 Santana FN, Hammond Wagner C, Berlin Rubin N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495701>
65. **ToxPoint: Health Disparities, COVID-19, and Owning Our Share.** Toxicol. Sci. 2021; 179:147-148 Pettit SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508082>
66. **Climate risk, culture and the Covid-19 mortality: A cross-country analysis.** World Dev 2021; 141:105412 Ozkan A, Ozkan G, Yalaman A, Yildiz Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495666>
67. **Risk of group aggregative behavior during COVID-19 outbreak: A case report.** World J Clin Cases 2021; 9:170-174 Zuo H, Hu ZB, Zhu F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511181>

Pathology (6 articles)

1. **Multi-organ proteomic landscape of COVID-19 autopsies.** Cell 2021; Nie X, Qian L, Sun R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503446>
2. **SARS-CoV-2 Causes a Systemically Multiple Organs Damages and Dissemination in Hamsters.** Front. Microbiol. 2020; 11:618891 Song Z, Bao L, Yu P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510731>
3. **Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy.** J Fungi (Basel) 2021; 7 Zurl C, Hoenigl M, Schulz E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513875>
4. **Evidence of SARS-CoV-2 Replication and Tropism in the Lungs, Airways and Vascular Endothelium of Patients with Fatal COVID-19: An Autopsy Case-Series.** J Infect Dis 2021; Bhatnagar J, Gary J, Reagan-Steiner S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502471>
5. **COVID-19 and kidney involvement: Pathology.** Nephrologie 2021; 16:14-19 Amann K, Boor P, Wiech T.
6. **Development of acute kidney injury with massive granular casts and microscopic hematuria in patients with COVID-19: two case presentations with**

literature review. Ren Replace Ther 2020; 6:59Fujimaru T, Shimada K, Hamada T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510902>

Protection (28 articles)

1. **Methods to Reduce the Risk of Exposure to Airborne Pathogens in the Operating Room.** AANA J. 2021; 89:71-75Accardo D, Isaac J, Strube P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501911>
2. **Access to personal protective equipment in exposed healthcare workers and COVID-19 illness, severity, symptoms and duration: a population-based case-control study in six countries.** BMJ Glob Health 2021; 6Kim H, Hegde S, LaFiura C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509841>
3. **[Assessment of the risk of infection from SARS-CoV-2 for healthcare workers-findings from practice].** Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2021;1-10Pfenninger EG, Christ P, Neumv^oller M, Dinse-Lambracht A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496803>
4. **The COVID-19 pandemic face mask waste: A blooming threat to the marine environment.** Chemosphere 2021; 272:129601Dharmaraj S, Ashokkumar V, Hariharan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497928>
5. **Surgical activation protocol COVID-19 (SAP COVID).** Cir. Cir. 2021; 89:4-11Juanz-Gonz^vlez A, Barreras-Espinoza JA, Leyva-Moraga E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498060>
6. **Bioaerosol sampling for SARS-CoV-2 in a referral center with critically ill COVID-19 patients March-May 2020.** Clin Infect Dis 2021; Lane MA, Brownsword EA, Babiker A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506256>
7. **The safety of anaesthetists and intensivists during the first COVID-19 surge supports extension of use of airborne protection PPE to ward staff.** Clin Med (Lond) 2021; Cook TM, El-Boghdadly K, Brown J, Pickering AE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509933>
8. **Effects of wearing a FFP2 mask on indirect calorimetry measurements: A pilot study.** Clin Nutr ESPEN 2021; 41:443-446Bertoli S, Leone A, De Amicis R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487305>
9. **The Importance of Personal Protective Equipment Design and Donning and Doffing Technique in Mitigating Infectious Disease Spread: A Technical Report.** Cureus 2020; 12:e12084McCarthy R, Gino B, d'Entremont P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489502>
10. **Analysis of the materials for the manufacture of masks: The challenge of facing the shortage of personal protective equipment.** Enferm. Clin. 2020; San Mart^vn-Rodr^vguez L, Camacho-Bejarano R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487530>
11. **Classical and alternative disinfection strategies to control the COVID-19 virus in healthcare facilities: a review.** Environ. Chem. Lett. 2021:1-7Choi H, Chatterjee P, Lichtfouse E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500689>
12. **Estimating Aerosol Transmission Risk of SARS-CoV-2 in New York City Public Schools During Reopening.** Environ. Res. 2021:110805Pavilonis B, Ierardi AM, Levine L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508262>
13. **Exploring the Applicability of Robot-Assisted UV Disinfection in Radiology.** Front Robot AI 2020; 7:590306McGinn C, Scott R, Donnelly N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501347>

14. **No secret hiding place? Absence of SARS-CoV-2 on the ocular surface of 1145 hospitalized patients in a pandemic area.** Graefes Arch Clin Exp Ophthalmol 2021;1-4Rokohl AC, Grajewski RS, Wawer Matos PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511435>
15. **Lack of viable SARS-CoV-2 among PCR-positive air samples from hospital rooms and community isolation facilities.** Infect Control Hosp Epidemiol 2021;1-17Ong SWX, Tan YK, Coleman KK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487210>
16. **Personal protective equipment related skin reactions in healthcare professionals during COVID-19.** Int. Wound J. 2021; Abiakam N, Worsley P, Jayabal H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507634>
17. **Can extraoral suction units minimize droplet spatter during a simulated dental procedure?** J. Am. Dent. Assoc. 2021; 152:157-165Chavis SE, Hines SE, Dyalram D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494869>
18. **Study of risk factors and psychological impact in physicians diagnosed with COVID-19: An online, postexposure, cross-sectional survey.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:345-349Bajaj JS, Solanki SL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487901>
19. **A survey of physicians' appreciation and knowledge about airway safety measures in the wake of COVID-19 pandemic.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:350-358Duggal S, Ahuja B, Biswas PS, Choudhuri AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487902>
20. **The Role of Imaging in COVID-19 Pneumonia Diagnosis and Management: Main Positions of the Experts, Key Imaging Features and Open Answers.** J Cardiovasc Echogr 2020; 30:S25-s30Landini N, Orlandi M, Fusaro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489733>
21. **Indoor transmission dynamics of expired SARS-CoV-2 virus in a model African hospital ward.** J Environ Health Sci Eng 2021;1-11Adeniran JA, Mohammed IA, Muniru OI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500782>
22. **COVID-19 prevalence among health-care workers of Gastroenterology department: An audit from a tertiary-care hospital in India.** JGH Open 2021; 5:56-63Kumar Goenka M, Bharat Shah B, Goenka U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490614>
23. **Hematology Patient Protection During the COVID-19 Pandemic in Italy: A Nationwide Nursing Survey.** Mediterr. J. Hematol. Infect. Dis. 2021; 13:e2021011Botti S, Serra N, Castagnetti F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489050>
24. **SARS-CoV-2: Outline, Prevention, and Decontamination.** Pathogens 2021; 10Janik E, Bartos M, Niemcewicz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498679>
25. **Safe On-Boat Resuscitation by Lifeguards in COVID-19 Era: A Pilot Study Comparing Three Sets of Personal Protective Equipment.** Prehosp. Disaster Med. 2021;1-21Barcala-Furelos R, Abelairas-Gómez C, Alonso-Calvete A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500008>
26. **Face coverings and respiratory tract droplet dispersion.** R Soc Open Sci 2020; 7:201663Bandiera L, Pavar G, Pisetta G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489292>
27. **Conducting a conventional multi-casualty incident in COVID-19 personal protective equipment - a semi-structured interview.** Scand. J. Trauma Resusc.

- Emerg. Med. 2021; 29:20 Raitt J, Watts B, Rayet J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33504350>
28. **Hospital Nursing Staff Perceptions of Resources Provided by Their Organizations During the COVID-19 Pandemic.** Workplace Health Saf. 2021:2165079920987543 Cho H, Sagherian K, Steege LM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33514301>

Pulmonary disease (14 articles)

1. **Asthma in Adult Patients with COVID-19: Prevalence and Risk of Severe Disease.** Am J Respir Crit Care Med 2021; Terry PD, Heidel RE, Dhand R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33493416>
2. **Management of life-threatening acute respiratory syndrome and severe pneumonia secondary to COVID-19 in pregnancy: A case report and literature review.** Clin Case Rep 2021; 9:137-143 Yaqoub S, Ahmad S, Mansouri Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33489149>
3. **An Intriguing Case of Pneumoperitoneum In a Patient With COVID-19: Do All Pneumoperitoneum Cases Need Surgery?** Cureus 2020; 12:e12279 Sharma M, Ojha P, Taweese PT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510986>
4. **SARS-CoV-2 Associated With Pneumothorax: A Case Report and Literature Review.** Cureus 2020; 12:e12191 Younes I, Mohammadian M, Elkattawy S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33489601>
5. **Bronchiolitis in COVID-19 times: a nearly absent disease?** Eur. J. Pediatr. 2021; Van Brusselen D, De Troeyer K, Ter Haar E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33517482>
6. **PEDIATRIC BRONCHOSCOPY: RECENT ADVANCES AND CLINICAL CHALLENGES.** Expert Rev. Respir. Med. 2021; Goussard P, Pohunek P, Eber E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512252>
7. **Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness.** J Allergy Clin Immunol Pract 2021; Ferastraoar D, Hudes G, Jerschow E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495097>
8. **Lung Semiotics Ultrasound in COVID-19 Infection.** J Cardiovasc Echogr 2020; 30:S1-s5 Barchitta A, Pepi M, Monte IP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489729>
9. **Neutrophil extracellular traps persist at high levels in the lower respiratory tract of critically ill COVID-19 patients.** J Infect Dis 2021; Ouwendijk WJD, Raadsen MP, van Kampen JJA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503244>
10. **Pulmonary vascular enlargement and lesion extent on computed tomography are correlated with COVID-19 disease severity.** Jpn J Radiol 2021:1-8 Aoki R, Iwasawa T, Hagiwara E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502657>
11. **COVID-19 in Children with Asthma.** Lung 2021:1-6 Chatziparasidis G, Kantar A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33496842>
12. **Case Report: Massive Spontaneous Pneumothorax-A Rare Form of Presentation for Severe COVID-19 Pneumonia.** Medicina (Kaunas) 2021; 57 Marza AM, Petrica A, Buleu FN, Mederle OA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33498180>
13. **[Role of the French national registry REIN in the health monitoring of patients with end-stage chronic renal failure infected with SARS-CoV-2: Organization**

- and initial data].** *Nephrol. Ther.* 2021; Lapalu S, Izaaryene G, Honoré N, Couchoud C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516618>
14. **Tracking the time course of pathological patterns of lung injury in severe COVID-19.** *Respir Res* 2021; 22:32Mauad T, Duarte-Neto AN, da Silva LFF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514373>

Renal disease (20 articles)

1. **Effective treatment with Tocilizumab in a COVID-19 patient on maintenance hemodialysis: A case report.** *CEN Case Rep* 2021;1-6Nourie N, Chamaa MA, Mouawad S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502716>
2. **First Reported Nosocomial Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 in a Pediatric Dialysis Unit.** *Clin Infect Dis* 2021; 72:265-270Schwierzeck V, König JC, Kühn J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501962>
3. **Trends in US Kidney Transplantation During the COVID-19 Pandemic.** *Cureus* 2020; 12:e12075Bordes SJ, Montorfano L, West-Ortiz W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489493>
4. **Anti-Glomerular Basement Membrane Disease as a Potential Complication of COVID-19: A Case Report and Review of Literature.** *Cureus* 2020; 12:e12089Nahhal S, Halawi A, Basma H, Sr. *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489507>
5. **Kidney diseases and COVID-19 infection: causes and effect, supportive therapeutics and nutritional perspectives.** *Heliyon* 2021; 7:e06008Askari H, Sanadgol N, Azarnezhad A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495739>
6. **The Role of Imaging in COVID-19 Pneumonia Diagnosis and Management: Main Positions of the Experts, Key Imaging Features and Open Answers.** *J Cardiovasc Echogr* 2020; 30:S25-s30Landini N, Orlandi M, Fusaro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489733>
7. **Kidney injury molecule-1 is a potential receptor for SARS-CoV-2.** *J. Mol. Cell. Biol.* 2021; Yang C, Zhang Y, Zeng X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493263>
8. **Identifying prognostic risk factors for poor outcome following COVID-19 disease among in-centre haemodialysis patients: role of inflammation and frailty.** *J Nephrol* 2021; Hendra H, Vajgel G, Antonelou M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515380>
9. **Clinical Features of Asymptomatic SARS-CoV-2 Infection in Hemodialysis Patients.** *Kidney Blood Press. Res.* 2021;1-9Pizarro-Sánchez MS, Avello A, Mas-Fontao S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503627>
10. **Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines.** *Nefrologia* 2021; Sánchez-Álvarez E, Quiroga B, de Sequera P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500159>
11. **[Role of the French national registry REIN in the health monitoring of patients with end-stage chronic renal failure infected with SARS-CoV-2: Organization and initial data].** *Nephrol. Ther.* 2021; Lapalu S, Izaaryene G, Honoré N, Couchoud C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516618>
12. **COVID-19 and kidney involvement: Pathology.** *Nephrologie* 2021; 16:14-19Amann K, Boor P, Wiech T.

13. **COVID-19 and the kidneys—Clinical aspects: How nephrology contributes to fundamentally improve care of patients.** Nephrologie 2021; 16:26-32Gross O.
14. **COVID-19 and acute kidney injury in the intensive care unit.** Nephrologie 2021; 16:20-25Hardenberg JHB, Stockmann H, Eckardt KU, Schmidt-Ott KM.
15. **Early Predictors of Acute Kidney Injury in COVID-19 Patients.** Nephrology (Carlton) 2021; Yildirim C, Ozger HS, Yasar E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33502771>
16. **Acute necrotizing glomerulonephritis associated with COVID-19 infection: report of two pediatric cases.** Pediatr. Nephrol. 2021:1-5Basiratnia M, Derakhshan D, Yeganeh BS, Derakhshan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495896>
17. **An early experience of COVID-19 disease in pediatric and young adult renal transplant recipients.** Pediatr. Transplant. 2021:e13972Solomon S, Pereira T, Samsonov D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502074>
18. **Immunosuppression in kidney transplant recipients with COVID-19 infection - where do we stand and where are we heading?** Ren. Fail. 2021; 43:273-280Daoud A, Alqassieh A, Alkhader D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491531>
19. **Intradialytic exercise in the treatment of social frailty: a single-center prospective study-preliminary results during the unexpected COVID-19 pandemic.** Ren Replace Ther 2020; 6:36Abe K, Shimamura Y, Maeda T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33510901>
20. **Development of acute kidney injury with massive granular casts and microscopic hematuria in patients with COVID-19: two case presentations with literature review.** Ren Replace Ther 2020; 6:59Fujimaru T, Shimada K, Hamada T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510902>

Reviews (43 articles)

1. **Review of Anesthesia Versus Intensive Care Unit Ventilators and Ventilatory Strategies: COVID-19 Patient Management Implications.** AANA J. 2021; 89:62-69Jackson K, Wands B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501910>
2. **The socioeconomic and environmental drivers of the COVID-19 pandemic: A review.** Ambio 2021:1-12Wu T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507498>
3. **Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey.** Ann. Rheum. Dis. 2021; Campochiaro C, Trignani G, Tomelleri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509795>
4. **A narrative review on the basic and clinical aspects of the novel SARS-CoV-2, the etiologic agent of COVID-19.** Ann Transl Med 2020; 8:1686Hokello J, Sharma AL, Shukla GC, Tyagi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490198>
5. **Electrocardiography in Early Diagnosis of Cardiovascular Complications of COVID-19; a Systematic Literature Review.** Arch Acad Emerg Med 2021; 9:e10Nemati R, Ganjoo M, Jadidi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490967>
6. **Burnout among Healthcare Providers of COVID-19; a Systematic Review of Epidemiology and Recommendations.** Arch Acad Emerg Med 2021; 9:e7Sharifi M, Asadi-Pooya AA, Mousavi-Roknabadi RS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490964>

7. **CRISPR-based detection of SARS-CoV-2: A review from sample to result.** *Biosens. Bioelectron.* 2021; 178:113012Nouri R, Tang Z, Dong M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33497879>
8. **Takotsubo's syndrome presenting as cardiogenic shock in patients with COVID-19: A case-series and review of current literature.** *Cardiovasc. Revasc. Med.* 2021; Kong N, Singh N, Mazzone S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33516638>
9. **Engineered Aptamers for Enhanced COVID-19 Theranostics.** *Cell. Mol. Bioeng.* 2021:1-13Acquah C, Jeevanandam J, Tan KX, Danquah MK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33488836>
10. **Surgical activation protocol COVID-19 (SAP COVID).** *Cir. Cir.* 2021; 89:4-11Juanz-González A, Barreras-Espinoza JA, Leyva-Moraga E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33498060>
11. **Diabetic Ketoacidosis on Hospitalization with COVID-19 in a Previously Nondiabetic Patient: A Review of Pathophysiology.** *Clin Med Insights Endocrinol Diabetes* 2020; 13:1179551420984125Eskandarani RM, Sawan S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33488135>
12. **ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease.** *Clin Sci (Lond)* 2021; 135:387-407Kuriakose J, Montezano AC, Touyz RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511992>
13. **Impact of COVID-19 outbreak on lifestyle behaviour: A review of studies published in India.** *Diabetes Metab Syndr* 2021; 15:331-336Rawat D, Dixit V, Gulati S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493852>
14. **An Alternative "Trojan Horse" Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology.** *Endocr. Metab. Immune Disord. Drug Targets* 2021; Balzanelli MG, Distratis P, Aityan SK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33504318>
15. **Association of ACE inhibitors and Angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: a pathway-based analytical study.** *Eur. J. Pharmacol.* 2021:173899Parit R, Jayavel S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33508281>
16. **Polyphenols as promising biologically active substances for preventing SARS-CoV-2: A review with research evidence and underlying mechanisms.** *Food Biosci* 2021:100891Mehany T, Khalifa I, Barakat H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33495727>
17. **Pathophysiological Processes Underlying the High Prevalence of Deep Vein Thrombosis in Critically Ill COVID-19 Patients.** *Front. Physiol.* 2020; 11:608788Voicu S, Kefi C, Stăpanian A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33488398>
18. **Covid-19 in Historical Context: Creating a Practical Past.** *HEC Forum* 2021; Forbes AW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515386>
19. **ACE2 Nascence, trafficking, and SARS-CoV-2 pathogenesis: the saga continues.** *Hum Genomics* 2021; 15:8Badawi S, Ali BR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33514423>
20. **A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy.** *Immunol. Res.* 2021; Devarasetti PK, Rajasekhar L, Baisya R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492637>
21. **A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations.** *Infect Dis (Lond)* 2021:1-10Piri SM, Edalatfar

- M, Shool S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508989>
22. **The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.** *Int J Environ Res Public Health* 2021; 18:Daou F, Abou-Sleymane G, Badro DA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499310>
 23. **The Impact of the COVID-19 Pandemic on Immunization Campaigns and Programs: A Systematic Review.** *Int J Environ Res Public Health* 2021; 18:Lassi ZS, Naseem R, Salam RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499422>
 24. **What can we learn from Israel's rapid roll out of COVID 19 vaccination?** *Isr J Health Policy Res* 2021; 10:5McKee M, Rajan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499901>
 25. **Surgical Interventions in Patients Hospitalised with COVID-19. A Review of Seven Months of Experience Working in a COVID-19 Dedicated Centre.** *J Clin Med* 2021; 10:Rymarowicz J, Pfo̧dziwiatr M, Major P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494183>
 26. **Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review.** *J. Clin. Pharmacol.* 2021; Khani E, Khiali S, Entezari-Maleki T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511638>
 27. **Tobacco control in the context of the COVID-19 pandemic in Uganda: a policy implementation review.** *J Glob Health Rep* 2020; 4:e2020095Kabwama SN, Nyamurungi KN, Davidson F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506110>
 28. **Probing CAS database as prospective antiviral agents against SARS-CoV-2 main protease.** *J. Mol. Struct.* 2021; 1231:129953Zia K, Khan SA, Ashraf S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500591>
 29. **COVID-19 and Spinal Cord Injury: Clinical Presentation, Clinical Course, and Clinical Outcomes: A Rapid Systematic Review.** *J. Neurotrauma* 2021; Hoogenes B, Querée M, Townson A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502924>
 30. **Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature.** *J. Neurovirol.* 2021; Emamikhah M, Babadi M, Mehrabani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492608>
 31. **A narrative review of pharmacologic treatments for COVID-19: safety considerations and ototoxicity.** *Laryngoscope* 2021; Little C, Cosetti MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491234>
 32. **Olecranon fractures in the elderly during the COVID-19 pandemic: Is non-operative treatment reasonable? Review of the current evidence.** *Musculoskelet. Surg.* 2021; 1-6Abdelmalek A, Crowther M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511549>
 33. **A systematic review of clinical and laboratory parameters of 3,000 COVID-19 cases.** *Obstet Gynecol Sci* 2021; Goel H, Gupta I, Mourya M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499580>
 34. **Pain during and after COVID-19 in Germany and worldwide: a narrative review of current knowledge.** *Pain Rep* 2021; 6:e893Meyer-Frießem CH, Gierthmühlen J, Baron R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490851>
 35. **Immunosuppression in kidney transplant recipients with COVID-19 infection - where do we stand and where are we heading?** *Ren. Fail.* 2021; 43:273-

- 280Daoud A, Alqassieh A, Alkhader D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491531>
36. **Development of acute kidney injury with massive granular casts and microscopic hematuria in patients with COVID-19: two case presentations with literature review.** Ren Replace Ther 2020; 6:59Fujimaru T, Shimada K, Hamada T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510902>
 37. **[COVID-19: Coagulopathy and thrombosis].** Rev. Med. Interne 2021; Tazi Mezalek Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509669>
 38. **Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: A French study and literature review.** Rheumatology (Oxford) 2021; Cherqaoui B, Konv©-Paut I, Yager H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493353>
 39. **Management and Prevention of Cerebrovascular Accidents in SARS-CoV-2-Positive Patients Recovering from COVID-19: a Case Report and Review of Literature.** SN Compr Clin Med 2021:1-12Yeganegi M, Fattahi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490876>
 40. **ABO Blood Types and COVID-19: Spurious, Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data.** Viruses 2021; 13Pendur JL, Breiman A, Rocher J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499228>
 41. **COVID-19: An overview and a clinical update.** World J Clin Cases 2021; 9:8-23Krishnan A, Hamilton JP, Alqahtani SA, Woreta TA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511168>
 42. **Lipidome is lipids regulator in gastrointestinal tract and it is a life collar in COVID-19: A review.** World J. Gastroenterol. 2021; 27:37-54Korim KMM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505149>
 43. **Current status quo on COVID-19 including chest imaging.** World J Radiol 2020; 12:272-288Mathew RP, Jose M, Jayaram V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510852>

Risk factors (66 articles)

1. **Hypercoagulation and myocardial injury as risk factors for mortality in patients with COVID-19 pneumonia.** Am J Emerg Med 2021; Kounis NG, Koniari I, Gogos C, Assimakopoulos SF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494959>
2. **COVID-19 as an occupational disease.** Am. J. Ind. Med. 2021; Carlsten C, Gulati M, Hines S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491195>
3. **Pregnancy as a risk factor for severe coronavirus 2019 (COVID-19) disease using standardized clinical criteria.** Am J Obstet Gynecol MFM 2021:100319Oakes MC, Kernberg AS, Carter EB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493707>
4. **EVERY BREATH YOU TAKE: IMPACTS OF ENVIRONMENTAL DUST EXPOSURE ON INTESTINAL BARRIER FUNCTION - FROM THE GUT-LUNG AXIS TO COVID-19.** Am. J. Physiol. Gastrointest. Liver Physiol. 2021; Crawford MS, Nordgren TM, McCole DF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501887>
5. **The CB index predicts prognosis of critically ill COVID-19 patients.** Ann Transl Med 2020; 8:1654Cao L, Zhang S, Wang E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490166>

6. **Factors associated with survival in older patients affected by COVID-19: A retrospective cohort study.** Arch. Gerontol. Geriatr. 2021; 94:104349Saifi ES, Giorgi-Pierfranceschi M, Salvetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508512>
7. **Association of menopausal status with COVID-19 outcomes: a propensity score matching analysis.** Biol. Sex Differ. 2021; 12:16Wang XW, Hu H, Xu ZY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514386>
8. **Identification of risk factors for in-hospital death of COVID - 19 pneumonia -- lessons from the early outbreak.** BMC Infect. Dis. 2021; 21:113Wang Z, Wang Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494706>
9. **No association between use of ACE inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEDicaTion (COMET) study.** Br. J. Clin. Pharmacol. 2021; Sablerolles RSG, Hogenhuis FEF, Lafeber M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507556>
10. **[Higher risk of COVID-19 hospitalization for unemployed: an analysis of health insurance data from 1.28 million insured individuals in Germany].** Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2021:1-8Wahrendorf M, Rupprecht CJ, Dortmann O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507323>
11. **Are All Patients with Cancer at Heightened Risk for Severe Coronavirus Disease 2019 (COVID-19)?** Clin Infect Dis 2021; 72:351-356Chamilos G, Lionakis MS, Kontoyiannis DP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501958>
12. **Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors.** Clin Infect Dis 2021; 72:249-253Erikstrup C, Hother CE, Pedersen OBV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501969>
13. **COVID-19 in Immunocompromised Hosts: What We Know So Far.** Clin Infect Dis 2021; 72:340-350Fung M, Babik JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501974>
14. **The nutritional status of the elderly patient infected with COVID-19: the forgotten risk factor?** Curr. Med. Res. Opin. 2021:1Abadía Otero J, Briongos Figuero LS, Gabella Mattín M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509001>
15. **The COVID-19 Worsening Score (COWS)-a predictive bedside tool for critical illness.** Echocardiography 2021; Boero E, Rovida S, Schreiber A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491261>
16. **Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity.** Endocrine 2021; De Groot CJ, Poitou Bernert C, Coupaye M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512658>
17. **Does exposure to noise pollution influence the incidence and severity of COVID-19?** Environ. Res. 2021; 195:110766Díaz J, Antonio-López-Bueno J, Culqui D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497680>
18. **Worsening of heart failure by coronavirus disease 2019 is associated with high mortality.** ESC Heart Fail 2021; Bocchi EA, Lima I, Biselli B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498096>
19. **Integration of heparin-binding protein and interleukin-6 in the early prediction of respiratory failure and mortality in pneumonia by SARS-CoV-2 (COVID-19).**

- [Eur J Clin Microbiol Infect Dis](http://www.ncbi.nlm.nih.gov/pubmed/?term=33515095) 2021; Saridaki M, Metallidis S, Grigoropoulou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515095>
20. **Is COVID-19 lockdown associated with vitamin D deficiency?** [Eur. J. Public Health](http://www.ncbi.nlm.nih.gov/pubmed/?term=33508085) 2021; Lippi G, Ferrari A, Targher G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508085>
 21. **Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients.** [Exp Hematol Oncol](http://www.ncbi.nlm.nih.gov/pubmed/?term=33504359) 2021; 10:5 Bao C, Tao X, Cui W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504359>
 22. **Application of a prediction model with laboratory indexes in the risk stratification of patients with COVID-19.** [Exp. Ther. Med.](http://www.ncbi.nlm.nih.gov/pubmed/?term=33488791) 2021; 21:182 Ye J, Zhang X, Zhu F, Tang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488791>
 23. **Cholesterol Metabolism Pathways- Are the Intermediates more Important than the Products?** [Febs j](http://www.ncbi.nlm.nih.gov/pubmed/?term=33506652) 2021; Wang Y, Yutuc E, Griffiths WJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506652>
 24. **Immunotoxic role of Organophosphates: an unseen risk escalating SARS-CoV-2 pathogenicity.** [Food Chem. Toxicol.](http://www.ncbi.nlm.nih.gov/pubmed/?term=33493637) 2021; 112:007 Rajak P, Ganguly A, Sarkar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493637>
 25. **Epigenetic Evolution of ACE2 and IL-6 Genes: Non-Canonical Interferon-Stimulated Genes Correlate to COVID-19 Susceptibility in Vertebrates.** [Genes \(Basel\)](http://www.ncbi.nlm.nih.gov/pubmed/?term=33503821) 2021; 12: Sang ER, Tian Y, Miller LC, Sang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503821>
 26. **Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study.** [Gut](http://www.ncbi.nlm.nih.gov/pubmed/?term=33514597) 2021; Weber S, Hellmuth JC, Scherer C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514597>
 27. **Chronic liver disease independently associated with COVID-19 severity: evidence based on adjusted effect estimates.** [Hepatol Int](http://www.ncbi.nlm.nih.gov/pubmed/?term=33507484) 2021; 1-6 Yang H, Xu J, Liang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507484>
 28. **ACE2 mutation might explain lower COVID-19 burden in malaria endemic areas.** [Hum. Cell](http://www.ncbi.nlm.nih.gov/pubmed/?term=33492586) 2021; De A, Tiwari A, Dash M, Sinha A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492586>
 29. **The Overlap between Genetic Susceptibility to COVID-19 and Skin Diseases.** [Immunol. Invest.](http://www.ncbi.nlm.nih.gov/pubmed/?term=33494631) 2021; 1-8 Jabalameli N, Rajabi F, Firooz A, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494631>
 30. **Clinical, biological and radiological features, 4-week outcomes and prognostic factors in COVID-19 elderly inpatients.** [Infect Dis Now](http://www.ncbi.nlm.nih.gov/pubmed/?term=33495763) 2021; Palich R, Wakim Y, Itani O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495763>
 31. **High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically-ill patients with Covid-19.** [Infect Dis Now](http://www.ncbi.nlm.nih.gov/pubmed/?term=33495765) 2021; Simonnet A, Engelmann I, Moreau AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495765>
 32. **Machine learning predictive model for severe COVID-19.** [Infect Genet Evol](http://www.ncbi.nlm.nih.gov/pubmed/?term=33515712) 2021; 104:737 Kang J, Chen T, Luo H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515712>
 33. **Mannose binding lectin gene 2 (rs1800450) missense variant may contribute to development and severity of COVID-19 infection.** [Infect Genet Evol](http://www.ncbi.nlm.nih.gov/pubmed/?term=33515713) 2021; 104:717 Medetalibeyoglu A, Bahat G, Senkal N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515713>

34. **Eosinopenia is a reliable marker of severe disease and unfavorable outcome in patients with COVID-19 pneumonia.** Int J Clin Pract 2021:e14047Cazzaniga M, Fumagalli L, D'Angelo L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497517>
35. **Are colorectal cancer patients at risk for COVID-19 infection during the postoperative period? The Covid-GRECCAR study.** Int. J. Colorectal Dis. 2021:1-5Tuech JJ, Manceau G, Ouaisi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495872>
36. **First Report on Smoking and Infection Control Behaviours at Outdoor Hotspots during the COVID-19 Pandemic: An Unobtrusive Observational Study.** Int J Environ Res Public Health 2021; 18Sun Y, Lam TH, Cheung YTD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503837>
37. **Neutrophil-to-lymphocyte ratio is independently associated with COVID-19 severity: An updated meta-analysis based on adjusted effect estimates.** Int. J. Lab. Hematol. 2021; Li Y, Hou H, Diao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506621>
38. **Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients.** Int. J. Lab. Hematol. 2021; Rodríguez Rodríguez M, Castro Quismondo N, Zafra Torres D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502080>
39. **Development and validation of a laboratory risk score for the early prediction of COVID-19 severity and in-hospital mortality.** Intensive Crit Care Nurs 2021:103012Bennouar S, Bachir Cherif A, Kessira A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487518>
40. **Inflammatory biomarkers as independent prognosticators of 28-day mortality for COVID-19 patients admitted to general medicine or ICU wards: a retrospective cohort study.** Intern Emerg Med 2021:1-10Pitre T, Jones A, Su J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496923>
41. **Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness.** J Allergy Clin Immunol Pract 2021; Ferastraoar D, Hudes G, Jerschow E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495097>
42. **Interleukin-6 as unfavorable prognostic factor in patients affected by Covid-19 and hip fracture.** J Biol Regul Homeost Agents 2021; 35Pantalone A, Bruni D, Pantalone P, Buda R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511825>
43. **Interactions between hypertension and inflammatory tone and the effect on blood pressure and outcomes in patients with COVID-19.** J. Clin. Hypertens. (Greenwich) 2021; Amar J, Touront N, Ciron AM, Pendaries C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491247>
44. **Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity.** J. Clin. Invest. 2021; Falck-Jones S, Vangeti S, Yu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492309>
45. **Predicting thromboembolic complications in COVID-19 ICU patients using machine learning.** J Clin Transl Res 2020; 6:179-186van de Sande D, van Genderen ME, Rosman B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501388>
46. **Circulating Levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients.** J Endocr Soc 2021; 5:bvaa199Ochoa-Callejero L, García-Sanmartín J, Villoslada-Blanco P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506161>
47. **Interpretation of COVID-19 case fatality risk measures in England.** J. Epidemiol. Community Health 2021; Harman K, Allen H, Kall M, Dabrera G.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33514625>

48. **Host-cell recognition through GRP78 is enhanced in the new UK variant of SARS-CoV-2, in silico.** J Infect 2021; Elfiky AA, Ibrahim IM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33493496>
49. **Role of cell adhesion molecules for disease development of patients with and without COVID-19 in the emergency department.** J Infect Dis 2021; Bauer W, Ulke J, Galtung N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502532>
50. **Prediction of patients requiring intensive care for COVID-19: development and validation of an integer-based score using data from Centers for Disease Control and Prevention of South Korea.** J Intensive Care 2021; 9:16Heo J, Han D, Kim HJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514443>
51. **Blood Group A Epitopes do not Facilitate Entry of SARS-CoV-2.** J Intern Med 2021; Schetelig J, Baldauf H, Wendler S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501658>
52. **Factors associated with COVID-19 severity and mortality among Hispanic patients living on the USA-Mexico border.** J. Investig. Med. 2021; Cervantes J, Sureen A, Galura G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514615>
53. **Vitamin D deficiency is associated with COVID-19 positivity and the severity of the disease.** J Med Virol 2021; Demir M, Demir F, Aygun H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33512007>
54. **Identifying prognostic risk factors for poor outcome following COVID-19 disease among in-centre haemodialysis patients: role of inflammation and frailty.** J Nephrol 2021; Hendra H, Vajgel G, Antonelou M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33515380>
55. **COVID-19 and Spinal Cord Injury: Clinical Presentation, Clinical Course, and Clinical Outcomes: A Rapid Systematic Review.** J. Neurotrauma 2021; Hoogenes B, Querée M, Townson A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502924>
56. **Socioeconomic factors and the probability of death by Covid-19 in Brazil.** J Public Health (Oxf) 2021; De Negri F, Galiezz R, Miranda P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33501982>
57. **Significance of Hypernatremia Due to SARS-CoV-2 Associated ARDS in Critically Ill Patients.** J Transl Int Med 2020; 8:255-260Redant S, Vanderhulst J, Maillart E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511052>
58. **Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.** Leuk. Lymphoma 2021; 1-16Bhogal T, Khan UT, Lee R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33508995>
59. **Peripheral Blood Smear Findings of COVID-19 Patients Provide Information about the Severity of the Disease and the Duration of Hospital Stay.** Mediterr. J. Hematol. Infect. Dis. 2021; 13:e2021009Berber I, Cagasar O, Sarici A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33489048>
60. **Early Predictors of Acute Kidney Injury in COVID-19 Patients.** Nephrology (Carlton) 2021; Yildirim C, Ozger HS, Yasar E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33502771>
61. **COVID-19 severity in obese patients: Potential mechanisms and molecular targets for clinical intervention.** Obes. Res. Clin. Pract. 2021; Sharma JR, Yadav UCS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509701>

62. **Comorbidities might be a risk factor for the incidence of COVID-19: Evidence from a web-based survey.** Prev Med Rep 2021; 21:101319 Alam MR, Kabir MR, Reza S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489728>
63. **Fast track triage for COVID-19 based on a population study: The soda score.** Prev Med Rep 2021; 21:101298 Lopez-Pais J, Otero DL, Ferreira TG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489725>
64. **Genotype-phenotype correlation identified a novel SARS-CoV-2 variant possibly linked to severe disease.** Transbound Emerg Dis 2021; Loney T, Khansaheb H, Ramaswamy S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506644>
65. **Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study.** Turk J Haematol 2021; Anakl f ± f, Ergin √ñzcan P, Polat ñ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486940>
66. **ABO Blood Types and COVID-19: Spurious, Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data.** Viruses 2021; 13 Pendu JL, Breiman A, Rocher J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499228>

Safety (8 articles)

1. **Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.** BMC Infect. Dis. 2021; 21:114 Wang W, Zhao X, Wei W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494713>
2. **NEUROLOGICAL RISKS AND BENEFITS OF CYTOKINE-BASED TREATMENTS IN COVID-19: FROM PRECLINICAL TO CLINICAL EVIDENCE.** Br. J. Pharmacol. 2021; Pignataro G, Cataldi M, Taglialatela M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512003>
3. **Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19.** Clin Case Rep 2021; 9:148-152 Khatib MY, Shaik KS, Ahmed AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489151>
4. **Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol.** Contemp Clin Trials Commun 2021; 21:100716 Solanich X, Antol √≠ A, Padull √©s N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495742>
5. **Immunosuppressants, Immunomodulators and COVID-19 Vaccines: Anticipating Patient Concerns.** J Dermatolog Treat 2021:1-9 Rick J, Thompson AM, Hsiao JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494626>
6. **A narrative review of pharmacologic treatments for COVID-19: safety considerations and ototoxicity.** Laryngoscope 2021; Little C, Cosetti MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491234>
7. **Immunosuppression in kidney transplant recipients with COVID-19 infection - where do we stand and where are we heading?** Ren. Fail. 2021; 43:273-280 Daoud A, Alqassieh A, Alkhader D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491531>
8. **Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy.**

Treatment options (80 articles)

1. **Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19).** 3 Biotech 2021; 11:89 Bessalah S, Jebahi S, Mejri N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500874>
2. **Biomarkers of COVID-19 and technologies to combat SARS-CoV-2.** Adv Biomark Sci Technol 2020; 2:1-23 Zhang L, Guo H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33511330>
3. **Perspectives: potential therapeutic approach with inhalation of ACE2-derived peptides for SARS-CoV-2 infection.** Am J Clin Exp Immunol 2020; 9:73-80 Talotta R, Roberston ES. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489475>
4. **The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients.** Am. J. Otolaryngol. 2021; 42:102892 Singh CV, Jain S, Parveen S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493729>
5. **Soluble ACE2 as a potential therapy for COVID-19.** Am. J. Physiol. Cell Physiol. 2021; Krishnamurthy S, Lockey RF, Kolliputi N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33502950>
6. **Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'.** Ann. Rheum. Dis. 2021; Kawada T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504481>
7. **Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'.** Ann. Rheum. Dis. 2021; Perricone C, Bartoloni E, Cafaro G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509794>
8. **Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome' by Kawada.** Ann. Rheum. Dis. 2021; Piantoni S, Andreoli L, Colombo E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504480>
9. **Response to: 'Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine' by Perricone et al.** Ann. Rheum. Dis. 2021; Shah B, Reyes AZ, Hu KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509798>
10. **Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development.** Antiviral Res 2021:105020 Liu C, Boland S, Scholle MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515606>
11. **Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.** Appl. Microbiol. Biotechnol. 2021; Gasmi A, Peana M, Noor S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515285>
12. **COVID-19 and pharmacotherapy.** Arzneimitteltherapie 2020; 38:491 Laux G.
13. **PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking.** Biochem. Pharmacol. 2021:114431 Lugnier C, Al-Kuraishi HM, Rousseau E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33515531>

14. **The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19.** Biomed. Pharmacother. 2021; 137:111267An X, Zhang Y, Duan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508618>
15. **Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking.** Bioorg. Med. Chem. 2021; 33:116040Vique-Sánchez JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515918>
16. **Strengthening regulatory systems for medicines in a changed world: where do we go from here?** BMJ Glob Health 2021; 6O'Brien J, Lumsden R, Macdonald J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495287>
17. **NEUROLOGICAL RISKS AND BENEFITS OF CYTOKINE-BASED TREATMENTS IN COVID-19: FROM PRECLINICAL TO CLINICAL EVIDENCE.** Br. J. Pharmacol. 2021; Pignataro G, Cataldi M, Taglialatela M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512003>
18. **Repurposing approved drugs for cancer therapy.** Br. Med. Bull. 2021; Schein CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517358>
19. **Virtual screening and molecular dynamics simulation study of plant-derived compounds to identify potential inhibitors of main protease from SARS-CoV-2.** Brief. Bioinform. 2021; Mahmud S, Uddin MAR, Paul GK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517367>
20. **Luteolin and abyssinone II as potential inhibitors of SARS-CoV-2: an in silico molecular modeling approach in battling the COVID-19 outbreak.** Bull Natl Res Cent 2021; 45:27Shawan M, Halder SK, Hasan MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495684>
21. **Engineered Aptamers for Enhanced COVID-19 Theranostics.** Cell. Mol. Bioeng. 2021:1-13Acquah C, Jeevanandam J, Tan KX, Danquah MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488836>
22. **COVID-19: Characteristics and Therapeutics.** Cells 2021; 10Chilamakuri R, Agarwal S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494237>
23. **Effective treatment with Tocilizumab in a COVID-19 patient on maintenance hemodialysis: A case report.** CEN Case Rep 2021:1-6Nourie N, Chamaa MA, Mouawad S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502716>
24. **Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19.** Clin Case Rep 2021; 9:148-152Khatib MY, Shaik KS, Ahmed AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489151>
25. **Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.** Comput Struct Biotechnol J 2021; 19:467-476Zhu H, Du W, Song M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505639>
26. **Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol.** Contemp Clin Trials Commun 2021; 21:100716Solanich X, Antol/÷ A, Padull/©s N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495742>
27. **Is There any Additional Benefit of Multiple Doses of Tocilizumab in COVID-19 Patients?** Cureus 2020; 12:e12214Mughal MS, Kaur I, Kakadia M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489621>
28. **Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale.** Cureus 2020; 12:e12290Nasir N, Mahmood F, Habib K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510989>

29. **Phenylbenzopyrone of flavonoids as a potential scaffold to prevent SARS-CoV-2 replication by inhibiting its MPRO main protease.** Curr. Pharm. Biotechnol. 2021; Potshangbam AM, Nongdam P, Kumar AK, Rathore RS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33504301>
30. **Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy.** Drug Dev Res 2021; Prasher P, Sharma M, Gunupuru R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33496060>
31. **The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.** EClinicalMedicine 2021:100720Chaccour C, Casellas A, Blanco-Di Matteo A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33495752>
32. **Is sitagliptin effective for the treatment of COVID-19?** Eur J Hosp Pharm 2021; Memiş H, Çakır A, Durmuş M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504509>
33. **Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh.** Euroasian J Hepatogastroenterol 2020; 10:68-75Islam MA, Mazumder MA, Akhter N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511068>
34. **Tocilizumab for the treatment of COVID-19.** Expert Opin Biol Ther 2021:1-4Fernández-Ruiz M, López-Medrano F, Aguado JM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33504238>
35. **Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain.** Expert Rev. Clin. Pharmacol. 2021:1-12Chamorro-de-Vega E, Rodriguez-Gonzalez CG, Manrique-Rodríguez S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33499687>
36. **Polyphenols as promising biologically active substances for preventing SARS-CoV-2: A review with research evidence and underlying mechanisms.** Food Biosci 2021:100891Mehany T, Khalifa I, Barakat H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33495727>
37. **Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19.** Front. Immunol. 2020; 11:598402Cooper RS, Fraser AR, Smith L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33488592>
38. **Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19.** Front Med (Lausanne) 2020; 7:613475Li XZ, Qiu Y, Jeffery L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33511147>
39. **Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study.** Front Nutr 2020; 7:613928Ceccarelli G, Borrazzo C, Pinacchio C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33505983>
40. **COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.** Front. Oncol. 2020; 10:599502Botta C, Indrieri A, Garofalo E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489899>
41. **Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial.** Front. Physiol. 2020; 11:624657Arnardottir H, Pawelzik SC, Öhlund Wistbacka U *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33505321>

42. **COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding.** *Geburtshilfe Frauenheilkd.* 2021; 81:46-60Cavalcante MB, Cavalcante C, Braga ACS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487665>
43. **Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19?** *Heliyon* 2021; 7:e05703Nagoor Meeran MF, Seenipandi A, Javed H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490659>
44. **A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy.** *Immunol. Res.* 2021; Devarasetti PK, Rajasekhar L, Baisya R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492637>
45. **COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options.** *Infect Dis Ther* 2021:1-21Rebold N, Holger D, Alosaimy S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495967>
46. **The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.** *Int J Environ Res Public Health* 2021; 18Daou F, Abou-Sleymane G, Badro DA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499310>
47. **Efficacy of ribavirin and interferon- α therapy for hospitalized patients with COVID-19: a multicenter, retrospective cohort study.** *Int J Infect Dis* 2021; Li H, Xiong N, Li C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515771>
48. **Could Dermaseptin Analogue be a Competitive Inhibitor for ACE2 Towards Binding with Viral Spike Protein Causing COVID19?: Computational Investigation.** *Int. J. Pept. Res. Ther.* 2021:1-14Sekar PC, Rajasekaran R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488318>
49. **Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods.** *J Biomol Struct Dyn* 2021:1-8Chandra A, Gurjar V, Ahmed MZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491573>
50. **Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19.** *J Biomol Struct Dyn* 2021:1-18Ishola AA, Joshi T, Abdulai SI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491579>
51. **Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 - a computational modeling.** *J Biomol Struct Dyn* 2021:1-16Noor H, Ikram A, Rathinavel T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491580>
52. **Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review.** *J. Clin. Pharmacol.* 2021; Khani E, Khiali S, Entezari-Maleki T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511638>
53. **SARS-CoV-2 viability on different surfaces after gaseous ozone treatment: a preliminary evaluation.** *J Hosp Infect* 2021; Percivalle E, Clerici M, Cassaniti I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516798>
54. **Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.** *J Infect Public Health* 2020; 14:227-237Gurung AB, Ali MA, Lee J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493919>
55. **The growing complexity of COVID-19 drug and vaccine candidates: challenges and critical transitions.** *J Infect Public Health* 2020; 14:214-220Shariare MH,

- Parvez MAK, Karikas GA, Kazi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493917>
56. **Anti-inflammatory potential of Quercetin in COVID-19 treatment.** J Inflamm (Lond) 2021; 18:3Saeedi-Boroujeni A, Mahmoudian-Sani MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509217>
 57. **Tocilizumab in COVID-19 interstitial pneumonia.** J Intern Med 2021; Pomponio G, Ferrarini A, Bonifazi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511686>
 58. **Perspectives of Ketamine Use in COVID-19 Patients.** J Korean Med Sci 2021; 36:e28Weinbroum AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496087>
 59. **Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?** J Microbiol Immunol Infect 2021; Devaux CA, Camoin-Jau L, Mege JL, Raoult D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500211>
 60. **Probing CAS database as prospective antiviral agents against SARS-CoV-2 main protease.** J. Mol. Struct. 2021; 1231:129953Zia K, Khan SA, Ashraf S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500591>
 61. **LETTER TO THE EDITOR: ON POTENTIAL USE OF RADIOLABELED ANTIBODIES FOR IMAGING AND TREATMENT OF COVID-19.** J Nucl Med 2021; Dadachova E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509969>
 62. **Safety and pharmacokinetic assessments of a novel ivermectin nasal spray formulation in a pig model.** J. Pharm. Sci. 2021; Errecalde J, Lifschitz A, Vecchioli G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493479>
 63. **Comments on potential re-purposing of medicines against high-altitude illnesses towards SARS-CoV2: possibilities and pitfalls.** J Proteins Proteom 2021:1-3Ahmad Y, Paul S, Varshney R, Kumar B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495677>
 64. **Antiviral activity of bioactive phytochemicals against coronavirus: An update.** J. Virol. Methods 2021:114070Bhattacharya R, Dev K, Sourirajan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497729>
 65. **Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study.** J. Voice 2021; Balouch B, Vontela S, Yeakel H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516648>
 66. **A narrative review of pharmacologic treatments for COVID-19: safety considerations and ototoxicity.** Laryngoscope 2021; Little C, Cosetti MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491234>
 67. **COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?** Mult Scler Relat Disord 2021; 49:102775Gelibter S, Orrico M, Filippi M, Moiola L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517176>
 68. **A contemporary insight of metabolomics approach for COVID-19: Potential for novel therapeutic and diagnostic targets.** Nepal J Epidemiol 2020; 10:923-927Asim M, Sathian B, Banerjee I, Robinson J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495710>
 69. **Identification of 37 Heterogeneous Drug Candidates for Treatment of COVID-19 via a Rational Transcriptomics-Based Drug Repurposing Approach.** Pharmaceuticals (Basel) 2021; 14Gelemanović A, Vidović T, Stepanić V, Trajković K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504008>
 70. **Localized Plasmonic Photothermal Therapy as a Life-saving Treatment Paradigm for Hospitalized COVID-19 Patients.** Plasmonics 2021:1-5Labouta HI,

- Hooshmand N, Upreti T, El-Sayed MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495692>
71. **Blood omega-3 fatty acids and death from COVID-19: A pilot study.** *Prostaglandins Leukot. Essent. Fatty Acids* 2021; 166:102250 Asher A, Tintle NL, Myers M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516093>
 72. **Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.** *Stem Cell. Res. Ther.* 2021; 12:91 Hashemian SR, Aliannejad R, Zarrabi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514427>
 73. **Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment.** *Stem Cell Rev Rep* 2021; 1-21 Basiri A, Mansouri F, Azari A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511518>
 74. **Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying miRNA as a Potential Multi Target Therapy to COVID-19: an In Silico Analysis.** *Stem Cell Rev Rep* 2021; 1-16 Schultz IC, Bertoni APS, Wink MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511519>
 75. **COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): a single institution report of two cases.** *Strahlenther. Onkol.* 2021; 1-9 Moreno-Olmedo E, Suárez-Gironzini V, Pérez M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502567>
 76. **Clinical analysis and pluripotent stem cells-based model reveal possible impacts of ACE2 and lung progenitor cells on infants vulnerable to COVID-19.** *Theranostics* 2021; 11:2170-2181 Zhang Z, Guo L, Lu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500718>
 77. **Early use of corticosteroids in non-critical patients with COVID-19 pneumonia (PREDCOVID): a structured summary of a study protocol for a randomised controlled trial.** *Trials* 2021; 22:92 Salinas M, Andino P, Palma L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499887>
 78. **Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study.** *Turk J Haematol* 2021; Anaklıf $\pm$ f, Ergin $\sqrt{\text{ñ}}$ zcan P, Polat $\tilde{\text{n}}$ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486940>
 79. **ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population.** *Vox Sang* 2021; Bloch EM, Patel EU, Marshall C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493365>
 80. **[Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:6053-6064 Yang YM, Chen LN, Qu SQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496147>

Trials (13 articles)

1. **The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients.** *Am. J. Otolaryngol.* 2021; 42:102892 Singh CV, Jain S, Parveen S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493729>
2. **OUTCOMES AFTER VASCULAR SURGERY PROCEDURES IN PATIENTS WITH COVID-19 INFECTION: A NATIONAL MULTICENTRE COHORT STUDY (COVID-**

- VAS).** Ann. Vasc. Surg. 2021; San Norberto EM, De Haro J, Peñalva R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33493590>
3. **Formative Evaluation of a Home-Based Physical Activity Intervention for Adolescent Girls-The HERizon Project: A Randomised Controlled Trial.** Children (Basel) 2021; 8Cowley ES, Watson PM, Foweather L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33499174>
 4. **Collaborative platform trials to fight COVID-19: methodological and regulatory considerations for a better societal outcome.** Clin Pharmacol Ther 2021; Collignon O, Burman CF, Posch M, Schiel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506495>
 5. **Clinical trial preparations for the next pandemic.** Contemp Clin Trials 2021;106292Herson J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515783>
 6. **Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh.** Euroasian J Hepatogastroenterol 2020; 10:68-75Islam MA, Mazumder MA, Akhter N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511068>
 7. **Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial.** Front. Physiol. 2020; 11:624657Arnardottir H, Pawelzik SC, Öhlund Wistbacka U *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33505321>
 8. **Are colorectal cancer patients at risk for COVID-19 infection during the postoperative period? The Covid-GRECCAR study.** Int. J. Colorectal Dis. 2021;1-5Tuech JJ, Manceau G, Ouaisi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33495872>
 9. **COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network.** Intensive Care Med 2021;1-8Buetti N, Ruckly S, de Montmollin E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33506379>
 10. **COVID-19 Vaccination and Obesity: Optimism and Challenges.** Obesity (Silver Spring) 2021; Townsend MJ, Kyle TK, Stanford FC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33506642>
 11. **Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations.** Trials 2021; 22:100. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509275>
 12. **Early use of corticosteroids in non-critical patients with COVID-19 pneumonia (PREDCOVID): a structured summary of a study protocol for a randomised controlled trial.** Trials 2021; 22:92Salinas M, Andino P, Palma L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33499887>
 13. **US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine.** Vaccine 2021; Dal-Ré R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33516602>

Vaccines (30 articles)

1. **Response to: 'Correspondence on 'Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries' by Nokhatha et**

- al. *Ann. Rheum. Dis.* 2021; Dejaco C, Bijlsma JW, Buttgereit F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33509796>
2. **Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2.** *Biology (Basel)* 2021; 10Sabanovic B, Piva F, Cecati M, Giulietti M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33513850>
3. **Examining Australian public perceptions and behaviors towards a future COVID-19 vaccine.** *BMC Infect. Dis.* 2021; 21:120Seale H, Heywood AE, Leask J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509104>
4. **Vaccines are not yet a silver bullet: The imperative of continued communication about the importance of COVID-19 safety measures.** *Brain Behav Immun Health* 2021; 12:100204Su Z, Wen J, McDonnell D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33495754>
5. **Engineered Aptamers for Enhanced COVID-19 Theranostics.** *Cell. Mol. Bioeng.* 2021:1-13Acquah C, Jeevanandam J, Tan KX, Danquah MK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33488836>
6. **Absence of vaccine-enhanced disease with unexpected positive protection against SARS-CoV-2 by inactivated vaccine given within three days of virus challenge in Syrian hamster model.** *Clin Infect Dis* 2021; Li C, Chen YX, Liu FF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515458>
7. **The impact of vaccination on COVID-19 outbreaks in the United States.** *Clin Infect Dis* 2021; Moghadas SM, Vilches TN, Zhang K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33515252>
8. **Assessment of U.S. health care personnel (HCP) attitudes towards COVID-19 vaccination in a large university health care system.** *Clin Infect Dis* 2021; Shaw J, Stewart T, Anderson KB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491049>
9. **The impact of COVID-19 infection on the cytokine profile of pregnant women: A prospective case-control study.** *Cytokine* 2021; 140:155431Tanacan A, Yazihan N, Erol SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503581>
10. **Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.** *Drug Deliv Transl Res* 2021; Milane L, Amiji M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512669>
11. **Willingness of Greek general population to get a COVID-19 vaccine.** *Glob Health Res Policy* 2021; 6:3Kourlaba G, Kourkouni E, Maistreli S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33509291>
12. **Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease.** *Infect Drug Resist* 2021; 14:151-161Belete TM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33500636>
13. **Worldwide inverse correlation between Bacille Calmette-Guérin (BCG) immunization and COVID-19 mortality.** *Infection* 2021:1-11Li WX.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33495884>
14. **Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project.** *Int J Environ Res Public Health* 2021; 18Carmona A, Muñoz-Quiles C, Stuurman A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504081>
15. **The Impact of the COVID-19 Pandemic on Immunization Campaigns and Programs: A Systematic Review.** *Int J Environ Res Public Health* 2021; 18Lassi ZS, Naseem R, Salam RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499422>

16. **A Short Discussion About The SARS-CoV-2 mRNA-1273 Vaccine.** Int J Infect Dis 2021; Oronsky B, Gruber HE, Reiners W, Reid TR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493690>
17. **What can we learn from Israel's rapid roll out of COVID 19 vaccination?** Isr J Health Policy Res 2021; 10:5McKee M, Rajan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499901>
18. **Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review.** J. Clin. Pharmacol. 2021; Khani E, Khiali S, Entezari-Maleki T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511638>
19. **Immunosuppressants, Immunomodulators and COVID-19 Vaccines: Anticipating Patient Concerns.** J Dermatolog Treat 2021;1-9Rick J, Thompson AM, Hsiao JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494626>
20. **COVID-19 vaccination in our transplant recipients: The time is now.** J. Heart Lung Transplant. 2021; Aslam S, Goldstein DR, Vos R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487534>
21. **The growing complexity of COVID-19 drug and vaccine candidates: challenges and critical transitions.** J Infect Public Health 2020; 14:214-220Shariare MH, Parvez MAK, Karikas GA, Kazi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493917>
22. **Persuasion, not coercion or incentivisation, is the best means of promoting COVID-19 vaccination.** J. Med. Ethics 2021; Pennings S, Symons X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33504627>
23. **FDA authorizes Moderna COVID-19 vaccine.** Med. Lett. Drugs Ther. 2021; 63:9-10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33512345>
24. **Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States.** Mult Scler Relat Disord 2021; 49:102788Ehde DM, Roberts MK, Herring TE, Alschuler KN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508570>
25. **Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines.** Nefrologia 2021; Sánchez-Álvarez E, Quiroga B, de Sequera P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500159>
26. **Psychological and Behavioral Predictors of Vaccine Efficacy: Considerations for COVID-19.** Perspect. Psychol. Sci. 2021;1745691621989243Madison AA, Shrout MR, Renna ME, Kiecolt-Glaser JK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33501900>
27. **SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis.** Rheumatol. Int. 2021; Velikova T, Georgiev T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515320>
28. **Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy.** Vaccines (Basel) 2021; 9Benest J, Rhodes S, Quaife M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499326>
29. **COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population.** Vaccines (Basel) 2021; 9Garzon-Chavez D, Rivas-Condo J, Echeverria A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513693>
30. **Impact of COVID-19 Pandemic on Flu and COVID-19 Vaccination Intentions among University Students.** Vaccines (Basel) 2021; 9Pastorino R, Villani L, Mariani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33498282>

Women – pregnancy (22 articles)

1. **Disease Severity, Pregnancy Outcomes and Maternal Deaths among Pregnant Patients with SARS-CoV-2 Infection in Washington State.** Am J Obstet Gynecol 2021; Lokken EM, Huebner EM, Taylor GG *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33515516>
2. **Pregnancy as a risk factor for severe coronavirus 2019 (COVID-19) disease using standardized clinical criteria.** Am J Obstet Gynecol MFM 2021:100319Oakes MC, Kernberg AS, Carter EB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33493707>
3. **Association of menopausal status with COVID-19 outcomes: a propensity score matching analysis.** Biol. Sex Differ. 2021; 12:16Wang XW, Hu H, Xu ZY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514386>
4. **Domestic violence and its relationship with quality of life in pregnant women during the outbreak of COVID-19 disease.** BMC Pregnancy Childbirth 2021; 21:88Naghizadeh S, Mirghafourvand M, Mohammadirad R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33509103>
5. **Addressing the urgent global need for later abortion care during COVID-19 and beyond.** BMJ Sex Reprod Health 2021; Kapp N, Edelman A, Gomperts R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33504511>
6. **Health-related quality of life among Ethiopian pregnant women during COVID-19 pandemic.** Brain Behav 2021:e02045Dule A, Hajure M, Mohammedhussein M, Abdu Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506639>
7. **Clinical characteristics, maternal and neonatal outcomes of pregnant women with SARS-CoV-2 infection in Turkey.** Bratisl. Lek. Listy 2021; 122:152-157Ozsurmeli M, Terzi H, Hocaoglu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502885>
8. **Women and COVID-19: severity and mortality in hospitalized middle-aged and older patients.** Climacteric 2021:1-6Balcázar-Hernández L, Martínez-Murillo C, Ramos-Peñafiel C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513033>
9. **COVID-19 in pregnancy: a systematic review of chest CT findings and associated clinical features in 427 patients.** Clin Imaging 2021; 75:75-82Oshay RR, Chen MYC, Fields BKK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508754>
10. **Outcomes of an In Vitro Fertilization Pregnancy With COVID-19 and the Perinatal Outcome in Riyadh, Saudi Arabia.** Cureus 2020; 12:e12296Alhamoud AH, Matary F, Bukhari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510990>
11. **SARS-CoV-2 Infection in Seven Childbearing Women at the Moment of Delivery, a Romanian Experience.** Cureus 2021; 13:e12811Radu MC, Boeru C, Marin M, Manolescu LS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500869>
12. **COVID-19 and Obstetrical Care: Coping With New Stress.** Cureus 2020; 12:e12116Sharma R, Seth S, Solanki HK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33489531>
13. **The impact of SARS-CoV-2 and COVID-19 on male reproduction and men's health.** Fertil. Steril. 2021; Patel DP, Punjani N, Guo J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33509629>
14. **Coronavirus Disease 2019 (COVID-19): Prevention and Control in Gynecological Outpatient Clinic.** Front Public Health 2020; 8:618494Yao D, Yan K, Duan J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33490027>
15. **COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding.** Geburtshilfe Frauenheilkd. 2021; 81:46-60Cavalcante MB,

- Cavalcante C, Braga ACS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487665>
16. **Protocolized approach to a COVID-19 parturient undergoing a cesarean section - A case report.** *J. Anaesthesiol. Clin. Pharmacol.* 2020; 36:407-410 Jain K, Alen J, Kumar S, Mitra S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487911>
 17. **Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission.** *J. Clin. Invest.* 2021; Cribián FM, Erra R, Pagni L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497369>
 18. **Limiting the Use of Oral Glucose Tolerance Tests to Screen for Hyperglycemia in Pregnancy during Pandemics.** *J Clin Med* 2021; 10 Nachtergaele C, Vicaut E, Tatulashvili S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494289>
 19. **COVID-19: can we treat the mother without harming her baby?** *J. Dev. Orig. Health Dis.* 2021;1-11 Wiese MD, Berry MJ, Hissaria P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33487213>
 20. **Inositol and vitamin D may naturally protect human reproduction and women undergoing assisted reproduction from Covid-19 risk.** *J Reprod Immunol* 2021; 144:103271 Bezerra Espinola MS, Bertelli M, Bizzarri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493945>
 21. **COVID-19 impact on reproduction and fertility.** *JBRA Assist Reprod* 2020; Mali AS, Magdum M, Novotny J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33507714>
 22. **Postpartum Depressive Symptoms during the Beginning of the COVID-19 Pandemic: An Examination of Population Birth Data from Central New Jersey.** *Matern Child Health J* 2021; McFarland MJ, McFarland CAS, Hill TD, D'Oria R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33492587>
 23. **Variations in health behaviors among pregnant women during the COVID-19 pandemic.** *Midwifery* 2021; 95:102929 Whitaker KM, Hung P, Alberg AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508485>
 24. **Laparoscopic gynecological surgery in COVID 19 pandemic.** *Obstet Gynecol Sci* 2021; Roy KK, Rai R, Zangmo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499581>
 25. **Patient characteristics associated with SARS-CoV-2 infection in parturients admitted for labour and delivery in Massachusetts during the spring 2020 surge: A prospective cohort study.** *Paediatr. Perinat. Epidemiol.* 2021; 35:24-33 Reale SC, Lumbreras-Marquez MI, King CH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496995>
 26. **POST-COVID-19 ASSOCIATED DECLINE IN LONG-TERM MALE FERTILITY AND EMBRYO QUALITY DURING ASSISTED REPRODUCTIVE TECHNOLOGY.** *QJM* 2021; Mannur S, Jabeen T, Khader MA, Rao LSS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508136>
 27. **Expanding Access to Fetal Telecardiology During the COVID-19 Pandemic.** *Telemed J E Health* 2021; Schwartz BN, Klein JH, Barbosa MB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513044>

to subscribe click [here](#)

lansberg@gmail.com

© P.J. Lansberg